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Abstract 
 
HER2-targeted therapies have greatly improved the outcome for patients with HER2-
positive breast cancer.  However, resistance to these therapies is an on-going clinical 
problem. Therefore, novel therapeutic strategies to overcome or prevent resistance are 
required. The aim of this PhD project was to investigate mechanisms of resistance to 
HER2-targeted therapies and to develop strategies to overcome resistance. 
Two lapatinib resistant cell lines (SKBR3-L and HCC1954-L) previously generated in 
our lab showed increased protein phosphatase 2A (PP2A) activity. In this study, the 
resistant cell lines were more sensitive to PP2A inhibition by okadaic acid and the 
therapeutic PP2A inhibitor LB-100. PP2A inhibition also enhanced the effect of 
lapatinib and the combination induced apoptosis in both cell lines. Addition of LB100 
to lapatinib prevented the development of lapatinib resistance in two lapatinib-naive 
cell lines. HCC1954-L cells produced xenograft tumours in mice. The combination of 
lapatinib and LB-100 did not cause systemic side effects, deeming the combination 
safe for efficacy testing in the HCC1954-L xenograft model. 
In a panel of HER2-positive cell lines, sensitivity to PP2A inhibition with okadaic 
acid correlated with lapatinib resistance. PP2A catalytic subunit and structural subunit 
expression did not correlate with lapatinib or PP2A inhibition response. However, 
expression levels of the PP2A inhibitor CIP2A correlated with improved survival in 
HER2-positive breast cancer patients in a publicly available dataset. 
An afatinib-resistant SKBR3 cell line (SKBR3-A) was analysed by reverse phase 
protein array. Phospho-Src (Y416) was elevated in SKBR3-A compared to SKBR3 
cells. SKBR3-A cells were more sensitive to Src inhibition by dasatinib and the 
combination of afatinib and dasatinib was highly synergistic. The combination 
inhibited both HER2/EGFR and Src signalling and caused non-apoptotic cell death. 
Addition of dasatinib prevented the development of afatinib resistance in three of four 
treatment-naive HER2-positive cell lines and two of three cell lines with acquired 
trastuzumab resistance. 
In conclusion, the drug combinations of lapatinib plus LB-100 and afatinib plus 
dasatinib show potential for the treatment of HER2-positive breast cancer. 
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1.1 Introduction 
 
Cancer is a heterogeneous disease that can be characterised by its ability to sustain 
proliferation, evade cell death, stimulate angiogenesis, circumvent growth suppression 
and invade other tissues [1, 2]. However, the term cancer does not refer to a single 
disease but to a spectrum of malignancies that arise through particular genetic 
abnormalities. 
Breast cancer is the most common malignant tumour diagnosed in women in Ireland, 
with a 1 in 10 chance of an Irish woman developing malignant breast cancer before 
her 75th birthday. Although the breast cancer five-year survival rate is 82%, it is still 
the second most common cause of cancer death in women. From 1994 to 2013, the 
number of invasive breast cancer incidences increased annually by approximately 
1.5%. A similar trend was observed in in situ breast cancer cases, with an 8.8% 
increased trend. In contrast, the mortality rate is declining on average by 1.9% 
annually [3]. 
 
1.2 Breast cancer subtypes 
 
Breast cancer is defined by its origins in breast tissue. Most commonly, breast 
tumours originate from ductal tissue, termed ductal carcinoma, or in the lobules, 
which is called lobular carcinoma. However, in rare cases, tumours can occur from 
other breast tissue types [4, 5]. 
Breast cancer can be divided into several subtypes by morphological or molecular 
characteristics, each subtype with different clinical prognoses. Traditionally, the 
classification of a cancer was simply based on the tissue from which it originated e.g. 
breast cancer. However, developments in molecular biology led to breast cancer 
classification by the presence or absence of certain extracellular receptors, for 
example, the hormone receptors estrogen receptor (ER) and progesterone receptor 
(PR), and epidermal growth factor receptor 2 (HER2). This defined three basic breast 
cancer subtypes: hormone receptor-positive, HER2-positive and triple negative breast 
cancer. With the application of gene expression profiling, this classification was 
revised and five intrinsic breast cancer subtypes were proposed: HER2-enriched, 
luminal A, luminal B, basal-like and normal-like. Recently, three additional subtypes 
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have been proposed: claudin-low, molecular apocrine and luminal-like [6–10] (Table 
1-1).  
Luminal breast cancers are characterised by their high expression of the ER and 
largely originate from the luminal epithelial cells of the mammary gland. The St. 
Gallen International Expert Consensus divides luminal breast cancer into luminal A 
and luminal B. The luminal subtypes are the most heterogeneous in terms of gene 
expression, mutation and gene copy number profile [11]. Luminal A and B are 
distinguished by their Ki-67 and PR status. Luminal A tumours are both ER and PR 
positive and are Ki-67 negative. These cancers are highly sensitive to hormone 
therapy and generally respond poorly to chemotherapy. Luminal B breast cancers are 
either PR-negative or have high Ki-67 levels, have lower levels of ER than luminal A 
and can also be HER2 over-expressing [12].  
HER2-enriched breast cancer is characterised by its over-expression of genes on the 
17q ERBB2 amplicon, most notably HER2 and other associated genes such as GRB7 
and STARD3 [8]. The 17q ERBB2 amplicon, a region of DNA on chromosome 17q, 
is amplified in roughly 20% of breast cancers and this amplification is the most 
commonly occuring mechanism of HER2 activation [13]. Tumours of this subtype are 
highly proliferative and, prior to the advent of HER2-targeted therapies, had an 
exceptionally poor prognosis [14]. The basal-like subtype cancers are generally triple 
negative and are categorised by expression of genes characteristic of basal 
myoepithelial cells; cytokeratin 5 and/or cytokeratin 17. The normal-like subtype 
expresses genes typical of adipose tissue. The claudin-low subtype has low expression 
of claudins 3, 4 and 7, E-cadherin and CD24 [15]. Molecular apocrine subtype 
tumours over-express the androgen receptor and lack ER [16]. 
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Table 1-1: Breast cancer subtypes and their molecular features [6–10]. 
Breast cancer 
subtype 
Features 
HER2-enriched Overexpression of genes on the 17q ERBB2 amplicon; such 
as HER2, GRB7 and STARD3 
Luminal A ER- and PR-positive, Ki67-negtive 
Luminal B ER-positive, either PR-negative or high Ki67 levels, can also 
have HER2 overexpression 
Basal-like Mostly HER2-, ER- and PR-negative, overexpression of 
cytokeratin 5 and/or cytokeratin 17 
Normal-like Overexpression of adipose tissue-associated genes 
Claudin-low Low expression of claudins 3, 4 and 7, E-cadherin and CD24 
Molecular apocrine Overexpression of androgen receptor and ER-negative 
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1.3 HER2-positive breast cancer 
1.3.1 HER family structure and function 
 
HER2 is a 185 kDa receptor tyrosine kinase (RTK) encoded by the HER2-neu proto-
oncogene on chromosome 17q21 and, along with EGFR (HER1 or ErbB1), HER3 
(ErbB3) and HER4 (ErbB4), is a member of the ERBB/HER family of RTKs (Figure 1-1). These membrane receptors are composed of a glycosylated extracellular 
domain, a transmembrane region and, an intracellular tyrosine kinase domain [17–19]. 
The extracellular domain is composed of approximately 630 amino acids and can be 
divided into four sub-domains. Sub-domain I contains the ligand binding site that, 
when activated binds to sub-domain III. This triggers a conformational change that 
exposes sub-domain II, the dimerization domain. The four HER family members 
originate from a gene duplication event, resulting in an EGFR/HER2 precursor and 
HER3/HER4 precursor, and subsequent gene duplications then produced the four 
receptors [20]. These receptors are ubiquitously expressed and are critical for normal 
development. 
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Figure 1-1: HER family members of receptor tyrosine kinase receptors. The 
extracellular domains of EGFR, HER3 and HER4 contain ligand binding 
domains for HER family ligands. EGF = epidermal growth factor, TGF-α = 
transforming growth factor alpha, HB-EGF = heparin-binding epidermal 
growth factor-like growth factor, NRG = neuregulin, PKD = protein kinase 
domain. HER3 has a truncated intracellular segment and does not have an active 
PKD (adapted from [19]). 
 
There are 12 known ligands that can activate members of the HER family of receptors 
[21]. These ligands can act in either a receptor-specific manner, such as EGF, TGF-α 
and epigen for EGFR, or a non-specific fashion, for example, neuregulins for HER3 
and HER4 and epiregulin for EGFR and HER4. They are approximately 55 amino 
acids in size and share a conserved EGF-like pattern of three disulphide bonds and 
loop-rich structure [20, 22]. In contrast to the other members of the HER family, 
HER2 does not require a ligand for activation. Instead, HER2 resides in a permanent, 
ligand-independent open conformation as sub-domain I of the extracellular domain is 
in constant contact with sub-domain III, which allows it to homo- or heterodimerise 
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[23]. In comparison, the EGFR subdomains II and IV are bound together by a β-
hairpin loop projecting from subdomain II. This can only be released through ligand 
binding, inducing an allosteric conformational change resulting in exposure of 
subdomain II similar to HER2 [24]. It must be noted though, that in order for HER2 
to heterodimerise, its binding partner must be ligand activated. Therefore, although 
HER2 is not reliant on specific ligands for activation, its level of dimerisation is 
governed by ligand binding to other HER receptors.  
There are ten possible HER family dimer combinations. However, HER2 is the 
preferred dimerisation partner of all other members of the HER family [22]. These 
HER2-containing dimers have a decreased dissociation rate and a greater transduction 
of the signal compared to the other possible dimers [25]. Dimerisation results in the 
trans-phosphorylation of the tyrosine kinase domain. This provides docking sites for 
signalling proteins that possess Src homology 2 (SH2) and phosphotyrosine binding 
domains. The number of tyrosine phosphorylation sites varies between HER 
receptors, HER2 having 19 different sites. This phosphorylation allows for activation 
of a number of signal transduction pathways, most notably the mitogen-activated 
protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways [26]. 
Through the activation of these pathways, HER signalling stimulates cell 
proliferation, migration invasion and regulation of apoptosis. 
 
1.3.2 HER2 in normal development 
 
The HER family receptors play a paramount role in normal mammalian development 
and HER2 is of particular significance in central nervous system and cardiac 
development [27, 28]. Gene mutation studies have shown that HER2-mutant mice 
develop nervous system defects and cannot survive gestation [29]. HER2, along with 
HER4 and neuregulin, are required for ventricular development. Mutations of HER2 
in ventricular cardiomyocytes results in dilated cardiomyopathy [30]. HER2 is 
expressed in epithelial cells in stomach, skin, heart, breast and kidney tissues [30–32]. 
This must be taken into consideration when assessing the clinical implications of 
HER2-targeted therapies. 
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1.3.3 HER2-positive breast cancer occurrence 
 
The incidence of HER2-positive breast cancer is reported as between 15% and 30% of 
all breast cancers [3, 33]. In Ireland, the average reported occurrence of HER2-
positive breast cancer from 2004 to 2013 was 15.4%, equalling approximately 448 
patients per year. Of those patients with HER2-positive status, 68% received 
trastuzumab within one year of diagnosis [3].  
 
1.4 HER2-targeted therapies 
1.4.1 Overview of approved HER2-targeted therapies 
 
There are currently five FDA-approved HER2-targeted therapies for the treatment of 
HER2-positive breast cancer: trastuzumab, pertuzumab, trastuzumab emtansine (T-
DM1), lapatinib and neratinib (Figure 1-2). These molecules can be divided into three 
main categories: anti-HER2 monoclonal antibodies, antibody-drug conjugate, and 
small molecule HER family tyrosine kinase inhibitors. 
Trastuzumab was the first HER2-targeted therapy approved and is approved for the 
treatment of both early-stage and metastatic HER2-positive breast cancer [34]. 
Lapatinib was next approved in combination with capecitabine as second-line therapy 
for metastatic HER2-positive breast cancer that has become refractory to trastuzumab 
[35]. The second anti-HER2 monoclonal antibody, pertuzumab, was approved in dual 
HER2-targeted therapy with trastuzumab for the treatment of both metastatic and 
early-stage HER2-positive breast cancer [36, 37]. T-DM1 then showed improved 
efficacy as a second-line therapy compared to lapatinib plus capecitabine and was 
therefore approved for second-line treatment after relapse following trastuzumab 
treatment for metastatic disease [38]. More recently, neratinib was approved for the 
treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab 
treatment [39]. Several additional clinical trials are on-going to determine the optimal 
combinations and order of treatment in HER2-positive breast cancer. 
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Figure 1-2: HER2-targeted therapies approved (red) and currently in clinical 
trials (blue) for HER2-positive breast cancer. 
 
1.4.2 Anti-HER2 monoclonal antibodies 
1.4.2.1 Trastuzumab 
1.4.2.1.1 Pre-clinical investigation of trastuzumab 
 
 
Trastuzumab (HerceptinTM, Genentech) is a humanised IgG1 monoclonal antibody 
that binds to the C-terminal region of domain IV of the extracellular domain [18] of 
HER2 causing suppression of HER2 signalling [40], antibody dependent cell-
mediated cytotoxicity (ADCC) through the recruitment of natural killer cells [41, 42], 
induction of HER2 internalisation [43], reduction in angiogenesis [44], and G1 cell 
cycle arrest [45].  
The development of trastuzumab stemmed from academic and industry research 
groups producing murine monoclonal antibodies against the extracellular domain of 
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HER2, p185HER2 [46, 47]. One of these antibodies, muMAb 4D5 showed pre-clinical 
efficacy in HER2-positive cancer cell lines [48]. The 4D5 murine antibody was 
humanised to avoid immune response against the antibody. The resulting monoclonal 
antibody actually bound to HER2 more effectively than the murine antibody and also 
elicited ADCC in vivo, which was not seen with the murine 4D5 [49]. 
 
1.4.2.1.2 Clinical investigation of trastuzumab 
 
The first clinical trials for the use of trastuzumab showed the potential of trastuzumab 
even in heavily-pre-treated HER2-positive metastatic patients [50, 51]. Single agent 
trastuzumab displayed an objective response rate (ORR) of 15% with a median 
overall survival (OS) of 13 months [50]. Trastuzumab also showed a clinical 
improvement in combination with chemotherapy versus chemotherapy alone. The 
addition of trastuzumab increased ORR from 32 months to 50 months, with OS after 
one year 78% versus 67% [51]. In 1998, trastuzumab was FDA approved for the 
treatment of metastatic HER2-positive breast cancer and was the first HER2-targeted 
therapy used clinically [34]. A recent study of response to trastuzumab in patients 
with metastatic breast cancer showed that 9.5% of patients achieved a durable 
complete response [52]. 
Meta-analysis of five clinical trials assessing trastuzumab treatment in the adjuvant 
setting showed that trastuzumab-containing therapy improves survival rates and 
lowers the rate of recurrence and metastasis compared to adjuvant therapy without 
trastuzumab [53]. Patients treated with a trastuzumab-based regimen had a reduced 
recurrence by approximately 50%. This also extends to small localised disease, 
tumours ≤ 2 cm, as adjuvant trastuzumab treatment improves both disease-free 
survival (DFS) and OS [54]. Based on the adjuvant clinical trials, trastuzumab 
approval was expanded to include early-stage HER2-positive breast cancer in 2006 
[55].  
The optimal duration of adjuvant trastuzumab treatment has been a controversial 
topic. The PHARE clinical trial of six-months versus 12-months trastuzumab 
treatment could not provide evidence of inferiority of the shorter treatment and 
shorter treatment had decreased occurrence of cardiotoxicity [56]. However, in a 
meta-analysis of four clinical trials, one year of trastuzumab treatment was shown to 
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improve overall survival and disease free survival compared to shorter treatment 
regimens [57]. This suggests 12-months of trastuzumab treatment should remain the 
standard of care. In addition, the HERA trial showed that two-years of trastuzumab 
treatment did not further improve response compared to one year of treatment [58].  
Trastuzumab has shown considerable efficacy against HER2-positive breast cancer in 
the neo-adjuvant setting. In the Phase III NOAH trial, neo-adjuvant trastuzumab plus 
chemotherapy produced increased event-free survival (58% versus 43%) and 
pathological complete response (pCR) (38% versus 19%) compared to chemotherapy 
alone in locally advanced HER2-positive breast cancer [59].  
The most commonly occurring adverse effect of trastuzumab is fatigue. However, the 
most clinically significant effect observed is cardiotoxicitiy. Trastuzumab was found 
to cause cardiotoxicity in 4.7% of 221 patients treated [50]. Other anti-neoplastic 
drugs such as anthracyclines can cause cardiomyopathy and congestive heart failure. 
This effect is increased by the addition of trastuzumab, but can be improved with 
angiotensin-converting enzyme (ACE) inhibitor and beta-blocker treatment [60, 61]. 
Therefore, anthracycline-containing chemotherapy regimens are not given 
concomitantly with trastuzumab [62]. 
 
1.4.2.2 Pertuzumab 
1.4.2.2.1 Pre-clinical investigation of pertuzumab 
 
Pertuzumab (PerjetaTM, Genentech) is a second-generation HER2-targeted humanised 
monoclonal antibody. Pertuzumab received FDA approval in 2012 for the treatment 
of metastatic breast cancer and in 2013 also gained accelerated approval for neo-
adjuvant treatment of early-stage breast cancer. Unlike trastuzumab that targets 
subdomain IV of the extracellular domain of HER2, the epitope targeted by 
pertuzumab is subdomain II of HER2, which prevents HER2 homo- and hetero-
dimerisation [63]. This dimerisation inhibition is more effective than that of 
trastuzumab [64]. Aside from inhibiting dimerisation, pertuzumab has also been 
shown, in vitro, to inhibit PI3K and MAPK signalling and to mediate ADCC [65]. 
Pre-clinical data showed that pertuzumab plus trastuzumab caused increased 
induction of apoptosis, enhanced Akt signalling suppression, and reduced hetero- and 
homo-dimerisation in the HER2-positive breast cancer cell line BT474 [66]. 
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1.4.2.2.2 Clinical investigation of pertuzumab 
 
Dual blockade of HER2 with the combination of both monoclonal anti-HER2 
antibodies was assessed in the phase III CLEOPATRA clinical trial (n = 808). This 
trial evaluated the efficacy of docetaxel plus trastuzumab and a placebo versus 
docetaxel plus trastuzumab and pertuzumab in HER2-positive metastatic breast 
cancer. Pertuzumab significantly enhanced trastuzumab and docetaxel response 
compared to the placebo addition. OS of the triple combination was 15.6 months 
longer (56.5 months versus 40.8 months) and PFS was 18.7 months compared to 12.4 
months [67]. Importantly, the addition of pertuzumab caused similar levels of adverse 
effects, with only febrile neutropenia and grade ≥ 3 diarrhoea increased in the 
pertuzumab-treated group [68]. The results of this trial led to the approval of 
pertuzumab in combination with trastuzumab and docetaxel as a first-line therapy for 
metastatic or locally recurrent disease [69].  
With pertuzumab showing enhancement in combination with trastuzumab and 
docetaxel in the metastatic setting, its possible role in neo-adjuvant treatment was 
examined. The NeoSphere trial (n = 417) compared the efficacy of trastuzumab plus 
pertuzumab, trastuzumab plus docetaxel, pertuzumab plus docetaxel, or the triple 
combination, using locoregional total pCR as the primary endpoint. The dual HER2 
blockade significantly increased total pCR rates, which was further improved by the 
addition of docetaxel . Of the patients on the triple combination 45.8% achieved pCR 
compared to 16.8% in the dual antibody combination, 29% of the trastuzumab plus 
docetaxel group and 24% of the pertuzumab plus docetaxel group [70, 71]. The triple 
combination marginally improved PFS and DFS compared to trastuzumab plus 
docetaxel, the group with the second best response (Table 1-2). This also then led to 
the approval of the triple combination in the neo-adjuvant setting for patients with 
locally advanced or early-stage HER2-positive breast cancer [37]. 
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Table 1-2: Percentage 5-year disease-free survival and progression-free survival 
per treatment group in the CLEOPATRA clinical trial  [67]. T = trastuzumab, P 
= pertuzumab, D = docetaxel. 
Treatment 
group 
Disease-free survival (%) Progression-free survival 
(%) 
T+D 81 81 
P+T+D 86 84 
T+P 73 80 
P+D 73 75 
 
 
1.4.3 Antibody-drug conjugate 
1.4.3.1 Trastuzumab emtansine (T-DM1) 
1.4.3.1.1 Pre-clinical investigation of T-DM1 
 
Trastuzumab-emtansine (T-DM1) (KadcylaTM, Genentech) is an antibody-drug 
conjugate of trastuzumab and DM1 (emtansine, a derivative of maytansine), linked by 
a non-reducible thioester linker. Antibody-drug conjugates provide a targeted delivery 
system of highly cytotoxic agents to cancer cells. T-DM1 carries approximately 3.5 
DM1 molecules per trastuzumab antibody. T-DM1 has shown significant anti-
proliferative effect in vitro and in vivo against HER2-positive breast cancer cell lines, 
including cell lines with innate or acquired trastuzumab and lapatinib resistance [72, 
73]. In a pre-clinical study of T-DM1 in a panel of HER2-positive breast cancer cell 
lines, including three cell lines that are innately resistant to trastuzumab and lapatinib, 
T-DM1 caused mitotic catastrophe and apoptosis and elicited ADCC similar to 
trastuzumab [74].  
 
T-DM1 binds to the extracellular domain of HER2 and is internalised by endocytosis. 
Cleavage of the linker molecule and release of DM1 occurs in lysosomal processing. 
Released DM1 can then inhibit microtubule assembly. Due to the anti-HER2 activity 
of the trastuzumab molecule and the cytotoxicity of DM1, T-DM1 as a single agent 
 18 
can cause cell death by several mechanisms, including apoptosis, mitotic catastrophe 
and ADCC [73, 75].  
 
1.4.3.1.2 Clinical investigation of T-DM1 
 
T-DM1 was safely tolerated and showed some clinical efficacy in heavily pre-treated 
patients in phase I clinical trials [76]. The dose limiting toxicity was 
thrombocytopenia, due to T-DM1 affecting platelet production. Cardiac toxicity 
requiring dose modification was not observed [76, 77]. The phase III EMILA trial 
assessed T-DM1 in metastatic HER2-positive breast cancer as a second line therapy 
against the approved combination of lapatinib and capecitabine. In this trial, T-DM1 
was superior in PFS (9.6 months versus 6.4 months) and OS (30.9 versus 25.1 
months) [78, 79]. On the basis of the EMILA trial, T-DM1 was approved for second-
line treatment of metastatic HER2-positive breast cancer [38, 80]. The combination of 
T-DM1 with pertuzumab is now under investigation, with a phase IIa trial showing 
clinical activity (ORR = 41%, 33% in metastatic disease, 57% in first-line therapy) 
[81]. T-DM1 is now being tested in neo-adjuvant and adjuvant treatment of HER2-
positive breast cancer. These trials include T-DM1 as a single agent and in 
combination with various chemotherapies, HER2-targeted therapies, immunotherapy 
and other targeted therapy agents, including neratinib, ONT-380, palbociclib and 
pembrolizimab. 
 
1.4.4 Small molecule tyrosine kinase inhibitors 
1.4.4.1 Lapatinib 
 
Lapatinib (TykerbTM, Novartis) (Figure 1-3) is a reversible, tyrosine kinase inhibitor 
of EGFR and HER2. In 2001, it received FDA approval in combination with 
capecitabine for the treatment of metastatic HER2-positive breast cancer that has 
failed trastuzumab therapy [82]. It was subsequently also approved for the treatment 
of HER2-positive, ER-positive breast cancer in combination with letrozole [83].  
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Figure 1-3: Chemical structure of lapatinib (reproduced from PubChem; CID 
no. = 208908 [84]) 
 
The predominant mechanism of action of lapatinib in HER2-positive breast cancer is 
inhibition of HER2 signalling (IC50 value = 9.2 nM). Downstream of HER2 signalling 
lapatinib can induce apoptosis, cause cell cycle arrest, senescence and has been 
indicated to induce autophagy [85–87]. Although lapatinib is also an EGFR inhibitor 
(IC50 value = 10.8 nM), its efficacy is independent of EGFR expression in HER2-
overexpressing breast cancer cell lines and patient tumours [88–90]. When bound to 
HER2, lapatinib inhibits both PI3K/Akt and MAPK signalling pathways [88]. This 
inhibition of MAPK signalling causes increased Bcl-2 interacting mediator of cell 
death (BIM), which results in apoptosis. Apoptosis can also be induced by lapatinib 
through decreased levels of survivin and increased myeloid cell leukaemia 1 (MCL-1) 
[91–94]. The intracellular binding site of lapatinib is advantageous as, unlike 
trastuzumab, lapatinib can also bind to and inhibit p95, the cleaved constitutively 
active form of HER2 [95]. Lapatinib also induces stabilisation and accumulation of 
HER2 on the cell surface which may allow for greater trastuzumab-mediated ADCC 
alone [42, 96]. Lapatinib in combination with trastuzumab increases growth inhibition 
in HER2-positive breast cancer cell lines compared to either single agent [88]. This 
effect was seen in cell lines sensitive to both single agents, resistant to trastuzumab, 
and innately resistant to both agents. 
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Lapatinib monotherapy was found to be ineffective in HER2-positive breast cancer 
compared to trastuzumab [97]. However, lapatinib combined with capecitabine 
showed a greater clinical benefit than capecitabine alone (PFS of 8.4 months vs. 4.4 
months) for patients with trastuzumab-refractory metastatic breast cancer [35, 98]. 
Capecitabine (Xeloda, Roche) is a chemotherapy pre-drug that is converted to 5-
fluorouracil in tumour cells. This combination also performed better than continued 
trastuzumab with capecitabine when the patient’s tumour progressed after initial 
trastuzumab treatment (median PFS of 6 months vs. 4.5 months) [99]. The results of 
this trial led to the FDA approval of lapatinib in combination with capecitabine. 
Therefore, proceeding clinical trials focused on possible lapatinib efficacy in 
combination with other HER2-targeted therapies or chemotherapies.  
The potential benefit of dual HER2 blockade with trastuzumab and lapatinib in 
HER2-positive breast cancer was examined in the metastatic setting with the 
EGF104900 trial and in early stage disease with the ALTTO trial. The addition of 
lapatinib to trastuzumab showed a 4.5 month increase in overall survival compared to 
lapatinib alone in trastuzumab-refractory metastatic disease [100]. In the ALTTO 
trial, patients with early-stage HER2-positive breast cancer received adjuvant 
chemotherapy combined with trastuzumab alone (T), lapatinib alone (L), trastuzumab 
followed by lapatinib (T->L), or trastuzumab plus lapatinib (T+L) [101]. The L arm 
was discontinued when inferiority to trastuzumab alone was observed. At a median 
follow-up of 4.5 years, there was a 16% reduction in the hazard ratio in T+L 
compared to T, but this was not statistically significant at the defined p<0.025 
significance level (p = 0.048). There was no significant difference in OS after 4 years. 
However, results of trials of this combination in the neo-adjuvant setting were more 
promising. The NeoALTTO trial (n = 455) compared the efficacy of lapatinib alone 
versus trastuzumab alone versus trastuzumab plus lapatinib for six weeks followed by 
the same targeted therapy plus paclitaxel for 12 weeks prior to surgery [102]. The 
combination of trastuzumab and lapatinib showed significantly improved pCR 
compared to trastuzumab alone (46.8% versus 27.6%), and those that achieved pCR 
had increased event-free survival (86% versus 72%) and OS (94% versus 87%) [102, 
103]. The combination of trastuzumab and lapatinib has also shown efficacy in 
patients with heavily trastuzumab pre-treated metastatic HER2-positive breast cancer. 
The combination arm showed increased PFS and clinical benefit rates (CBR) 
compared to lapatinib alone, with a satisfactory safety profile [104]. Preliminary 
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results from the EPHOS-B trial (n = 257) further highlighted the potential benefit of 
neoadjuvant lapatinib plus trastuzumab. In this trial, patients were given the 
combination of lapatinib and trastuzumab, trastuzumab alone or a placebo without 
any chemotherapy during an 11-day treatment window after diagnosis and prior to 
surgery. Remarkably, in the combination arm, 17% of patients had tumours of less 
than 5 mm in diameter, defined as minimum residual disease (MRD), and a further 
11% had pCR. In comparison, the trastuzumab only arm produced no pCR and 3% 
MRD while the control group had no occurrences of pCR or MRD [105].  
Clinically, HER2-positive breast cancer presents as a heterogeneous disease; 
incorporating HER2-enriched, luminal A, luminal B, basal-like, and normal-like 
cancers. In the phase II PAMELA trial, patients were characterised by PAM50 breast 
cancer subtype predictor and given lapatinib plus trastuzumab. Patients with hormone 
receptor positive disease also received endocrine therapy. Of the HER2-positive 
breast cancer patients 67% had HER2-enriched disease. Of these patients 41% 
achieved pCR compared to 10% of the non-HER2 enriched patients [106]. This result 
therefore indicates that PAM50 HER2 subtype classification may be a better predictor 
of response to lapatinib and trastuzumab than traditional HER2-positive 
characterisation. 
In summary, the assessment of trastuzumab plus lapatinib in combination has shown 
mixed response. Adjuvant dual therapy did not significantly improve survival 
outcomes and although the combination increased pCR in the NeoALTTO trial, this 
did not translate into improved OS. However, trials like the EPHOS-B trial hold 
promise, as trastuzumab plus lapatinib without chemotherapy significantly increased 
pCR, but the effect on OS is not yet known. The PAMELA trial suggests that the 
combination may perform better against a trastuzumab alone regimen with PAM50 
HER2-enriched patient selection. 
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1.4.4.3 Neratinib 
1.4.4.3.1 Pre-clinical investigation of neratinib 
 
Neratinib (NerlynxTM, Puma Biotechnologies) (Figure 1-4) is an anilinoquinoline 
derivative of pelitinib (EKB-569, Wyeth), an irreversible EGFR inhibitor [107]. It is a 
pan-HER family tyrosine kinase inhibitor that is approved for the treatment of early-
stage HER2-positive breast cancer [39]. 
 
 
Figure 1-4: Chemical structure of neratinib (reproduced from PubChem; CID 
no. =  9915743 [84]) 
 
Neratinib is a potent inhibitor of HER2-amplified or HER2-driven cancers. It has 
shown significantly greater activity in HER2-amplified breast cancer cell lines 
compared to HER2-low or non-amplified cells and sensitivity to neratinib correlated 
with baseline and phosphorylated HER2 levels, but not EGFR levels. Neratinib 
suppressed HER receptor activation and decreased downstream pathway signalling, 
through PI3K and MAPK. However, AKT and HER3 activity was restored after drug 
withdrawal, which was prevented when neratinib was combined with trastuzumab 
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[108]. This suggests the combination of trastuzumab and neratinib may be more 
effective than single agent therapy. Furthermore, neratinib has demonstrated in vitro 
and in vivo efficacy against trastuzumab-resistant HER2-positive breast cancer. 
Innately trastuzumab resistant cell lines are also sensitive to neratinib. The 
combination of neratinib and trastuzumab enhanced the single agent effect in acquired 
trastuzumab resistant SKBR3 and BT474 cell lines. The addition of neratinib to 
trastuzumab treatment can also inhibit HER4 cleavage and nuclear translocation, 
which is associated with trastuzumab resistance [109]. 
 
1.4.4.3.2 Clinical investigation of neratinib 
 
Neratinib has been investigated in several cancer types, including breast, lung, 
bladder, and colorectal cancer [110–112], with a focus on HER2-amplified and 
HER2-mutated cancers. Phase I clinical investigation showed that neratinib was well 
tolerated up to 320 mg daily dosage, with a therapeutic dose set at 240 mg [110]. The 
most common neratinib-related toxicity and the primary dose-limiting toxicity was 
diarrhoea, with 32% of patients experiencing grade 3 or higher diarrhoea.  Neratinib 
showed significant efficacy in the breast cancer setting. Partial responses were 
observed in eight breast cancer patients, accounting for 32% of breast cancer patients 
enrolled in the phase I study. These 8 patients had HER2-positive breast cancer, with 
7 of the 8 partial responders having HER2 immunohistochemical staining of 3 [110].  
Neratinib has shown clinical activity in HER2-positive breast cancer, regardless of 
previous trastuzumab treatment. However, there is some reduction in efficacy in 
cancers previously treated with HER2-targeted therapies. In a phase II clinical trial, 
patients were divided into two cohorts: 63 with prior trastuzumab therapy and 64 
being trastuzumab-naïve. Both cohorts received 240 mg neratinib monotherapy daily, 
with the primary endpoint of 16-week PFS rate. Patients with prior trastuzumab 
therapy had a 16-week PFS rate of 59% and ORR of 24%. For patients with no 
previous trastuzumab, the 16-week PFS rates were 78% and ORR 56% [113]. 
Neratinib has also demonstrated efficacy in lapatinib-treated breast cancer. A phase 
I/II clinical trial showed tolerability of neratinib in combination with capecitabine and 
examined this combination in patients with metastatic HER2-positive breast cancer, 
of which seven patients had previously received lapatinib therapy. Clinical response 
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was observed at the MTD in 64% of lapatinib-native patients and 57% of patients that 
previously received lapatinib. Median PFS was 40 weeks for patients with no prior 
lapatinib and 26 weeks for those who received lapatinib [114]. Neratinib was 
observed to significantly improve invasive disease free survival (iDFS) compared to a 
placebo when given after two years of trastuzumab therapy for early-stage HER2-
positive breast cancer in the phase III ExteNET trial. After two years follow-up, iDFS 
was 94.2% for the neratinib arm compared to 91.9% for placebo. The results of this 
trial led to the approval of neratinib for the treatment of early-stage HER2-positive 
breast cancer following adjuvant trastuzumab. 
A number of trials have been launched to test the efficacy of neratinib compared to 
lapatinib. One phase II clinical trial compared neratinib monotherapy to lapatinib plus 
capecitabine in patients with advanced HER2-positive breast cancer who previously 
received trastuzumab. Lapatinib and capecitabine showed higher ORR and median 
PFS than the neratinib monotherapy. However, this difference was not statistically 
significant [115]. This led to the phase III NALA trial which is currently examining 
neratinib plus capecitabine versus lapatinib plus capecitabine in metastatic HER2-
positive breast cancer patients who have received two or more previous HER2-
targeted therapies(excluding HER2-targeted TKIs). This clinical trial should 
determine if neratinib shows superiority over lapatinib in the HER2-positive 
metastatic setting. The primary outcomes of this study are PFS and OS and the 
estimated primary completion date is 2019 [116]. 
Several trials are underway or completed examining combinations of neratinib with 
other HER2-targeted therapies. The FB-8 trial showed that neratinib combined with 
trastuzumab and paclitaxel is safe, but suggested reducing the therapeutic dose of 
neratinib to 200 mg daily when in combination with trastuzumab and paclitaxel [117]. 
 
1.4.4.4 Afatinib 
1.4.4.4.1 Pre-clinical investigation of afatinib 
 
Afatinib (GilotrifTM, Boehringer Ingelheim) (Figure 1-5) is a quinazoline derivative 
small molecule tyrosine kinase irreversible inhibitor of EGFR, HER2 and HER4 
[118]. Afatinib is FDA approved for metastatic non-small cell lung cancer (NSCLC) 
with either EGFR exon-29 deletions or Leu858Arg mutation [119]. In vitro assays 
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showed afatinib is a potent inhibitor of wild type EGFR (EC50 = 0.5 nM), HER2 (14 
nM), HER4 (1 nM) and mutant EGFR variants (EGFRL858R = 0.4 nM and 
EGFRL585R/T790M = 10 nM) [120]. Afatinib covalently binds to Cys-773 and Cys-805 
of EGFR and HER2, respectively, which are situated in the ATP binding pocket of 
the kinase domain.  
 
 
Figure 1-5: Chemical structure of afatinib (reproduced from PubChem; CID no. 
=  10184653 [84]) 
 
Pre-clinical assessment of afatinib demonstrated efficacy in HER2-overexpressing 
and/or EGFR-amplified breast, lung, pancreatic, prostate and gastric cancer cell lines 
[118, 121, 122]. Afatinib showed high specificity and potency to suppress 
phosphorylation of both wild type and mutant EGFR and HER2. In particular, HER2-
positive breast cancer cell lines were highly sensitive to afatinib and an additive effect 
was seen with the combination of afatinib and trastuzumab in four trastuzumab 
sensitive cell lines and an acquired trastuzumab resistant cell line. This sensitivity was 
also reflected in an in vivo xenograft model [123].  
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1.4.4.4.2 Clinical investigation of afatinib 
 
The described pre-clinical data led to the initiation of multiple phase I clinical trials to 
investigate the safety and clinical activity of afatinib, alone or in combination with 
chemotherapy, in advanced solid cancers.  
Four afatinib monotherapy phase I clinical trials were performed to determine the 
safety and tolerability of afatinib in solid tumours. Two of these trials used a 
continuous dosing schedule, one study used a 14-days on/14-days off programme and 
another used a three-weeks on/one-week off schedule [124–127]. The adverse effects 
observed in these trials were typical of EGFR inhibitors and were most commonly 
gastrointestinal-related, skin rashes and fatigue. These trials demonstrated that 
afatinib is orally bioavailable and the maximum plasma concentration at the MTD 
was 25- to 700-fold higher than required to inhibit EGFR phosphorylation in vitro 
[126]. However, EGFR-associated biomarkers were unchanged but Ki-67 levels were 
significantly reduced on therapy. From these trials, the recommended dose for phase 
II trials was established as 50 mg daily [127].  
Clinical investigation of afatinib in breast cancer has focused on two areas: second-
line therapy after progression on trastuzumab, and as a neo-adjuvant therapy. A phase 
II clinical trial of afatinib as a second-line therapy examined afatinib monotherapy in 
a single-arm study [128]. Eleven percent of patients achieved a partial response, with 
37% having stable disease. These patients had all previously been treated with 
trastuzumab and had also received a median of three chemotherapies. This indicated 
that afatinib might have efficacy in trastuzumab-refractory disease. The LUX-Breast 
phase III clinical trials further investigated second-line afatinib therapy. The LUX-
Breast 1 trial compared afatinib plus vinorelbine to continued trastuzumab plus 
vinorelbine in metastatic breast cancer patients [129]. This trial was stopped early as 
independent benefit-risk analysis showed that afatinib was inferior to trastuzumab. 
Median PFS of the afatinib group was 5.5 months and 5.6 months for the trastuzumab 
group. As CNS metastasis is a common occurrence in HER2-positive disease, the 
LUX Breast 3 trial was carried out to determine if afatinib could improve current 
therapy. Afatinib alone and afatinib plus vinorelbine were compared to the 
investigator’s choice of treatment [130]. Neither afatinib-based therapy showed a 
greater clinical benefit compared to investigator’s choice. Clinical benefit was defined 
as no additional CNS tumour development or tumour-related worsening of 
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neurological symptoms at 12 weeks. The LUX-Breast 2 trial examined afatinib in 
metastatic breast cancer that progressed on trastuzumab and/or lapatinib. This trial 
compared three treatment arms: afatinib alone, afatinib followed by paclitaxel after 
progression on afatinib, and afatinib followed by vinorelbine. Results of this trial are 
so far unpublished [131]. 
In the neo-adjuvant setting, a phase II clinical trial examined the potential of afatinib 
in the treatment of locally advanced HER2-positive breast cancer [132]. Patients on 
this trial received afatinib, trastuzumab, or lapatinib for six weeks prior to surgery. 
This trial was terminated early due to low accrual rate. However, 28 patients were 
enrolled in the trial. Objective responses were observed in 8 of 10 afatinib treated 
patients, 4 of 11 that received trastuzumab, and 6 of 8 of the lapatinib group. Afatinib 
was associated with a much higher rate of adverse events compared to trastuzumab or 
lapatinib. The DAFNE phase II clinical trial was a single arm study of neo-adjuvant 
afatinib plus trastuzumab, followed by afatinib, trastuzumab and paclitaxel, then 
epirubuicin, cyclophosphamide and trastuzumab prior to surgery [133]. This regimen 
showed a tolerable safety profile and similar pCR (49.2%) to other HER2-targeted 
neo-adjuvant treatment. However, pCR achieved was still below desired the 
significant pCR of 55%.  
 
1.5 HER2-targeted therapy resistance 
 
HER2-targeted therapies have significantly improved clinical outcome for HER2-
positive breast cancer patients; especially in early stage disease. However, de novo 
and acquired resistance to HER2-targeted therapies is a pertinent clinical problem. 
Therefore, there is a need to investigate the mechanisms of HER2-targeted therapy 
resistance. This can be achieved by examining primary tumour samples of HER2-
positive breast cancer patients treated with HER2-targeted therapies or by establishing 
in vitro cell line models of drug resistance. Cell lines are the most commonly used 
models of drug resistance. Cancer cell lines provide a sustainable, indefinite supply of 
highly homogeneous cells that are largely representative of the tumours from which 
they are derived [134]. Nonetheless, there are several limitations to cancer cell lines. 
Cell lines lack the supporting stromal cells, which interacts with the cancer cells and 
can alter response. In addition, most breast cancer cell lines are derived from pleural 
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effusions of metastatic cancers. This limits the representation of the different stages of 
breast cancer [135]. 
 
1.5.1 Trastuzumab resistance 
 
Several mechanisms of resistance have been discovered using both in vitro resistance 
models and patient samples [Reviewed in 132–135]. With inhibition of HER2 by 
trastuzumab, other RTKs can become over-expressed or up-regulated. For example, 
HER3 has been shown to be increased in trastuzumab resistant cells, which causes 
increased HER2-HER3 dimerisation and maintenance of PI3K activation [140]. The 
RTK Met can also be increased in trastuzumab resistance and correlates with poor 
survival in trastuzumab-treated patients [141, 142]. Previous work from our lab 
implicated IGF-1R in trastuzumab resistance [143]. In this study, trastuzumab-
resistant SKBR3 and BT474 cells displayed increased levels of IGF-1R and IGF-1R 
inhibition enhanced trastuzumab response in these cell lines. As trastuzumab response 
is reliant on trastuzumab/HER2 binding, cancer cells can cleave the ECD of HER2 or 
sterically hinder the binding of trastuzumab. HER2 ECD shedding is associated with 
poor response to trastuzumab [144–146]. This can be analysed by examining levels of 
cleaved HER2 ECD in the blood and tumour levels of p95 HER2 [95, 147]. Mucin 4 
(MUC4) can also be increased in trastuzumab-resistant breast cancer to prevent 
efficient binding of trastuzumab to HER2 ECD [144–146].  
 
1.5.2 In vitro models of lapatinib resistance 
 
This study focuses particularly on resistance and response to HER2-targeted tyrosine 
kinase inhibitors. Nine different HER2-positive breast cancer cell lines have been 
used to produce acquired lapatinib resistant cell lines. The majority of cell lines used 
were luminal adenocarcinomas that are HER2-positive and ER/PR-negative. 
Although, two ER-positive cell lines have been used to generate lapatinib-resistant 
cell lines, BT474 and MDA-MB-361 cell lines.  
There are several methods to develop drug resistant cell lines [148]. Lapatinib 
resistant cell lines have been developed through continuous exposure to lapatinib, by 
dose escalation treatments and by single cell cloning techniques (Table 1-3). The 
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published lapatinib resistant cell lines have been produced from a variety of different 
HER2-positive cell lines and the concentrations used, both starting and fixed 
concentrations, vary between studies; lapatinib concentrations used range between 50 
nM and 5 µM. Only two established cell lines were generated using concentrations in 
excess of the steady state concentrations achieved in patients’ blood. Xia and 
colleagues [149] exposed the BT474 cell line to increasing concentrations of lapatinib 
from 250 nM to 5 μM and Liu and colleagues pooled 21 resistant BT474 clones, 
which had been exposed to 1, 3 or 5 μM lapatinib [150]. A number of different 
approaches have been used in the development of the clinically relevant models. Most 
resistant cell lines were exposed to a low dose of lapatinib, which was gradually 
increased. However, both the starting concentration and final maintaining 
concentration vary widely. SKBR3 cells have been exposed to 5 nM lapatinib 
increasing to 250 nM over six months [151], 250 nM increasing to 1 μM over six 
months [152], 100 nM to 1 μM for 3 to 12 months and an escalating lapatinib 
concentration up to 2.6 μM [153]. In our laboratory, a resistant SKBR3 cell line was 
developed using continuous treatment with 250 nM lapatinib for six months [154]. 
The variation in lapatinib concentrations used, length of exposure, and numerous 
parental cell lines used has resulted in the wide variety of lapatinib resistance 
mechanisms discovered. 
 
1.5.3 Mechanisms of lapatinib resistance 
 
Twenty mechanisms of lapatinib resistance have been proposed utilising acquired 
resistance cell line models (Table 1-3). These mechanisms can be largely divided into 
three categories: activation of alternative RTKs, re-activation of downstream 
signalling, and phenotypic switching.  
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Table 1-3: Mechanisms of lapatinib resistance and the methods used to generate lapatinib resistant cell lines. 
Author Parental cell lines Method of resistant cell line development Proposed mechanism of resistance 
Azuma, et al. [155] UACC-812 0.01 μM to 1 μM over 8 months Switching addiction to FGFR2 
Bi, et al. [156] BT474 Continuous exposure to lapatinib up to 2 µM (cell line 
developed in [157]) 
Not stated. Biochemical composition difference 
observed with Raman spectroscopy 
Brady, et al. [158] BT474, UACC-893 2.1 μM lapatinib for >9 months (BT474) or increasing doses 
until reaching 2.1 μM for a total of >5 months (UACC893) Enhanced PI3K p110α signalling 
Chen, et al. [159] BT474-L, AU565-L Continuous 2 µM lapatinib exposure for 12 months Protective autophagy 
Corcoran, et al. 
[151] SKBR3, HCC1954 5 nM to 250 nM over 6 months 
IGF1R stimulates resistance. Increasing miR-
630 reduces resistance 
Formisano, et al. 
[160] MDA-MB-361 Not stated Src mediated EGFR activity 
Huang, et al. [161] BT474 Increasing concentrations 0.1 to 1 μM for 3-12 months β-integrin mediated survival 
Jegg, et al. [153] SKBR3 Increasing lapatinib concentration up to final concentration of 
2.6 μM 
Constitutive activation of mTORC1 in the 
absent of upstream PI3K/AKT signalling 
Komurov, et al. 
[162] SKBR3 Increasing doses of lapatinib over one year Glucose deprivation network alterations 
Lesniak, et al. 
[163] SKBR3 
Selection of mesenchymal colony clusters of SKBR3 and beta-
integrin transfected-SKBR3 Spontaneous EMT 
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Liu, et al. [150] BT474 Continuous exposure to 1, 3 or 5 μM lapatinib. 21 L-resistant 
clones generated and pooled. Activation of AXL 
Ma, et al. [152] SKBR3 Increasing lapatinib concentration from 0.25 μM up to final 
concentration of 1 μM for at least 6 months 
Proteasome alterations. Shows synergy of 
lapatinib and bortezomib 
McDermott, et al. 
[154] 
SKBR3, HCC1954 Continuous exposure to 250 nM lapatinib (SKBR3) and 1 μM 
(HCC1954) Increased PP2A activity 
Puig, et al. [164] AU565 3.5 μM to 7 μM lapatinib over 6 months Fatty acid synthase activity 
Rani, et al. [165] SKBR3 Continuous exposure over 6 months NeuromedinU causes HER2 stability 
Rexer, et al. [157] 
SKBR3, HCC1954, 
BT474, MDA-MB-361, 
UACC-893, 
SUM190PT 
Continuous exposure increasing to 1μM or 2 μM lapatinib Src family kinases maintaining PI3K/AKT 
signalling 
Wang, et al. [166] SKBR3, BT474 Increasing from 0.1 to 1 μM over 3-12 months Role of ER and HER2 reactivation 
Wang, et al. [167] SKBR3 0.05 μM escalating to 2 μM over 12 months RON activation of PI3K/AKT pathway 
Xia, et al. [168] BT474 Pool of single cell clones. Gradual increase from 0.25-5 μM 
over at least 2 months and then maintained in 5 μM lapatinib Switching to ER signalling 
Xia, et al. [169] BT474, SKBR3, 
AU565, SUM190 Generated and maintained in 1 μM lapatinib Heregulin-EGFR-HER3 autocrine signalling 
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1.5.3.1 Activation of alternative RTKs 
 
Although proliferation of HER2-positive breast cancer cells is driven by HER2 
signalling, there are redundant survival mechanisms that can be activated when HER2 
signalling is suppressed. This can occur through up-regulation of other RTKs, 
including other HER family members, or MET, FGFR2 and IGF-1R. 
In one study of four acquired lapatinib resistant cell lines, lapatinib was found to 
inhibit HER2 activity but downstream PI3K signalling persisted despite no changes in 
PTEN levels and a lack of PI3K mutation [169].  This was determined to be mediated 
by switching to EGFR-HER3 dimerisation, which was regulated by increased levels 
of membrane-bound heregulin. Acquisition of HER2 mutations such as T798I, 
L755S, and T733I can prevent effective lapatinib binding, nullifying the growth 
inhibitory effect of lapatinib [170, 171].  
Insulin-like growth factor 1 receptor (IGF-1R) has been associated with several 
cancer types, including lung, colorectal and breast [172, 173]. IGF-1R is regulated by 
miR-630 and increased miR-630 results in degradation of IGF-1R [174]. Corcoran et 
al. investigated the role that miR-630 may have in lapatinib response and resistance. 
The introduction of miR-630 into acquired lapatinib resistant SKBR3 and HCC1954 
cells resulted in restored lapatinib sensitivity. Likewise, inhibition of miR-630 in 
sensitive cell lines resulted in reduced sensitivity to HER2-targeted TKIs. The main 
mechanism of action of miR-630-mediated lapatinib insensitivity proposed is through 
regulating the expression of IGF-1R [151]. 
MET-related RTKs have been implicated in lapatinib resistance. A lapatinib resistant 
cell line was developed by escalating SKBR3 exposure to lapatinib (0.05 to 2 µM) 
over a 12-month period. This cell line utilised Recepteur d’Origine Nantais (RON), a 
member of the MET proto-oncogene family. This RON activation sustained PI3K 
signalling even with HER2 inhibition. RON inhibition with siRNA and the RON-
selective inhibitor RON I reversed lapatinib resistance [167]. A BT474-L cell line 
exploited AXL to overcome lapatinib treatment. AXL activation results in stimulation 
of the PI3K signalling pathway and thereby induces cell survival, proliferation, 
migration and differentiation [175]. Overexpression of AXL has been associated with 
poor prognosis in breast, gastric, ovarian, glioma and lung cancer. The lapatinib 
resistant cell line maintained Akt activation despite decreased EGFR and HER2 
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levels. Inhibition of AXL with foretinib, a small molecule TKI inhibitor of AXL, 
MET and VEGFR, restored sensitivity to lapatinib. Lapatinib plus foretinib is 
currently undergoing clinical investigation. The combination was demonstrated to be 
safe in a phase Ib trial. The combination showed little efficacy which  could be due to 
low levels of MET in the cohort [176]. 
Fibroblast growth factor receptor 2 (FGFR2) has also been implicated in lapatinib 
resistance [155]. FGFR2 is one of four members of the FGFR RTK family. Like 
HER2, FGFR2 dimerisation leads to autophosphorylation and activation of the PI3K 
and MAPK pathways. FGFR2 overexpression has been observed in breast and gastric 
cancer [177]. UACC812 cells were treated with 0.01 – 1 µM lapatinib over 8 months 
until lapatinib resistance emerged. This cell line had FGFR2 amplification and over-
expression and was highly sensitive to an FGFR2 inhibitor. The reliance on FGFR2 in 
lapatinib resistant breast cancer was also examined in tumour samples, which showed 
a correlation between poor survival outcome and FGFR2 levels [155]. FGFR1 and 
FGF3 amplification have also been correlated with poor response to HER2-targeted 
therapies. In a xenograft BT474 cell line model of acquired lapatinib and trastuzumab 
resistance, FGF3, 4 and 9 genes were amplified, which conferred increased FGFR 
phosphorylation and reduced lapatinib uptake. These resistant tumours were 
sensitised to FGFR inhibition [178]. 
 
1.5.3.2 Re-establishment of downstream signalling 
 
HER2 signalling results in the activation of the PI3K pathway, which is inhibited by 
HER2-targeted therapies. Hyperactivity of PI3K may be due to mutation of the 
catalytic subunit 110α [179], loss of PTEN [180] or INPP4B, mutation of AKT1 
[181] or amplification of AKT2 [182]. This increase in PI3K activity is found in 
approximately 25-30% of all breast cancers [179]. Although HER2-targeted therapies 
should inhibit PI3K signalling, its activation or re-activation is associated with 
resistance to trastuzumab and lapatinib [40, 153, 158, 183, 184], though, there is 
evidence of lapatinib sensitivity in some cell lines with PI3K mutations [184]. Four 
different mechanisms of resistance have been found that utilise activation of the PI3K 
signalling pathway [153, 157, 158, 183]. Six HER2-positive cell lines with acquired 
lapatinib resistance have maintained PI3K signalling, despite suppression of HER2 
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activation, indirectly through Src family kinases [157]. The up-regulation of Src 
family kinases was identified using global phospho-tyrosine profiling. The inhibition 
of the Src family kinases using sarcatinib and dasatinib repressed growth and 
PI3K/AKT signalling and the combination of sarcatinib with lapatinib was synergistic 
in xenografts. Significantly, Src family kinase expression was increased in patient 
tumours after lapatinib treatment [157]. Src was also implicated in another study 
involving an acquired lapatinib resistant MDA-MB-361 model and innately lapatinib 
resistant cell lines such as JIMT-1. The combination of lapatinib and the Src inhibitor 
saracatinib significantly decreased HER2 signalling and Akt and ERK activation 
compared to either single agent [160].  
PI3K inhibition with copanlisib restored sensitivity to both lapatinib and trastuzumab 
in acquired resistant cell line models. These cell lines included SKBR3-L, SKBR3-
TL, and HCC1954-L cell lines. Copanlisib plus lapatinib was also synergistic in 
lapatinib resistant cells and trastuzumab resistant cell lines [185]. 
Insulin receptor substrate 4 (IRS4) is another indirect cytoplasmic activator of PI3K 
signalling associated with HER2-targeted therapy resistance. IRS4 was found to be 
associated with innate and acquired trastuzumab and lapatinib resistance by causing 
hyper-activation of the PI3K pathway, independent of HER2 [186]. 
Lapatinib-resistant BT474 cells were found to have reactivated PI3K signalling 
through up-regulation of PI3K p110α mutants and possibly through the acquisition of 
secondary mutations such as a p100α E542K-activating mutation. An increase in 
p110α H1047R was also found in a lapatinib resistant UACC-893 cell line. PI3K 
inhibition with BYL719, a p100α-selective inhibitor, overcame lapatinib resistance in 
vitro and, in combination with lapatinib, in vivo [158]. 
HER2 signalling reactivation can also occur due to HER2 mutation. The HER2L744S 
mutation occurred in BT474 cells with acquired resistance to lapatinib, to 
trastuzumab, and to trastuzumab plus lapatinib. When this mutation was simulated in 
trastuzumab- and lapatinib-sensitive cell lines, sensitivity to both HER2-targeted 
agents was reduced [170]. 
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1.5.3.3 ER signalling 
 
Phenotypic switching of dependency on HER2 and ER is often observed in the clinic, 
especially after HER2-targeted therapy or anti-oestrogen treatment [187]. Lapatinib 
resistance has been shown to up-regulate ER expression in a lapatinib resistant model 
of the triple-positive cell line BT474. This was mediated by increased activity of 
FOXO3a. This increased FOXO3a activity was observed in patients tumour samples 
following treatment with lapatinib [168].  
 
1.5.3.4 Epithelial-mesenchymal transition 
 
Cancer cells treated with anti-neoplastic drugs can undergo adaptive changes such as 
epithelial-mesenchymal transition (EMT). EMT results in a stem cell-like phenotype 
that is more resistant to conventional anti-cancer therapy [188]. Random isolation and 
expansion of SKBR3 colony clusters resulted in spontaneous EMT. The resulting 
cells expressed EMT markers and had decreased HER2 expression. These 
basal/mesenchymal cells were resistant to both trastuzumab and lapatinib. This 
mesenchymal lapatinib-resistant SKBR3 cell line had high expression of N-
glycosylated β1-integrin, which is involved with EMT induction and has previously 
been associated with breast cancer, and inhibition of β1-integrin, with the anti-integrin 
inhibitory antibody AIIB2, restored the epithelial phenotype [163]. β1-integrin has 
been implicated in lapatinib resistance in BT474 and HCC1954 lapatinib resistant cell 
lines. These lapatinib resistant cell lines were highly sensitive to AIIB2 [161]. 
Another EMT marker, SLUG/SNAIL2, has been implicated in trastuzumab 
resistance. Knockdown of SLUG in JIMT-1, a cell line from a trastuzumab-refractory 
HER2-positive breast cancer patient that is also resistant to lapatinib, resulted in 
increased trastuzumab sensitivity [189]. 
 
1.5.3.5 Protective autophagy 
 
One of the proposed mechanisms of action of lapatinib as an anti-cancer therapy is 
induction of autophagy [87]. Interestingly, two lapatinib resistant HER2-positive 
breast cancer cell lines, BT474-L and AU565-L, displayed increased levels of 
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autophagosome formation compared to their parental cell lines. Inhibition of 
autophagy with lapatinib treatment resulted in reduced cell proliferation and an 
induction of apoptosis [159]. 
 
1.5.3.6 Protein phosphatase 2A activity 
 
The functioning of approximately a third of all cellular proteins is governed by 
phosphorylation, controlling key cellular activities such as cell cycle regulation, 
proliferation and apoptosis. Phosphatases play a key role in this process by regulating 
de-phosphorylation. The serine/threonine phosphatase protein phosphatase 2A 
(PP2A) is involved in the modulation of several survival and proliferation pathways, 
such as Akt, MAPK and Wnt pathways [190–192]. Our research group found that 
PP2A activity was significantly increased in two lapatinib resistant cell lines [154]. 
Phosphorylation of PP2A has been correlated to HER2 signalling, which results in 
inactivation of PP2A. Heregulin-induced BT474 cells had increased phosphorylated 
PP2A and, upon treatment with AG825, a HER2 inhibitor, the level of PP2A 
phosphorylation was reduced, resulting in increased activity [193]. Potentially, PP2A 
could be a therapeutic target in the clinical setting as LB-100, a PP2A inhibitor, is 
currently in phase I/II clinical trials [194–196]. In contrast, the endogenous PP2A 
inhibitor protein CIP2A has been shown to be elevated in lapatinib resistant breast 
cancer cells [197]. This illustrates that the role of PP2A in lapatinib response and 
resistance is complex and is context dependent. 
 
1.5.4 Mechanisms of afatinib resistance 
 
Afatinib is currently in phase III clinical trials in HER2-positive breast cancer but is 
FDA approved for the treatment of NCSLC. Resistance to afatinib has not yet been 
examined in HER2-positive breast cancer. However, several mechanisms of 
resistance have been proposed in lung cancer. 
In one study, three afatinib resistant variants of the lung cancer cell line PC-9 were 
developed and showed three independent mechanisms of resistance to afatinib. All 
three resistant cell lines had increased expression of EGFR compared to untreated 
cells. In one resistant cell line, wild-type KRAS was amplified and over-expressed. 
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Interestingly, withdrawal of afatinib treatment resulted in a loss of KRAS 
amplification and the cells were re-sensitised to afatinib. Another resistant variant 
switched its survival signalling to the IGF1R pathway to overcome the effect of 
afatinib. Finally, the third variant had gained a secondary EGFR mutation, EGFR 
T790M [198]. This mutation has been previously associated with afatinib resistance 
in lung cancer; 47.6% of tumour samples from afatinib-resistant lung cancers had 
acquired a T790M mutation [199]. Other studies have shown no survival differences 
between patients with tumours harbouring T790M mutations and those without [200]. 
Other mutations can confer reduced sensitivity to afatinib. The combination of EGFR 
L858R and V8431 mutations alter the protein conformation of EGFR, thereby 
reducing the binding potential of afatinib [201]. 
Kinases downstream of EGFR and HER2 have also been associated with afatinib 
resistance. Up-regulation of mTORC activity has previously been associated with 
trastuzumab and lapatinib resistance [153, 202]. In a xenograft model of acquired 
resistance to afatinib and the EGFR monoclonal antibody cetuximab, mTORC activity 
was found to be increased due to loss of the genes TSC1 and NSF2. This afatinib plus 
cetuximab resistant model was generated by implanting PC9 lung cancer cells with 
EGFR mutations in immunocompromised mice and treating for one month, followed 
by a one-month drug holiday, for three cycles [203].  
Src has also been implicated in afatinib resistance. An afatinib resistant model was 
generated by treating the lung cancer cell line H1975 with afatinib in vivo. The 
resulting afatinib resistant tumours had no additional mutations but had elevated Src 
phosphorylation and increased MET, KIT and PDGRβ levels. Combining afatinib 
with dasatinib overcame resistance to afatinib by enhancing autophagy. The 
combination of Src inhibition and afatinib was more effective than afatinib plus the 
multi-kinase inhibitor sunitinib, the ALK/ROS1 inhibitor crizotinib, or the c-Kit, 
PDGFRα and Flt3 inhibitor amuvatinib [204]. The combination of afatinib and 
dasatinib has also been demonstrated to be tolerable in a phase I clinical trial in 
EGFR-mutant NSCLC [205]. No significant interaction was observed between the 
drugs and the MTD for the combination was deemed to be 30 mg afatinib with 100 
mg dasatinib. 
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1.5.5 Mechanisms of neratinib resistance 
 
Neratinib has been approved for the treatment of early-stage HER2-positive breast 
cancer after at least one year of trastuzumab treatment [39]. However, resistance has 
been observed in the clinic and with acquired resistance cell line models. 
The innately trastuzumab resistant cell line HCC1954 and the trastuzumab-sensitive 
SKBR3 and EFM192A cell lines were used to generate neratinib resistant models. In 
this study, the neratinib resistant cell lines were cross-resistant to other HER2-
targeted therapies and more aggressive than their parental cell lines. These cell lines 
had decreased expression of HER family members and increased CYP3A4 levels, a 
cytochrome P450 enzyme. It was hypothesised that this increased CYP3A4 activity 
increases metabolism of neratinib [206]. 
Neratinib is currently being investigated in non-amplified HER2-mutant breast cancer 
and has been shown to actively inhibit common occurring HER2 mutations in vitro 
[111, 207]. However, a HER2 mutation has also been shown to cause neratinib 
resistance. A patient with HER2 L869R mutant breast cancer initially responded to 
neratinib, until the emergence of a secondary HER2 mutation, HER2T798I. This 
mutation caused a conformational change which sterically hindered neratinib binding. 
Interestingly, this HER2 L869R/T798I-mutant breast cancer still responded to afatinib 
[208].  
 
1.6 Proteins of interest 
 
As PP2A and Src are investigated in detail in this study, the role of both proteins in 
cancer and their therapeutic potential are described below. 
 
1.6.1 The role of Src in cancer 
 
The proto-oncogene Src has been implicated in several cancer types, such as 
leukaemia, breast, pancreatic, lung and skin cancers [209–211]. Src is one of ten 
members of the Src family of non-receptor tyrosine kinases (SFKs). Each SFK 
member is composed of a N-terminal Src homology 4 (SH4) domain, an SH3 domain, 
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an SH2 domain, a linker sequence, tyrosine kinase domain, and the C-terminal tail. 
SFKs contain a tyrosine 416 residue that, once phosphorylated, activates the kinase 
and a tyrosine 527 reside that deactivates the protein when phosphorylated [212]. 
SFKs can be divided into three families. Src family A consists of Src, Yes, Fyn, and 
FGR, and are ubiquitous in all tissues. Src family B is made up of Lck, Hck, Blk, and 
Lyn.  Frk, Fyn-related kinase, is its own subfamily.  
 
Src has demonstrated a role in hormone-receptor-positive, HER2-positive, and triple 
negative breast cancers. In vitro testing of a Src inhibitor, dasatinib, showed triple 
negative breast cancer cell lines were most sensitive to Src inhibition [213]. 
Src/EGFR signalling can up-regulate β4-integrin-FAK interaction in triple-negative 
breast cancer. This increases the metastatic potential of the cell line tested [214]. In 
estrogen-receptor positive disease, Src activation was observed in tamoxifen 
resistance [215, 216]. In HER2-positive breast cancer, Src inhibition reduced 
mammary tumour development in vivo by inhibiting ERK 1/2 signalling, c-Myc 
translation and reducing glucose metabolism [216]. Src activation is also associated 
with brain metastasis, which is more common in HER2-positive breast cancer. In vivo 
Src inhibition with saracatinib in combination with lapatinib prevented brain 
metastasis growth and caused cancer cell cycle arrest [217]. This combination 
inhibited both AKT and ERK signalling in SKBR3-L cells and restored lapatinib 
sensitivity [218]. 
 
1.6.1.1 Src inhibitors in cancer 
 
Dasatinib (Sprycel, Bristol-Myers Squibb) is a multi-kinase inhibitor, which targets 
SFK, BCR-Abl, C-Kit, PDGFR, and ephrin-A, and most potently inhibits Src kinase 
with an IC50 value of 3 nM [219]. Dasatinib was FDA approved for the treatment of 
chronic myeloid leukaemia and philadelipha-positive acute lymphocytic leukaemia 
[220]. It has also been shown to have preclinical activity against several solid tumour 
types [213, 219]. However, dasatinib failed to show single-agent efficacy in the 
clinical setting [221–223]. Therefore, clinical investigation of dasatinib has now 
focused on combinations of dasatinib with chemotherapy or other targeted therapies. 
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There are two trials of dasatinib in combination with HER family-targeted therapies 
currently underway. The safety of dasatinib in combination with trastuzumab plus 
paclitaxel is underway in HER2-positive metastatic breast cancer (NCT01306942). 
The safety of dasatinib plus lapatinib is being investigated in patients with solid 
tumours that cannot be removed by surgery (NCT01306942). In addition, a phase I 
trial of dasatinib plus afatinib showed that the combination was well tolerated, as 
discussed in Section 1.5.4. 
 
1.6.2 PP2A 
 
Protein phosphorylation allows cells to rapidly respond to external stimuli and is 
tightly regulated by a balance of kinases and phosphatases. PP2A is a ubiquitously 
expressed serine/threonine phosphatase that is responsible for up to 90% of serine and 
threonine dephosphorylation. PP2A regulates a myriad of cellular processes including 
cell cycle progression, migration, metabolism and proliferation. PP2A is a complex 
heterotrimeric holoenzyme composed of three subunits (Figure 1-6). The structural 
(A) subunit, which acts as a scaffold for the other subunits, exists in two isoforms 
(PPP2R1A and PPP2R1B). Approximately 90% of PP2A holoenzymes contain the 
PPP2R1A isoform and knockdown of this subunit cannot be substituted by the 
PPP2R1B isoform. Likewise, the catalytic (C) subunit also exists in two isoforms 
(PPP2CA and PPP2CB). The C subunit carries out the phosphatase activity of the 
holoenzyme. Although dimerisation of the A and C subunits can stably occur, the 
regulatory (B) subunit is required for substrate specificity and cellular localisation of 
the holoenzyme. There are at least 26 regulatory subunit isoforms that can form the 
PP2A holoenzyme, which includes splice variants and alternate transcripts of 15 
different genes. The regulatory subunits can be divided into four subfamilies: the B, 
B’, B’’, and B’’’ families. The array of regulatory subunits allows for both substrate 
specificity and functional diversity. For example, PP2A-B55 holoenzyme can interact 
with Akt, RAF, Rb, p53 and Src. With two isoforms each for structural and catalytic 
subunits and 26 regulatory subunits, there are 96 possible combinations of PP2A 
composition. Therefore, PP2A composition differs between cell types and can 
respond rapidly to cell stress.  
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Figure 1-6: PP2A holoenzyme composition and subunit isoforms (adapted from 
[224]). 
 
1.6.2.1 PP2A as a tumour suppressor 
 
Knockdown of PPP2CA causes embryonic lethality and infertility in adults. 
Interestingly, PPP2CB knockdown does not cause an abnormal phenotype and these 
knockdown mice remain fertile [225]. PP2A is a vital negative regulator of several 
cellular growth pathways. PP2A dephosphorylates JAK3 and STAT5, which have a 
role in angiogenesis, cancer cell survival and immunosuppression [226, 227]. PP2A 
also deactivates the MAPK signalling molecules ERK2 and MEK 1/2 [228], and 
dephosphorylates c-Myc, which destabilises the protein for proteasomal degradation 
[229]. This indicates that some PP2A holoenzymes are tumour suppressors. In fact, 
some oncogenic viruses generate viral proteins that inhibit PP2A activity. One 
mechanism of PP2A suppression by viruses, including the simian virus small t and 
polyoma middle T virus, is by direct interaction with the core dimer and disruption of 
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regulatory subunit binding. This interaction then allows for the activation of survival 
pathways such as the MAPK and AKT pathways. 
Cancerous inhibitor of PP2A (CIP2A) is a negative regulator of PP2A and has been 
shown to decrease PP2A activity, promoting c-Myc stabilisation. CIP2A expression 
has been shown to be over-expressed and associated with poor survival in a number 
of cancers [230, 231]. An array of PP2A inhibitor proteins are over-expressed and 
correlates with poor outcome in acute myeloid leukaemia, including SET, CIP2A and 
SETBP1 [232].  
 
1.6.2.2 PP2A as an oncogene 
 
As discussed, PP2A regulates several signalling pathways, including PI3K/AKT 
signalling and Wnt/β-catenin pathway. PP2A complexes with APC, GSKα and 
dishevelled (Dsh), which then targets β-catenin for degradation. PP2A can also 
stimulate Wnt signalling. In a colon cancer cell line model, aspirin caused 
phosphorylation of the PP2A catalytic subunit, deactivating the phosphatase. This led 
to suppression of Wnt signalling. Moreover, PP2A inhibition was vital for the Wnt 
signalling inhibition effect of aspirin and indicates that inhibition of PP2A is a 
mediator of the cancer preventative properties of aspirin [233]. 
As well as having a pro-apoptotic function, PP2A can also act as an anti-apoptosis 
enzyme. This anti-apoptotic activity occurs through regulation of p53 and Bcl-2 [234, 
235]. PP2A inhibition can aid in the induction of apoptosis by regulating p53 in two 
ways: increased p53 S15 phosphorylation can decrease p53 levels, block cell cycle 
arrest and thereby improve chemotherapy response, or paradoxically, PP2A inhibition 
can activate over-expressed p53 and induce up-regulation of the pro-apoptotic Bax 
and p21 causing cell cycle arrest [236].  
 
1.6.2.3 Targeting PP2A in cancer 
 
There are several naturally occurring and synthetic compounds that alter PP2A 
activity, either directly or indirectly (Figure 1-7). Inhibitors of PP2A include okadaic 
acid, fostricien, cantharidin, and LB-100.  
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Figure 1-7: PP2A inhibitory molecules that have been used in in vitro testing 
(Structures adapted from PubChem; CID numbers: okadaic acid = 446512, 
fostriecin = 6913994, cantharadin = 5944, and LB-100 = 3578572, [84]) 
 
1.6.2.3.1 Okadaic acid 
 
Okadaic acid (OA) is a toxin produced by dinoflagellates and is used as a defence 
mechanism by molluscs. It is a potent phosphatase inhibitor with selectivity for PP2A 
and PP1 (IC50 = 0.1 – 1 nM and 3 – 15 nM, respectively).  OA was the first classified 
PP2A inhibitor [237]. It has been used in in vitro and in vivo testing to examine the 
role of PP2A. OA has been used to demonstrate the dual role of PP2A as a tumour 
suppressor and oncogene. Treatment of OA was shown to inhibit apoptosis induction 
by radiation in leukemia cells and also induce apoptosis, necrosis, cell cycle arrest and 
DNA damage in other cancer cell lines [238, 239].  
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1.6.2.3.2 Fostriecin 
 
Fostriecin is a highly specific PP2A inhibitor (IC50 = 3.2 nM, PP1 IC50 = 131 µM) 
[240]. It is an antibiotic molecule, first isolated from Streptomyces pulveraceus [241]. 
Originally, fostriecin was classified as a topoisomerase II inhibitor, by mechanisms 
independent of anthracyclines such as doxorubicin. However, its complete 
topoisomerase II inhibitory effect occurs at high concentrations (100 µM) [242].  It is 
a phosphate monoester that binds covalently to Cys269 of the PP2A catalytic subunit 
[243]. Fostriecin has shown anti-cancer activity in several cancer types including 
leukemia and ovarian, breast, and lung cancers [244, 245]. A phase I clinical trial was 
initiated with fostriecin as a single agent. Of the 46 patients in the trial, 16 achieved 
stable disease with a median response time of 2.6 months [246]. An MTD could not 
be reached in this trial due to problems with fostriecin supply. Novel synthesis 
methods have been developed, which may lead to further clinical investigation of 
fostriecin [247, 248]. 
 
1.6.2.3.3 Cantharidin 
 
Cantharidin is another PP2A inhibitor that is a naturally found toxin, derived from 
blister beetles, and has been used in traditional Chinese medicine. Cantharidin is 10-
fold more specific to PP2A than PP1 [249]. Cantharidin induced apoptosis and DNA 
damage in leukaemia cells [250]. Some cantharidin-induced cell death seems to be 
p53-dependent and can be affected by Bcl-2 levels [251]. However, p53-independent 
cell death has also been observed in cantharidin-treated cells [252]. Cantharidin 
stimulated G1 cell cycle arrest and inhibited cell migration in the triple negative 
breast cancer cell line, MDA-MB-231 [253]. It has also shown apoptotic activity in 
oral squamous cell carcinoma cell lines as a single agent. Cantharidin caused 
increased activation of pro-Bcl-2 family member proteins and induced endoplasmic 
reticulum stress [254]. Efficacy of cantharidin was seen in pancreatic cancer [255]. 
Cantharidin inhibits the invasive behaviour of pancreatic cells by down-regulating 
matrix metalloproteinase 2, MMP2. Interestingly, the anti-cancer effect of 
cantharidin, and its de-methylated derivative noracantharidin, was enhanced in 
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pancreatic cancer cells with the addition of tamoxifen [256]. This effect was found to 
be independent of ER levels and mediated through PKC inhibition. 
Cantharidin has not been tested clinically as an anti-cancer agent, but it has been 
evaluated in a phase I clinical trial for pediatric molluscum contagiosum, a viral 
dermatalogical condition. Although it showed no effect against this disease, its topical 
application had minimal side effects [257]. 
 
1.6.2.3.4 LB-100 
 
LB-100 is a synthetic cantharidin derivative that does not exhibit the toxicities 
associated with cantharidin. LB-100 has shown in vitro and in vivo efficacy against 
hepatocellular carcinoma, glioblastoma, breast, pancreatic and ovarian cancers [258–
264]. It has demonstrated single agent activity as well as enhancing the cytotoxic 
effects of chemotherapy and radiotherapy in vitro and in vivo. The radiation-
enhancing effect was observed in glioblastoma, nasopharyngeal carcinoma, and 
pancreatic cancer cell lines [262–264]. The addition of LB-100 induced mitotic 
catastrophe and increased DNA damage. LB-100 can enhance the cytotoxicity of 
chemotherapy through a number of mechanisms. In hepatocellular carcinoma, LB-100 
increased tumour levels of doxorubicin and cisplatin tumour accumulation and 
increased vascularity of in vivo tumours [265]. LB-100 also improved cisplatin 
response in ovarian cancer and medulloblastoma in cell lines [258, 260]. The 
combination of cisplatin and LB-100 induced apoptosis, inhibited migration, and 
increased cisplatin uptake. The enhancement of doxorubicin was also observed in 
pancreatic cancer. Interestingly, the increase in doxorubicin efficacy with LB-100 was 
found in vivo, but not in vitro. This was reported to be due to elevated vascular 
permeability in vivo [265]. There is also evidence of LB-100 improving response to 
targeted therapies. LB-100 enhanced sorafenib induced apoptosis in hepatocellular 
carcinoma cell lines [266]. LB-100 treatment increased levels of phospho-Smad3 and 
down-regulated Bcl-2 levels. This enhancement was hypoxia-dependent, as hypoxia 
elevated p38 MAPK activity, which further increases phospho-Smad3 levels. The 
combination effect of LB-100 was also observed in gefitinib-resistant EGFR-mutant 
NSCLC. LB-100 and gefitinib were synergistic in vitro and in vivo [267]. With this 
pre-clinical evidence, LB-100 was tested for tolerability and preliminary efficacy in 
 46 
patients with solid tumours [268]. LB-100 was given by intra-veneous injection for 
three days in 21-day cycles. Twenty-nine patients were treated in this trial, with 20 of 
these patients evaluable for tumour response. Half of all patients achieved stable 
disease. Dose limiting toxicity was determined to be related to elevated serum 
creatinine, anemia, dyspnea, hyponatremia, and lymhopenia. The recommended phase 
II dosage was deemed to be 2.33 mg/m2.  
 
1.7 Summary 
 
There are now several HER2-targeted therapies approved for the treatment of HER2-
positive breast cancer. However, despite the clinical success of these therapies, de 
novo and acquired resistance is a significant challenge. Therefore, novel treatment 
options are essential. In this study, cell lines with acquired resistance to HER2-
targeted therapies were examined for sensitivity to other HER2-targeted therapies and 
novel treatment strategies were tested. PP2A was previously identified as a potential 
target to overcome lapatinib resistance [154]. This study further investigated its role 
in HER2-targeted therapy response. In addition, resistance to the irreversible pan-
HER TKIs and the role of Src kinase were examined. 
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1.8 Study aims 
 
The main objectives of this study were: 
 
x To determine if lapatinib-resistant HER2-positive breast cancer cell lines are 
cross-resistant to other HER2-targeted therapies. 
x To evaluate PP2A inhibition in cell line models of resistance to HER2-
targeted therapies, by examining the activity and mechanisms of action of 
PP2A inhibitors. 
x To test the potential of the PP2A inhibitor LB-100 in vitro and in vivo against 
lapatinib resistant cells.  
x To examine the potential of PP2A inhibition in a panel of HER2-positive 
breast cancer cell lines representing cell lines that are innately sensitive or 
resistant to lapatinib and/or trastuzumab. 
x To evaluate the relationship between PP2A expression and sensitivity to 
HER2-targeted therapies. 
x To investigate mechanisms of resistance to afatinib and neratinib in HER2-
positive breast cancer and to identify novel targets to overcome resistance.  
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2 Methods
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2.1 Cell lines and reagents 
 
Seventeen HER2-positive cell lines were used in this project, ten established HER2-
positive cell lines and seven HER2-targeted therapy resistant human breast cancer cell 
lines. This includes two lapatinib resistant cell lines (SKBR3-L and HCC1954-L) 
three trastuzumab resistant cell lines (SKBR3-T, BT474-T, EFM192A-T), a neratinib 
resistant cell line (HCC1954-N), an afatinib resistant cell line (SKBR3-A), and their 
respective parental cell lines. The cell lines EFM192A, HCC1419, HCC1569, 
HCC1954, JIMT-1, MDA-MB-453, SKBR3, and UACC-732 were cultured in 
Roswell Park Memorial Institute-1640 medium (RPMI-1640) (Sigma Aldrich) 
supplemented with 10% foetal bovine serum (FBS) (Gibco). MDA-MB-361 were 
cultured in Leibovitz’s L-15 medium (ATCC) supplemented with 10% FBS and L-
glutamine (Table 2-1). Dr. Brigid Browne (NICB) established the SKBR3-L cell line 
by continuous culturing of SKBR3 cells in RPMI-1640 supplemented with 250 nM 
lapatinib over six months [154]. Dr. Martina McDermott (NICB) generated the 
HCC1954-L cell line by six months continuous culturing in 1 μM lapatinib [148]. Dr. 
Alexandra Canonici (NICB) generated the afatinib resistant SKBR3 cells by 
continuous culture with 150 nM afatinib (Boehringer Ingelheim). Dr. Susan Breslin 
(TCD) produced the HCC1954-N cell line by continuous exposure of 250 nM 
neratinib (Sequoia) [206]. The SKBR3-T cell line was created by Dr. Brigid Browne 
(NICB) and the EFM192A-T and BT474-T cell lines were generated in the lab of Dr. 
Dennis Slamon (UCLA). All cell culture procedures were performed as per the 
guidelines set out in NICB standards of practice (SOP) [#001-01, #002-01 and #003-
01]. All compounds used in this study and their storage conditions are listed in Table 
2-3. 
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Table 2-1: The cell lines used in this project and the culture conditions required. 
Cell line Culture medium Culture conditions 
BT474 RPMI-1640 + 10% FBS  37ºC, 5% CO2 
EFM192A RPMI-1640 + 10% FBS 37ºC, 5% CO2 
HCC1419 RPMI-1640 + 10% FBS 37ºC, 5% CO2 
HCC1569 RPMI-1640 + 10% FBS 37ºC, 5% CO2 
HCC1954 RPMI-1640 + 10% FBS 37ºC, 5% CO2 
JIMT-1 RPMI-1640 + 10% FBS 37ºC, 5% CO2 
MDA-MB-361 Leibovitz's L-15 medium + 10% FBS 37ºC, no CO2 
MDA-MB-453 RPMI-1640 + 10% FBS 37ºC, 5% CO2 
SKBR3 RPMI-1640 + 10% FBS 37ºC, 5% CO2 
UACC-732 MEM + 15% FBS 37ºC, 5% CO2 
HCC1954-L RPMI-1640 + 10% FBS 37ºC, 5% CO2 
SKBR3-L RPMI-1640 + 10% FBS 37ºC, 5% CO2 
HCC1954-N RPMI-1640 + 10% FBS 37ºC, 5% CO2 
SKBR3-A RPMI-1640 + 10% FBS 37ºC, 5% CO2 
BT474-A RPMI-1640 + 10% FBS 37ºC, 5% CO2 
SKBR3-T RPMI-1640 + 10% FBS 37ºC, 5% CO2 
BT474-T RPMI-1640 + 10% FBS 37ºC, 5% CO2 
EFM192A-T RPMI-1640 + 10% FBS 37ºC, 5% CO2 
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Table 2-2: Description of HER2-targeted therapy resistant cell lines used in this 
study. 
Cell line Method of resistant cell line generation Reference 
SKBR3-L Continuous exposure to 250 nM lapatinib 
for 6 months 
[154] 
HCC1954-L Continuous exposure to 1 μM lapatinib for 6 
months 
[148] 
SKBR3-T Continuous exposure to 10 µg/mL 
trastuzumab for 6 months 
[269] 
BT474-T Continuous exposure to 100 µg/mL 
trastuzumab for 6 months 
[88] 
EFM192A-T Continuous exposure to  100 µg/mL 
trastuzumab for 6 months 
 
SKBR3-A Continuous exposure to 150 nM afatinib for 
6 months 
[123] 
HCC1954-N Continuous exposure to 250 nM neratinib 
for 6 months 
[206] 
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Table 2-3: List of compounds used in this study, stock concentrations and long- 
(> 3months) and short-term storage conditions. 
Compound Supplier Stock 
concentration 
Long-term 
storage (> 
3 months) 
Short-term 
storage 
Lapatinib Sequioa Research 
Products 
10 mM in 
DMSO 
−20 ºC Room 
temperature 
Afatinib Sequioa Research 
Products 
10 mM in 
DMSO 
−20 ºC Room 
temperature 
Neratinib Sequioa Research 
Products 
10 mM in 
DMSO 
−20 ºC Room 
temperature 
Trastuzumab St. Vincent’s 
University 
Hospital 
21 mg/mL 4 ºC 4 ºC 
Pertuzumab St. Vincent’s 
University 
Hospital 
30 mg/mL 4 ºC 4 ºC 
Okadaic acid Cell Signalling 
Technologies 
1 mM in 
DMSO 
−20 ºC −20 ºC 
LB-100 Sequoia Research 
Products 
50 mM in PBS −80 ºC −80 ºC 
Dasatinib Sequioa Research 
Products 
10 mM in 
DMSO 
−20 ºC Room 
temperature 
FTY720 Cell Signalling 
Technologies 
10 mM in 
DMSO 
−20 ºC −20 ºC 
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2.3 Mycoplasma testing 
 
All cell lines were routinely tested for mycoplasma as follows. Cell culture 
supernatant was collected for each cell line, a minimum of three passages after 
thawing and 72 hours (h) post media change. For cell lines cultured in the presence of 
drug, cells were grown for at least one week without drug. The presence of 
mycoplasma was tested by two methods: fluorescent microscopy, and MycoAlert 
mycoplasma detection kit. 
The supernatant was added to normal rat kidney epithelial cells (NRKs) that were 
cultured on glass coverslips to 70% confluence in technical duplicates. The 
supernatant and NRKs were incubated for four days at 37ºC with 5% CO2. 
Supernatant and NRK medium was removed and NRKs were fixed in Carnoy’s 
Fixative (1:2 glacial acetic acid: methanol) for 20 minutes (mins) on ice and allowed 
to air dry. After fixation, NRKs were stained with Hoechst 33258 (Sigma) for 10 
mins. Each coverslip was washed twice with ultra high purity water and read on a 
fluorescent microscope at an excitation wavelength of 400 nm.  
Alternatively, conditioned medium was tested for the presence of mycoplasma using 
the MycoAlert kit (Lonza). Briefly, 100 µL of conditioned medium was added to a 
white 96-well plate.  100 µL of MycoAlert reagent was added to the medium and 
incubated at room temperature for 5 mins. Luminescence was determined on a plate 
reader (Biotech). 100 µL of MycoAlert substrate was added and the plate was 
incubated for a further 10 mins. Luminescence was measured again. Mycoplasma 
presence was determined by calculating the ratio of reading two to reading one (Table 
2-4).  
 
Table 2-4: Interpretation of luminescence ratio for the presence of mycoplasma 
using MycoAlert kit. 
Ratio Interpretation 
< 1 Mycoplasma negative 
1 – 1.2 Borderline 
> 1.2 Mycoplasma positive 
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2.4  Immunoblotting 
 
Cells were seeded in 100 mm petri dishes or 6 well plates and grown to 70% 
confluency. Cells were washed three times with phosphate buffer saline (PBS) and 
300 μl/dish or 150 μl/well RIPA buffer ((Sigma) 5 mM Tris-HCl pH 7.4, 1% NP-40, 
0.1% SDS, 150 mM NaCl, 1% Triton x-100) containing 1X Protease Inhibitor 
cocktail (Calbiochem), 2 mM PMSF (Sigma), and 1 mM sodium orthovanadate 
(Sigma) was added and cells were incubated on ice for 20 mins. Cells were scraped 
and lysis buffer was collected. Lysates were sheared with a 21 gauge needle and 
centrifuged at 10,000 rpm for 10 mins at 4ºC. Supernatant was collected and stored at 
-80°C. Protein quantification was carried out using a bicinchoninic acid (BCA) 
quantification kit (Pierce).  
Thirty μg of protein was electrophoretically resolved on 4-12% Bis-Tris 
polyacrylamide gels (Life Technologies). The proteins were transferred to a 
nitrocellulose membrane using the iBlot 2 transfer system (Invitrogen) or Power 
blotter system (Thermo Scientific). Ponceau S (Sigma) was used to confirm protein 
transfer and the membrane was blocked with 1X Odyssey PBS blocking buffer 
(Licor). Primary antibodies were prepared in 1:1 Odyssey buffer: PBS-Tween 
(0.15%) as detailed in Table 2-5 and the membrane was incubated at 4 °C overnight 
in primary antibody. Membranes were washed for 10 mins three times with PBS-
Tween before and after 1h incubation in the appropriate secondary antibody at room 
temperature. Blots were visualised using the Licor Odyssey with Odyssey V2 
software. Densitometry was also performed using the Odyssey V2 software. 
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Table 2-5: Antibody conditions, secondary antibodies, positive control, suppliers and catalogue numbers for immunoblotting. 
Antibody Post-translational 
modification 
Dilution Blotting 
conditions 
Secondary 
antibody 
Positive 
Control 
Supplier Cat. No. 
Anti-mouse secondary - 1:5000 1:1 Odyssey 
buffer: PBS-T 
- - LiCor  
Anti-rabbit secondary - 1:5000 1:1 Odyssey 
buffer: PBS-T 
- - LiCor  
Anti-α-tubulin - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Mouse - Sigma Aldrich T6199 
Anti-HER2 - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Mouse BT474 Calbiochem OP15 
Anti-phospho-HER2 Tyr1221/1222 
phosphorylation 
1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit BT474 CST #2249 
Anti-EGFR - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit A431 CST #2232 
Anti-eEF2 - 1:1000 1:1 Odyssey Rabbit MDA-MB- CST #3021 
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buffer: PBS-T 453 
Anti-phospho-eEF2  Thr56 
phosphorylation 
1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit MDA-MB-
453 
CST #3022 
Anti-PPP2CA - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Mouse A431 Millipore 05-421 
Anti-phospho-PPP2CA Tyr307 
phosphorylation 
1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit A431 Abcam Ab32104 
Anti-methyl-PPP2CA Leu309 methylation 1:1000 1:1 Odyssey 
buffer: PBS-T 
Mouse HEK293 Abcam Ab66597 
Anti-PPP2R1A - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit MDA-MB-
231 
Antibodies-
online GmbH 
ABIN18816
82 
Anti-PPP2R1B - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit HeLa Antibodies-
online GmbH 
ABIN15303
62 
Anti-PPP2CB - 1:1000 1:1 Odyssey 
buffer: PBS-T 
Rabbit A431 Abcam Ab32673 
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Anti-Src - 1:500 1:1 Odyssey 
buffer: PBS-T 
 MCF7 Millipore  
Anti-phospho-Src Tyr416 
phosphorylation 
1:1000 1:1 Odyssey 
buffer: PBS-T 
 MCF7 CST  
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2.5 Reverse Phase Protein Array 
 
Cells were grown to 70% confluency, and treated for 18 h with 500 nM lapatinib, 3 
nM okadaic acid or the two combined. Cells were washed twice with PBS and lysis 
buffer was added (1% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM 
MgCl2, 1 mM EGTA,100 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 
10% glycerol, plus freshly added Roche protease (#04693116001) and phosphatase 
(#04906845001) inhibitors). Plates were incubated for 20 mins on ice. Cells were 
scraped from the plates and lysate was transferred to eppendorf tubes. Lysates were 
centrifuged at 14,000 rpm for 10 mins at 4 oC.  Supernatant was collected and stored 
at -80 oC. Protein quantification was determined by bicinchoninic acid (BCA) assay 
and protein concentration was adjusted to 1.5 mg/mL. Cell lysates were mixed with 
4X SDS buffer (40% glycerol, 8% SDS, 0.25 M Tris-HCl, pH 6.8, 10% 2-
mercaptoethanol) (three parts lysate to one part 4X SDS buffer). 
RPPA was carried out by Dr. Mattia Cremona in RCSI, Beaumont as described in 
[270]. A 2470 arrayer (Aushon) created an 850-sample array on Oncyte Avid 
nitrocellulose-coated slides (Grace Bio-Labs). The slides were stored at −20 °C prior 
to immunostaining.  
Immunostaining was performed on an automated slide stainer (Dako), according to 
manufacturer’s instructions. Each slide was incubated with a single primary antibody 
at room temperature for 30 mins. Secondary antibody was goat anti-rabbit IgG 
(1:5000) (Vector Laboratories) or rabbit anti-mouse IgG (1:10) (Dako). Secondary 
antibodies (Dako) were used as a starting point for amplification via horseradish 
peroxidase-mediated biotinyl tyramide with chromogenic detection 
(diaminobenzidine) according to the manufacturer's instructions (Dako). 
Scanned TIFF images of slides were analysed using Microvigene software version 5.1 
(VigeneTech Inc.) to generate spot signal intensities. Instead of generating multiple 
linear regression curves for data quantification over each series of serial dilutions, the 
QRPPA module of Microvigene using a 4 parameter logistic-log model 
("SuperCurve" algorithm) that uses all spots within one array to form a sigmoid 
antigen-binding kinetic curve. Finally, the spots are normalised by protein loading 
using the entire panel of antibodies. Briefly, normalisation was processed as follows: 
the median was determined for each antibody across the sample set and each raw 
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linear value was divided by the median within each antibody to get the median-
centred ratio. After that, the median was calculated from median-centred ratio for 
each sample across the entire panel of antibodies. This median functions as a 
correction factor (CF) for protein loading adjustment. Samples were considered an 
outlier if the CF was above 2.5 or below 0.25. Finally, the raw data was divided in 
linear value by the CF to obtain the normalised value. 
 
2.6 Immunohistochemistry 
2.6.1 Fresh frozen cell line slide preparation 
 
HCC1954-L cells were grown in a T75 to approximately 70% confluency, trypsinised 
and resuspended. Cells were placed dropwise onto a SuperFrost Plus slide 
(ThermoFisher, 4591PLUS4) marked with a wax pen border. The slides were placed 
in petri-dishes with a moist lint-free wipe in a 37 °C incubator overnight. The slides 
were then rinsed with PBS three times and allowed to dry. The slides were formalin 
fixed for immediate immunohistochemistry analysis or covered in aluminium foil and 
stored at -80 °C. 
  
2.6.2 Sectioning 
 
Sectioning of in vivo tumour samples was carried out using a Reichert-Jung 2030 
microtome. Blocks were cut into 5 µM sections, which were floated in a water bath at 
40 ˚C and mounted onto SuperFrost Plus slide (ThermoFisher, 4591PLUS4) and 
allowed to dry at 180 ˚C for 2h. 
 
2.6.3 Immunostaining 
 
Automated immunohistochemistry (IHC) was performed using a DAKO autostainer 
Plus. An antibody against human mitochondria (1/1000) was used as a control to 
differentiate human and mouse cells. Antigen retrieval was performed on cell line 
block and in vivo tumour block slides using the Dako PT Link with Target Retrieval 
Solution pH 6 (Dako S1699). Slides was placed in the Dako PT link at 65 ˚C, heated 
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to 97 ˚C, and maintained at 97 ˚C for 20 mins. The slides were cooled to 65 ˚C and 
removed. After de-paraffinisation, the slides were placed in the DAKO Autostainer, 
which performed the programmed application of reagents in order as listed in Table 2-
6Table 2-6. Washes were performed, with DAKO wash buffer, before and after the 
application of each reagent, except in the case of the Real HP Block, where a blow 
step was performed. Slides were subsequently dehydrated in grading alcohols 70 %, 
90 %, and 100 %, cleared in xylenes (2 x 3 mins each) and mounted in di(nbutyl) 
phthalate in xylene (DPX) (Sigma).   
 
Table 2-6: Steps for immunostaining on DAKO Autostainer 
Reagent Time (mins) 
Real HP Block (DAKO) 10 
Antibody 30 
Real EnVision (DAKO) 30 
Real DAB (DAKO) 5 
Haematoxylin 5 
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2.7 Proliferation Assays 
2.7.1 Acid phosphatase proliferation assay 
 
Cell lines were seeded in 96 well plates at a cell density as detailed in Table 2-7. After 
24 h, cells were treated with a drug or combination of drugs of interest in 100 μL of 
medium. After five days’ incubation, proliferation was measured using the acid 
phosphatase assay. Medium was removed and cells were washed three times with 
PBS. 100 μL of acid phosphatase substrate (10 mM p-nitrophenol phosphate (Sigma) 
in 0.1 M sodium acetate (Sigma), 0.1% Triton X-100 (BDH, pH 5.5) was added to 
each well and the plate was then incubated at 37°C for one to 2 h. The reaction was 
halted with the addition of 50 μL of 0.1 M sodium hydroxide. The absorbance was 
then read at 405 nm and at 620 nm as a reference on a plate reader (Biotek) using 
Gen4 software. Percentage growth was calculated relative to an untreated control. All 
assays were performed in triplicate. 
Table 2-7: The number of cells seeded per well in 96 well plates for proliferation 
assays determined by assay optimisation and previously published data. 
Cell line Cells seeded/well 
BT474 5000 
EFM192A 5000 
HCC1419 3000 
HCC1569 3000 
HCC1954 2500 
JIMT-1 2500 
MDA-MB-361 5000 
MDA-MB-453 3000 
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SKBR3 3000 
UACC-732 3000 
HCC1954-L 2500 
SKBR3-L 3000 
HCC1954-N 2500 
SKBR3-A 3000 
 
2.7.2  Three-dimensional growth assay 
 
96-well plates were coated with 50 μL poly-HEMA (Sigma Aldrich, 5 mg/mL in 96% 
ethanol) and incubated at 50ºC for 48 h. Poly-HEMA–coated plates were stored at 
room temperature for up to six months. Cells were seeded in 90 μL of medium 
containing 10% FBS and 4% Matrigel (BD Biosciences) at the same density as for the 
two-dimensional (2D) acid phosphatase assay (Table 2-7). After which, the plate was 
incubated overnight at 37ºC. 30 μL of medium containing 10% FBS with/without 
drugs of interest was added to each well and incubated at 37ºC for 7 days. 12 μL of 
PrestoBlue cell viability reagent (Life Technologies) was added to each well and 
incubated for 2-4 h at 37ºC. Fluorescence was measured at 535/590 
excitation/emission wavelengths on a plate reader (Biotek) using Gen4 software. 
Background fluorescence was calculated by using a blank consisting of medium 
containing 10% FBS and 4% Matrigel (BD Biosciences). Percentage viability was 
calculated relative to untreated controls. 
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2.8 Small interfering RNA (siRNA) transfection 
 
A pool of four PPP2CA siRNA molecules targeting PPP2CA (L-003598-01, 
Dharmacon) and a scrambled sequence siRNA (D-00180-10) were obtained from 
Millipore. A validated siRNA molecule targeting kinesin was obtained from Sigma as 
a transfection control. All siRNAs were transfected at a final concentration of 25 nM. 
The siRNA was diluted in Opti-MEM reduced serum medium (Invitrogen) and Trans-
IT X2 transfection reagent (Mirius) was added, as per Table 2-8Table 2-8. The 
transfection solution was incubated for 20 mins at room temperature. Meanwhile, 2 x 
105 cells/well in 10% FBS RPMI-1640, for protein expression analysis, or 1 x 105 
cells/well in 10% FBS RPMI-1640, for growth inhibition assay, were prepared for a 
6-well plate. The appropriate transfection solution was added to each well, followed 
by the cell suspension. After 24 h, the medium in each well was replaced with fresh 
medium with or without DMSO or 500 nM lapatinib. Cells were either lysed after a 
further 48 h for Western blotting analysis or after 72 h for proliferation analysis. 
Proliferation was measured by harvesting cells. Ten µL of cell suspension was 
combined with 10 µL trypan blue. Cells were then counted using a haemocytometer. 
 
Table 2-8: siRNA transfection reaction mixture (6-well plate). 
Solution Volume 
Cell suspension 1.5 mL 
Opti-MEM reduced 
serum medium 
250 µL 
Trans-IT X2 7.5 µL 
siRNA 6.8 µL 
 
 
 
 
 64 
2.9 Short-term drug resistance development assay 
 
Cells were seeded in two or three 12-well plates (1-3 x 104 cells/well), as shown in 
Figure 2-1 and incubated at 37 ºC overnight. After this, cells were fed or treated with 
drugs alone or in combination. Cells were then treated twice weekly. The first plate 
was fixed and stained with 0.1% crystal violet once the control cells became 
confluent. The second plate was fixed and stained when cells had developed 
resistance to one of the drugs alone. If the cells did not develop resistance to Drug A, 
a third plate was used, which was fixed and stained when the cells treated with Drug 
A only developed resistance (Figure 2-9). 
 
 
 
      
Figure 2-1: Plate layout for drug resistance development assay. If the cell line is 
resistant to Drug B, a third plate is required. Plate 1 is fixed and stained when 
control cells become confluent. Plate 2 is fixed and stained when cells that are 
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treated with either Drug A or Drug B become confluent. Plate 3 is stopped when 
cells treated with drug A developed resistance and were actively growing. 
 
2.10 Cell cycle assay 
 
2.5 x 104 cells were seeded per well in a 24 well plate and incubated at 37 °C. After 
24 h, appropriate treatments were added to each well. Following 48 h incubation, 
medium was collected and the wells were rinsed with PBS. Cells were trypsinised and 
added to collected medium. The medium was centrifuged at 1500 rpm for 5 mins and 
the supernatant was aspirated. The pellet was re-suspended in 150 µL PBS and 
transferred to a round bottom 96-well plate. The plate was centrifuged at 1500 rpm for 
5 mins and the supernatant was removed, leaving approximately 15 μL per well. The 
remaining volume was resuspended and 200 μL of ice cold 70% ethanol was added. 
The plate was stored for 2 h at -20°C. After fixing the cells, the plate was spun at 
2000 rpm for 5 minute. The supernatant was removed, 200 μL of PBS was added and 
the plate was centrifuged again at 450 x g for 5 mins. The PBS was removed and 200 
μL of Guava Cell Cycle reagent (Merck Millipore) was added to each well. The cells 
were resuspended and stored at room temperature in the dark for 30 mins. Cells were 
then analysed on the Guava EasyCyte (Merck Millipore) and the data was analysed 
using Modfit LT software (Verify). 
 
2.11 Apoptosis assay 
 
Apoptosis induction and activation of caspase 3/7 was examined using the Caspase-
Glo 3/7 assay (Promega). Briefly, 9 x 103 cells were seeded per well in a white-walled 
96-well plate. After 24 h, medium was removed and 100 µL of fresh medium with or 
without drug was added. The plate was further incubated for 48 h. Caspase-Glo 3/7 
reagent was equilibrated to room temperature and 100 µL of the reagent was added to 
each well. After 1 h of incubation, luminescence was analysed using a plate reader 
(Biotek) with Gen4 software.  
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2.12 Autophagy assay 
 
CYTO-ID autophagy detection kit (Enzo Bioscience) was used to determine 
autophagy levels. 9 x 103 cells were seeded in a white-walled, clear-bottomed, 96-
well plate. After 24 h, cells were treated and incubated for 48 h. Medium was then 
removed and the cells were washed twice with PBS. Phenol-red free RPMI 1640 with 
10% FBS with 0.1% Hoescht stain and 0.1% Autophagy marker was added to wells 
for quantitative analysis using fluorescence spectrophotometry. Fluorescence was 
analysed for autophagy marker at excitation 480 nm and emission 530 nm, and at 360 
nm excitation and 480 nm emission for Hoeschst nuclear staining. Phenol-red free 
RPMI-1640 with 10% FBS containing 0.1% Hoeschst stain and 0.2% autophagy 
marker was added to wells for fluorescence microscopy. Images were taken using a 
Leica DFC 500 fluorescent microscope with FITC and DAPI filters. 
 
2.13 DNA extraction 
 
Genomic DNA was isolated using the Qiagen AllPrep DNA/RNA kit. SKBR3-Par 
and SKBR3-A cells were grown to 80% confluency in a T175 flask. Cells were 
trypsinised and resuspended in medium and counted. Cells were centrifuged at 900 
rpm for four mins and washed twice with PBS. Cells were homogenised in 600 µL 
Buffer RLT, containing 0.1% β-mercaptoethanol. The cell lysate was mixed and 
sheared using a syringe with a 20 guage blunt needle. The lysate was transferred to an 
AllPrep DNA spin column in a 2 mL collection tube and centrifuged for 30 seconds at 
14,000 rpm. 500 µL Buffer AW1 was added to the column and centrifuged for 15 
seconds at 14,000 rpm. Flow through was discarded and 500 µL Buffer AW2 was 
added to the column. Tubes were centrifuged for 2 mins at 14,000 rpm. The column 
was transferred to a fresh 1.5 mL collection tube, 100 µL of 70 ºC Buffer EB was 
added and incubated at room temperature for 2 mins. Tubes were centrifuged for one 
minute at 10,000 rpm and DNA elution was collected. DNA was purified by sodium 
acetate precipitation. DNA was quantified using the Nanodrop V1000.  
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2.14 Whole exome sequencing 
 
Whole exome sequencing was conducted by Beijing Genomic Institute using the 
Agilent SureSelect system (Figure 2-2). Twenty µg of genomic DNA is randomly 
fragmented by Covaris sonication to approximately 150 to 200 bp fragments. 
Adapters were then added which ligated to both ends of the fragments. Adapter-
ligated fragments were purified using Agencourt AMPur SPRI beads. The DNA was 
then amplified by ligation-mediated PCR, purified and hybridised to the SureSelect 
Biotinylated RNA library for enrichment. Non-hybridised fragments were washed out 
after 24 h and hybridised fragments were captured by streptavidin beads. Captured 
fragments were analysed by Agilent 2100 Bioanalyser to determine the magnitude of 
enrichment. High-throughput sequencing was then performed on each captured 
library using the HiSeq2000 system. Raw image files were processed by Illumina 
basecalling softare 1.7 with default parameters and the sequences of each sample were 
generated as 90/100 bp pair-end reads. 
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Figure 2-2: Agilent SureSelect system exome capture and sequencing protocol [271]. 
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Bioinformatic analysis was carried out by BGI to determine the insertions and 
deletions (InDels), copy number variations, and single nucleotide polymorphisms. 
Data was cleaned by removing adapter sequence and low quality read from the raw 
data. Alignment was carried out using Burrows-Wheeler Aligner. The SKBR3-A and 
SKBR3-Par cell line samples were treated as a pair. Single nucleotide variants 
(SNVs), were detected by Varscan, InDels by SAMtools, and copy number variants 
(CNVs) by ExomeCNV.  
 
 70 
2.15 In vivo experiments 
 
All in vivo experiments were reviewed and approved by the DCU BioResource 
Advisory Group, the DCU Research Ethics Committee, and the Health Products 
Regulatory Authority.   
 
2.15.1 Sample size calculation 
 
Sample size calculations for the drug efficacy study were performed using the 
G*Power statistical software, in consultation with biostatisticians, Dr. Michael 
Parkinson and Dr. Tim Downing. Briefly, the desired minimum significant difference 
in tumour volume was < 20%. Using data from a previous in vivo study with 
HCC1954-L cells, the expected tumour volumes for untreated controls and lapatinib 
treated after 51 days was approximately 680 mm3 and 600 mm3, respectively. 
Therefore, a tumour volume of 500 mm3 or less would be deemed a significant effect. 
Therefore, the minimum effect size for single agent lapatinib versus the lapatinib and 
LB-100 combination would be 1.25. The sample size calculation is described in Equation 1 below. 
 
Equation 1: The effect size (dimensionless) was calculated using the mean 
untreated tumour volume (µ1) and desired maximum significant treatment 
tumour volume (µ2), divided by the variation of tumour volume (σ).  
 
(μ1−μ2)
σ 
 = (600−500)
80
 = 100
80
 = 1.25  
 
The allocation ratio between groups was 1, a power of 80% was required and the error 
probability was set at 0.05. The tumour take rate was observed to be approximately 
95%, data obtained from collaborators. Therefore, it was calculated that 12 animals 
were required per group and 60 animals in total for the drug efficacy study. 
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2.15.2 Tumour induction via subcutaneous injection 
 
HCC1954-L cells were trypsinised, counted and resuspended to 5 x 106 and 1 x 107 
cells/50 µL in serum-free RPMI-1640 medium. Cell suspension was combined with 
Cultrex (R&D Systems) in a 1:1 ratio on ice. This was then drawn into a syringe and a 
25 gauge needle (BD) was attached. The animal was restrained by the scruff and held 
upright. The needle was inserted under the skin on the flank of the animal and 200 µL 
of the cell solution was injected. The mouse was then returned to its cage and 
monitored. 
 
2.15.3 Tumour induction via mammary fat pad injection 
 
HCC1954-L cells were trypsinised, counted and resuspended to 1 x 107 cells/mL in 
serum-free RPMI-1640 medium. The cell suspension was mixed with an equal 
volume of Cultrex (R&D Systems). This suspension was drawn into a 1 mL syringe 
and a 25 guage needle was attached. The mouse was anaesthetised with isoflurane, 
with O2 as a carrier gas. The cell suspension (50 µL = 5 x 105 cells) was injected into 
the mammary fat pad of the fourth inguinal nipple by raising the nipple with a forceps 
and inserting the needle under the skin. The mouse was then given a subcutaneous 
injection of saline to aid recovery. The mouse was placed in a clean cage, which was 
partially on a heated mat, and monitored until full recovery. 
 
2.15.4 Tumour measurements 
 
The mouse was restrained by the scruff and held upright. Tumours were measured by 
height, width, and depth, using electronic calipers. Tumour volume was calculated by: 
 
Tumour volume = (Height x width x depth)
1.9
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2.15.5 Oral gavage 
 
Lapatinib solution was prepared in 0.5% hydroxypropylmethyl cellulose 
(HPMC)/0.1% Tween-80 in UHP water to 18.75 mg/mL (75 mg/kg) and sonicated for 
15 mins. The solution was drawn into a 1 mL syringe and a bulb-tipped steel gavage 
needle was attached. The mouse was restrained and held upright. The tip of the 
gavage needle was dipped in filter-sterilised 1 g/mL sucrose solution. The needle was 
inserted along the roof of the mouth toward the stomach and 100 µL of lapatinib 
solution was injected. The needle was carefully removed and the mouse was 
monitored. 
 
2.15.6 Intra-peritoneal injection 
 
LB-100 was prepared under sterile conditions in PBS to 375 µg/mL (1.5 mg/kg). LB-
100 was aliquoted and stored at -80°C before use. LB-100 was drawn into a 1 mL 
syringe and a 25 gauge needle was attached. The mouse was restrained by the scruff, 
inverted and held at a downward angle to avoid intestinal injection. The needle was 
inserted into the abdomen and 100 µL of LB-100 was injected. The needle was 
removed and the mouse was monitored for adverse response.  
 
2.15.7 Tumour retrieval and processing 
 
When mice were culled at the termination of study or due to adverse events, tumours 
were excised from the mouse. The tumour was then quickly divided into sections and 
preserved by liquid nitrogen flash freezing or formalin fixation. Flash frozen samples 
were stored at -80°C and formalin fixed samples were dehydrated in 50%, 70%, 90%, 
100% ethanol, followed by 100% xylene, and then embedded in paraffin. FFPE 
blocks were stored at 4°C until sectioning. Some tumour material was also taken for 
cell culture. To do this, tumour tissue was digested in 300 U/mL collagenase/ 100 
U/mL hyaluronidase in DMEM for 1 h, after which cells were centrifuged at 1500 
rpm for 5 mins, re-suspended in RPMI-1640 supplemented with 10% FBS and 100 
IU/mL penicillin and 100 µg/mL streptomycin, and allowed to attach in 25 cm2 
flasks.  
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2.16 Statistical analysis 
 
P values were calculated (unless otherwise stated) using the student’s t-test (two tailed 
with unequal variance). Analysis was performed on biological triplicates. P < 0.05 
was considered significant.  
 
Correlation co-efficient values were calculated using Spearman Rank test with two-
tailed p value [272]. 
 
IC50 values were calculated using the dose effect analyser Calcusyn (Biosoft, Version 
1.1). IC50 values were represented as an average of triplicate biological experiments ± 
the standard deviation. 
 
For fixed-ratio assays, combination indices (CI) at the ED50 (effective dose of 
combination that inhibits 50% of growth) were determined using the Chou and 
Talalay equation, on CalcuSyn software (Biosoft) [273]. The combination index 
equation is based on the multiple drug-effect equation of Chou-Talalay derived from 
enzyme kinetic models. The equation determines only the additive effect rather than 
synergism or antagonism. Synergism is defined as a more than expected additive 
effect, and antagonism as a less than expected additive effect. Determination of 
synergy/antagonism used in this study was based on the recommended descriptions as 
shown in Table 2-9. As recommended by Chou et al., the prerequisites for CI 
calculations included a dose-effect curve, at least four data points for each drug 
condition was used. 
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Table 2-9: Range of combinations index values that determine synergism or 
antagonism in drug combination studies analysed with the Combination Index 
method. 
Range of CI Symbol Description 
<0.10 +++++ Very strong synergism 
0.10-0.30 ++++ Strong synergism 
0.31-0.70 +++ Synergism 
0.71- 0.85 ++ Moderate synergism 
0.86-0.9 + Slight synergism 
0.91- 1.10 ± Nearly additive 
1.11-1.20 _ Slight antagonism 
1.21-1.45 _ _ Moderate antagonism 
1.45-3.30 _ _ _ Antagonism 
3.30- 10.00 _ _ _ _ Strong antagonism 
>10.00 _ _ _ _ _ Very strong antagonism 
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3 The role of PP2A in acquired 
lapatinib resistant breast cancer 
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3.1 Introduction 
 
Previous work in our laboratory produced two lapatinib resistant cell lines, SKBR3-L 
and HCC1954-L [148, 154]. The SKBR3-L cell line was generated by Dr Brigid 
Browne by treating SKBR3 cells for six months with 250 nM lapatinib. The 
HCC1954-L cells were established by Dr Martina McDermott by treating HCC1954 
cells for six months with 1 µM lapatinib. Untreated SKBR3-Par and HCC1954-Par 
were maintained alongside the lapatinib-treated cells. In this study, these cell lines 
were further characterised to determine their sensitivity to other HER2-targeted 
therapies, including the novel HER family tyrosine kinase inhibitors neratinib and 
afatinib, in lapatinib resistant breast cancer. 
To identify potential mediators of resistance, the SKBR3-L cells were previously 
examined for proteomic and phospho-proteomic alterations compared to the parental 
cell line [154]. In this analysis, levels of phosphorylated (Thr56) eukaryotic 
elongation factor 2 (eEF2) were found to be down-regulated; this was validated in the 
HCC1954-L cell line. eEF2 is a monomeric GTPase that is involved in protein 
synthesis and is inhibited by Thr56 phosphorylation. Lapatinib treatment of SKBR3-
Par cells caused an increase in phospho-eEF2 levels, whereas in SKBR3-L cells 
phospho-eEF2 levels were not altered following lapatinib treatment. This suggested 
that lapatinib cannot inhibit eEF2-mediated protein synthesis in the SKBR3-L cell 
line and that eEF2 may therefore play a role in acquired lapatinib resistance. Analysis 
of the numerous signalling pathways that regulate phosphorylation of eEF2 revealed 
that protein phosphatase 2A (PP2A) is the key regulator of eEF2 activity in SKBR3-L 
cells and PP2A activity was shown to be increased in both SKBR3-L and HCC1954-L 
lapatinib resistant cell lines. PP2A is a trimeric holoenzyme that regulates multiple 
survival pathways [154]. 
In this study, PP2A was examined as a novel therapeutic target to overcome lapatinib 
resistance. The effects of and mechanism of action of two PP2A inhibitors, okadaic 
acid and LB-100, were assessed, alone and in combination with HER2-targeted 
therapies. Okadaic acid is a lab-grade inhibitor of PP2A and LB-100 is a PP2A 
inhibitor that is currently in clinical investigation.  
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3.2 Characterisation of lapatinib resistant cell lines  
3.2.1 SKBR3-L and HCC1954-L cells are resistant to lapatinib 
 
Lapatinib is given to patients orally at a dosage of 1.25 g daily. The pharmacokinetics 
of lapatinib is dependent on the patient’s fasting state. Peak plasma concentrations 
range from 2.54 ± 0.84 µg/mL (4.37 ± 1.44 µM) to 0.91 ± 0.52 µg/mL (1.57 ± 0.894 
µM) when fasted [274]. With this in mind, cell lines with an IC50 value of 1 µM were 
deemed lapatinib resistant. Both SKBR3-L and HCC1954-L cell lines were confirmed 
to be resistant to lapatinib at clinically relevant concentrations (Figure 3-1). The 
lapatinib IC50 value for SKBR3-Par cells was 0.05 ± 0.02 µM and 2.37 ± 0.58 µM for 
SKBR3-L cells. This represents a 46-fold decrease in sensitivity to lapatinib. The 
lapatinib IC50 value for the HCC1954-L cell line was 1.67 ± 0.34 µM. This is 5.2-fold 
greater than the lapatinib IC50 value in HCC1954-Par cells, 0.32 ± 0.19 µM. IC50 
values are summarised in Table 3-1. 
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Figure 3-1: Proliferation of (A) SKBR3-L and (B) HCC1954-L cells after 5 days 
of treatment with lapatinib (0 – 10 µM) was examined by acid phosphatase assay. 
Percentage growth was calculated relative to untreated control cells. Error bars 
represent standard deviation of biological triplicate experiments. 
 
3.2.2 SKBR3-L and HCC1954-L cells have reduced sensitivity to afatinib and 
neratinib 
 
The pan-HER inhibitors, afatinib and neratinib, have been shown to be effective 
against trastuzumab-resistant HER2-positive breast cancer [108, 123]. Therefore, to 
assess the potential of the irreversible pan-HER inhibitors in lapatinib-resistant breast 
cancer, both acquired lapatinib resistant cell lines and their respective parental cell 
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lines were assessed for sensitivity to afatinib and neratinib (Figure 3-2). The parental 
cell lines, SKBR3-Par and HCC1954-Par, were both highly sensitive to afatinib and 
neratinib. The afatinib IC50 values for SKBR3-Par and HCC1954-Par cells were 10.9 
± 3.4 nM and 15.0 ± 4.6 nM, respectively, and the neratinib IC50 values for these cell 
lines were 3.4 ± 1.1 nM and 26.1 ± 1.2 nM, respectively. In comparison, the SKBR3-
L and HCC1954-L cell lines showed significantly reduced sensitivity to both pan-
HER inhibitors. The afatinib IC50 values for SKBR3-L and HCC1954-L cells were 
152.0 ± 12.1 nM and 1.13 ± 0.18 µM, respectively, and neratinib IC50 values were 
77.5 ± 9.6 nM and 272.9 ± 109.6 nM, respectively. IC50 values are summarised in 
Table 3-1. 
 
 
Figure 3-2: Proliferation of (A) SKBR3-L and (B) HCC1954-L cells after 5 days 
of treatment with afatinib or neratinib was examined by acid phosphatase assay. 
Percentage growth was calculated relative to untreated control cells. Error bars 
represent standard deviation of biological triplicate experiments. 
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3.2.3 Response to trastuzumab and pertuzumab in SKBR3-L and HCC1954-L 
cells  
 
A trastuzumab-based regimen is standard of care in first-line treatment of metastatic 
and early stage HER2-positive breast cancer and trastuzumab treatment after disease 
progression on lapatinib has been investigated in a small clinical study [275, 276]. 
Furthermore, the addition of pertuzumab to trastuzumab has shown remarkable 
clinical efficacy and may become standard of care for patients with metastatic disease 
[67]. Therefore, the lapatinib resistant and parental cell lines were assessed for their 
sensitivity to trastuzumab and pertuzumab. SKBR3-Par cells were sensitive to 
trastuzumab in vitro; with 28.9 ± 2.1% growth inhibition relative to untreated controls 
after 5 days of 10 µg/mL treatment (p = 1.8 x 10-5). In comparison, the SKBR3-L 
cells were significantly less sensitive to trastuzumab (p = 0.008), with 15.1 ± 4.3% 
growth inhibition. Both cell lines showed a similar response to 10 µg/mL pertuzumab 
(SKBR3-Par =14.2 ± 1.0% growth inhibition and SKBR3-L = 8.2 ± 4.6% growth 
inhibition, p = 0.09). Pertuzumab enhanced response to trastuzumab in SKBR3-Par 
cells (42.2 ± 2.2% compared to 4.1 ± 7.0% growth inhibition, p = 0.0016), which was 
not observed in the SKBR3-L cell line (p = 0.08) (Figure 3-3). 
In contrast to SKBR3-Par cells, HCC1954-Par cells are innately resistant to 
trastuzumab. In HCC1954-Par cells 10 µg/mL trastuzumab inhibited growth by 6.8 ± 
7.1%. Similarly, HCC1954-Par displayed resistance to 10 µg/mL pertuzumab (5.6 ± 
10.1% growth inhibition) and trastuzumab plus pertuzumab (6.0 ± 4.1% growth 
inhibition). The HCC1954-L cells maintained this resistance to trastuzumab, 
pertuzumab, and trastuzumab plus pertuzumab (4.4 ± 1.5%, 7.9 ± 3.6%, and -7.2 ± 
3.3% growth inhibition, respectively) (Figure 3-5). Responses to all HER2-targeted 
therapies are summarised Table 3-1. 
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Figure 3-3: Proliferation of SKBR3-Par and SKBR3-L cells treated for 5-days 
with 10 µg/mL trastuzumab, 10 µg/mL pertuzumab, or trastuzumab plus 
pertuzumab was measured by acid phosphatase assay. Error bars represent 
standard deviation of biological triplicate experiments. The Student’s t test was 
used to determine statistical significance. ** denotes a p value < 0.01. 
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Figure 3-4: Proliferation of HCC1954-Par and HCC1954-L cells treated for 5-
days with 10 µg/mL trastuzumab, 10 µg/mL pertuzumab, or trastuzumab plus 
pertuzumab was measured by acid phosphatase assay. Error bars represent 
standard deviation of biological triplicate experiments. The Student’s t test was 
used to determine statistical significance.  * denotes a p value < 0.05. 
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Table 3-1: Lapatinib resistant and parental cell line response to HER2-targeted 
therapies. 
 SKBR3-L SKBR3-Par HCC1954-L 
HCC1954-
Par 
Lapatinib IC50 
value (µM) 
2.37 ± 0.58 0.05 ± 0.02 1.67 ± 0.34 0.32 ± .019 
Afatinib IC50 
value (nM) 
152.0 ± 12.1 10.9 ± 3.4 
1130.0 ± 
180.0 
15.0 ± 4.6 
Neratinib IC50 
value (nM) 
77.5 ± 9.6 3.4 ± 1.1 272.9 ± 109.6 26.1 ± 1.2 
% Growth 
inhibition with 
10 µg/mL 
trastuzumab 
15.1 ± 4.3 28.9 ± 2.1 4.4 ± 1.5 6.8 ± 7.1 
% Growth 
inhibition with 
10 µg/mL 
pertuzumab 
8.2 ± 4.6 14.2 ± 1.0 7.9 ± 3.6 5.6 ± 10.1 
% Growth 
inhibition with 
10 µg/mL 
trastuzumab 
and 
pertuzumab 
4.1 ± 7.0 42.2 ± 2.2 -7.2 ± 3.3 6.0 ± 4.1 
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3.3 SKBR3-L and HCC1954-L cells are sensitive to okadaic acid 
 
SKBR3-L and HCC1954-L cells were previously shown to have increased PP2A 
activity relative to their parental cell line [148, 154]. Both lapatinib resistant cell lines 
and their parental cell lines were tested for sensitivity to 3 nM okadaic acid, a lab-
grade PP2A inhibitor, by acid phosphatase assay (Figure 3-5 A and B). Both SKBR3-
L and HCC1954-L cell lines were more sensitive to okadaic acid compared to their 
respective parental cell lines (p = 0.03 and 0.04, respectively). Combined treatment 
with lapatinib and okadaic acid enhanced the growth inhibitory effect in SKBR3-L 
and HCC1954-L cells (p = 0.03 and 0.01, respectively) (Figure 3-6 A and C). 
Trastuzumab did not significantly alter the growth effect of okadaic acid in either cell 
line (p = 0.17 and 0.99, respectively) (Figure 3-6 B and D). 
 
 
Figure 3-5: Proliferation of SKBR3-Par, SKBR3-L (A), HCC1954-Par, and 
HCC1954-L (B) after 5 days of treatment with 3 nM okadaic acid was examined 
by acid phosphatase assay. Percentage growth was calculated relative to 
untreated control cells. Error bars represent standard deviation of biological 
triplicate experiments. The Student’s t test was used to determine statistical 
significance. * denotes a p value of < 0.05. 
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Figure 3-6: Proliferation of SKBR3-L after 5 days of treatment with 500 nM 
lapatinib, 3 nM okadaic acid, lapatinib plus okadaic acid (A) or 10 µg/mL 
trastuzumab, okadaic acid, or trastuzumab plus okadaic acid (B) was examined 
by acid phosphatase assay. Proliferation of HCC1954-L after 5 days of treatment 
with 500 nM lapatinib, 3 nM okadaic acid, lapatinib plus okadaic acid (C) or 10 
µg/mL trastuzumab, okadaic acid, or trastuzumab plus okadaic acid (D) was 
examined by acid phosphatase assay. Percentage growth was calculated relative 
to untreated control cells. Error bars represent standard deviation of biological 
triplicate experiments. The Student’s t test was used to determine statistical 
significance. * denotes a p value of < 0.05. 
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3.4 The effect of okadaic acid on cell cycle progression 
 
SKBR3-L proliferation was inhibited by the combination of okadaic acid and 
lapatinib (Figure 3-6). To determine if okadaic acid combined with lapatinib was 
cytostatic or cytocidal, cell cycle assays were performed. SKBR3-L cells were treated 
with 500 nM lapatinib, 3 nM okadaic acid, or lapatinib plus okadaic acid for 48 h. The 
percentage of the cell population in each phase of the cell cycle was measured by 
propidium iodide staining and flow cytometry analysis. Lapatinib alone (500 nM) 
induced G1 arrest (51.8 ± 1.6% compared to 41.8 ± 2.9% for untreated cells). OA 
alone induced a small increase in the sub-G1 population (12.8 ± 6.3% versus 8.9 ± 
3.4% for untreated cells) and the combination induced an increase in the sub-G1 
fraction (23.1 ± 8.5%) compared to either lapatinib (9.1 ± 6.7%, p = 0.044) or OA 
(12.8 ± 6.3%, p = 0.083) alone (Figure 3-7). 
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Figure 3-7: SKBR3-L cells were treated with 500 nM lapatinib, 3 nM okadaic 
acid, or lapatinib plus okadaic acid for 48 h. Cell cycle progression was 
measured by flow cytometry. Cell cycle stage was calculated using ModFit 
software. Error bars represent standard deviation of biological triplicate 
experiments. The Student’s t test was used to determine statistical significance. 
 
3.5 PP2A subunit expression in lapatinib resistant cell lines 
 
PP2A is a holoenzyme, composed of three subunits: the structural A subunit, the 
regulatory B subunit, and the catalytic C subunit. Expression levels of the two 
isoforms of the catalytic subunit, PPP2CA and PPP2CB, and the levels of the catalytic 
subunit phosphorylation and methylation were measured by Western blotting (Figure 
3-8Figure 3-8). Total levels of either catalytic subunit isoform were not significantly 
altered in HCC1954-L cells compared to HCC1954-Par cells (p = 0.19 and 0.66, 
respectively). Both post-translational modifications were decreased in the lapatinib 
resistant cell lines (p = 0.015 and 0.045, respectively). The lower levels of 
phosphorylated PPP2CA suggests that PP2A activity is increased in the HCC1954-L 
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cells, which was previously observed [154]. The methylation levels affect the 
substrate specificity of the holoenzyme and the decreased methylation would suggest 
that the lapatinib resistant cell line may have different substrate targets to the parental 
cells. 
 
 
Figure 3-8: Western blotting of PPP2CA, PPP2CB, phosphor-PPP2CA and 
methyl-PPP2CA in HCC1954-Par and HCC1954-L cells untreated (Con) and 
treated with 1 µM lapatinib (Lap). Densitometry was carried out with LiCor 
Odyssey 3.0. Error bars represent standard deviation of triplicate experiments. 
Blot image shown is representative of triplicate blots. Tubulin was used as a 
loading control. The Student’s t test was used to determine statistical 
significance. * denotes a p value of < 0.05. 
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3.6 The effect of PPP2CA siRNA knockdown on HCC1954-L proliferation 
 
In order to ensure the growth inhibition effect of PP2A inhibition was not an off-
target effect of the okadaic acid, HCC1954-L cells were reverse transfected with anti-
PP2A catalytic subunit A, PPP2CA, siRNA (Figure 3-10). PPP2CA is the dominant 
catalytic subunit that carries out the phosphatase activity of the holoenzyme and is the 
substrate of okadaic acid [277]. The effectiveness of PPP2CA knockdown in 
HCC1954-L cells by anti-PPP2CA siRNA was measured by Western blotting after 72 
h of treatment. PPP2CA protein expression was significantly reduced relative to 
scrambled siRNA treated cells (61.2% decrease in protein expression) (p = 0.047) 
(Figure 3-9). Lapatinib treatment did not significantly alter the effectiveness of 
PPP2CA knockdown (p = 0.77). 
To measure the growth effects of PPP2CA siRNA, cells were treated with transfection 
reagent (Trans-IT X2), anti-PPP2CA siRNA, or anti-kinesin siRNA for 24 h, after 
which medium was changed. Cells were then treated with DMSO or 500 nM lapatinib 
for a further 72 h. Efficient transfection was confirmed using an anti-kinesin siRNA. 
Kinesin knockdown resulted in a 88.2 ± 3.4% growth inhibition. Anti-PPP2CA 
siRNA caused a significant decrease in cell growth compared to scrambled siRNA 
control (p = 0.015). Lapatinib plus anti-PPP2CA siRNA increased growth inhibition 
(57.9 ± 1.2% growth inhibition) compared to anti-PPP2CA siRNA alone (43.8 ± 10.5 
% growth inhibition) but this difference did not achieve statistical significance (p = 
0.08). This may be due to the shorter assay time of four days and lapatinib treatment 
for only the last three days. 
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Figure 3-9: Western blotting of PPP2CA in HCC1954-L cells treated with Trans-
IT X2, scrambled siRNA, 500 nM lapatinib, anti-PPP2CA siRNA, or anti-
PPP2CA siRNA plus lapatinib. Densitometry was carried out with LiCor 
Odyssey 3.0. Error bars represent standard deviation of triplicate experiments. 
Blot image shown is representative of triplicate blots. Tubulin was used as a 
loading control. The Student’s t test was used to determine statistical 
significance. * denotes a p value of < 0.05. 
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Figure 3-10: HCC1954-L cells were treated with TransIT-X2 transfection 
reagent, anti-PPP2CA siRNA, or anti-kinesin siRNA. After 24 h, medium was 
removed and fresh medium, DMSO, or 500 nM lapatinib was added. After a 
further 72 h, proliferation was measured by trypan blue exclusion cell counting. 
Error bars represent standard deviation of biological triplicate experiments. * 
denotes a p value of < 0.05. 
 
3.7 PP2A activation decreases lapatinib sensitivity 
 
In order to assess if increasing PP2A activity alters the response of lapatinib-naive 
cells to lapatinib, SKBR3-Par and HCC1954-Par cells were treated with FTY720, a 
PP2A activator [278], and then treated with serial dilution concentrations of lapatinib 
from 5 µM. 24 h pre-treatment of SKBR3 cells with 2.5 μM FTY720 resulted in a 5.3 
fold increase in the lapatinib IC50 value. The lapatinib IC50 value of FTY720-
pretreated SKBR3-Par cells was 136.1 ± 2.3 nM, compared to 25.8 ± 3 nM in 
FTY720-untreated SKBR3-Par cells (p = 8.9 x 10-7) (Figure 3-11 A). FTY720 
treatment also decreased lapatinib sensitivity in HCC1954-Par cells, increasing the 
lapatinib IC50 value 2.1-fold, from 582 ± 31 nM to 1.22 ± 0.1 μM (p = 7.8 x 10-4) 
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(Figure 3-11 B). This suggests that increased PP2A activity causes decreased 
sensitivity to lapatinib. 
 
 
Figure 3-11: (A) SKBR3-Par and (B) HCC1954-par cells treated with 2.5 μM 
FTY720 for 24 h, followed by lapatinib treatment for five days. FTY720-treated 
cells were compared to an untreated control. Error bars are representative of 
biological triplicate results.  
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3.8 Okadaic acid blocks development of lapatinib resistance  
 
As increased PP2A activity can decrease lapatinib sensitivity and lapatinib treatment 
can increase PP2A activity [154], the potential of inhibiting PP2A in conjunction with 
lapatinib treatment to prevent the development of lapatinib resistance was 
investigated. SKBR3 cells were treated twice weekly with 250 nM lapatinib, 3 nM 
okadaic acid, or lapatinib plus okadaic acid. The two endpoints of the assay were 
when the control cells became confluent (14 days), as a comparison for baseline 
lapatinib sensitivity, and when lapatinib resistant cells emerged and actively 
proliferated (28 days). At 14 days when control cells were confluent, lapatinib caused 
a 95% reduction in cell growth compared to control cells. Okadaic acid caused 52% 
growth inhibition and the combination treatment caused similar inhibition as lapatinib 
alone (98%). After a further 14 days of treatment, lapatinib-treated cells had started to 
grow in tight colonies and were now at 30% of the control cell number at day 14. In 
contrast, the growth of cells treated with lapatinib plus okadaic acid was still 
significantly inhibited (p = 3.5 x 10-5) (Figure 3-12). 
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Figure 3-12: SKBR3-Par cells were treated twice weekly with 250 nM lapatinib, 
3 nM okadaic acid, and lapatinib plus okadaic acid until control cells and 
lapatinib-treated cells approached confluency. Images represent triplicate 
experiments. Graphs represent absorbance levels of eluted crystal violet relative 
to control. Error bars represent standard deviation of triplicate assays. The 
Student’s t test was used to determine statistical significance. *** denotes p < 
0.001. 
 
This experiment was repeated with the HCC1954-Par cells (Figure 3-12). As 
HCC1954 cells are less sensitive to lapatinib compared to SKBR3 cells, HCC1954 
cells were treated with 1 µM lapatinib in this assay. HCC1954 cells were sensitive to 
both single agents and had an enhanced response to the combination (p = 0.03). After 
the additional week of treatment, HCC1954 cells began to actively grow again in 
okadaic acid (p = 0.005). Importantly, the combination treatment did not become 
resistant and had significantly less growth compared to either single agent (p = 0.001). 
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Figure 3-13: HCC1954-Par cells were treated twice weekly with 1 µM lapatinib, 
3 nM okadaic acid, and lapatinib plus okadaic acid until control cells and 
lapatinib-treated cells approached confluency. Images represent triplicate 
experiments. Error bars represent standard deviation of triplicate assays. 
Student’s t test used to determine statistical significance. 
 
3.9 RPPA analysis of lapatinib and okadaic acid treated HCC1954-L cells 
 
PP2A dephosphorylates a myriad of proteins [279]. In order to understand the 
signalling effects of PP2A inhibition, alone and in combination with lapatinib, 
HCC1954-L cells treated with 500 nM lapatinib, 3 nM okadaic acid, and lapatinib 
plus okadaic acid for 18 h were examined by reverse phase protein array (RPPA) 
analysis. RPPA experiment was carried out by Dr. Mattia Cremona. HCC1954-L cells 
were chosen for this experiment as they showed a greater combination effect of 
okadaic plus lapatinib than the SKBR3-L cell line. 
Lapatinib treatment significantly altered the total or phosphorylated levels of 10 
proteins (Table 3-2). As lapatinib is an EGFR/HER2 inhibitor, it is unsurprising HER 
family member levels and activity was altered with lapatinib treatment. 
Phosphorylated HER2 (Y1248) and HER3 (Y1289) were both significantly decreased 
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(p = 0.016 and 0.047, respectively). Total protein levels of EGFR were also decreased 
compared to DMSO-treated cells (p value = 0.009). Downstream of HER2, Akt and 
Akt2 levels were significantly increased. Phosphorylated Akt (S473 and T308) were 
slightly reduced but this change was not significant. Interestingly, 18 h lapatinib 
treated caused increases in levels of the RTK MET. Grb2-associated binding protein 1 
(GAB1) phosphorylation was also decreased. GAB1 is an adapter protein that 
interacts with several RTKs, including EGFR and MET [280, 281]. This may indicate 
after the 18 h treatment, downstream signalling may be suppressed. Previous work in 
our lab, showed decreased Akt and ERK 1/2 phosphorylation after 24 h of lapatinib 
treatment [154].  
Eighteen hour 3 nM okadaic acid treatment significantly altered only two 
phosphorylated protein levels and decreased total levels of one protein, Akt2 (Table 3-3). Okadaic acid caused significant decrease in Src (Y416) levels (p = 0.035) and 
increased p38 MAPK (T180) (p = 0.039). The RPPA analysis examined 67 total or 
phosphorylated protein levels. However, PP2A regulates a large amount of proteins 
outside of the pathways encompassed in this analysis. PP2A inhibition with okadaic 
acid may be altering proteins outside of the remit of the RPPA platform used. 
The combination of 500 nM lapatinib plus 3 nM okadaic acid caused 15 protein 
expression and activation changes, five of these were common to the lapatinib 
treatment (Akt, EGFR Y1068, HER2 Y1248, GAB1 Y627, NFκB p65 S536) and one 
with okadaic acid treatment (Src Y416) (Table 3-4). Combination treatment showed 
decreased phosphorylation of EGFR (Y1063 and Y1172) (p = 0.003 and 0.0001, 
respectively), HER2 (Y1248) (p = 0.0025), and HER3 (Y1289) (p = 0.006). 
Downstream from HER family member signalling, combination treated HCC1954-L 
cells showed significant decreases in phosphorylation of MAPK (T202/Y204) (p = 
0.027), MEK 1/2  (S217) (p = 0.0007), Shc (Y317) (p = 0.04), Src (Y416) (p = 
0.016), total and phosphorylated levels of mTOR (S2448) ( p = 0.042 and 0.019, 
respectively) and total Raf levels (p value = 0.003). Total levels of the pro-angiogenic 
receptor, VEGFR2, was also decreased (p = 0.042). Akt2 levels were increased with 
lapatinib and decreased with okadaic acid, combination treatment negated these 
changes and total Akt levels were significantly increased to similar levels to lapatinib 
alone treatment. 
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These changes indicate that the combination of PP2A inhibition and EGFR/HER2 
inhibition have an enhanced effect at inhibiting survival signalling.  
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Table 3-2: Statistically significant alterations in HCC1954-L cells treated with 
lapatinib versus DMSO control by RPPA analysis. 
DMSO v Lapatinib 
Protein Phosphorylation site Fold change p value 
EGFR - 0.37 0.009 
GAB1 Y627 0.47 0.008 
HER2 Y1248 0.74 0.016 
HER3 Y1289 0.84 0.047 
Akt2 - 1.40 0.034 
Akt - 1.50 0.027 
GSKβ - 1.64 0.029 
MET - 2.13 0.040 
PKCα - 2.43 0.016 
NFκB p65 S536 2.48 0.007 
 
 
Table 3-3: Statistically significant alterations in HCC1954-L cells treated with 
okadaic acid versus DMSO control by RPPA analysis. 
DMSO v Okadaic acid 
Protein Phosphorylation site Fold change p value 
Akt2 - 0.11 0.0004 
Src Y416 0.78 0.0350 
p38 MAPK T180 1.62 0.0390 
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Table 3-4: Statistically significant alterations in HCC1954-L cells treated with 
lapatinib plus okadaic acid versus DMSO control by RPPA analysis. 
DMSO v Lapatinib + Okadaic acid 
Protein Phosphorylation site Fold change p value 
EGFR Y1068 0.41 0.003 
MEK 1/2 S217 0.41 0.001 
GAB1 Y627 0.49 0.017 
EGFR Y1173 0.68 0.001 
HER2 Y1248 0.73 0.003 
mTOR - 0.74 0.042 
HER3 Y1289 0.75 0.006 
MAPK T202/Y204 0.76 0.027 
Src Y416 0.76 0.016 
Shc Y317 0.76 0.040 
RAF - 0.78 0.003 
mTOR S2448 0.79 0.019 
VEGFR2 - 0.86 0.042 
Akt - 1.39 0.048 
NFκB p65 S536 2.99 0.001 
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Figure 3-14: Pathway analysis of HCC1954-L cells treated with lapatinib plus 
okadaic acid using PANTHER software. 
 
3.10 Sensitivity of lapatinib resistant cell lines to LB-100 
 
Although okadaic acid is a potent PP2A inhibitor, it is not safe as a therapeutic 
treatment [237, 282]. However, several PP2A inhibitors have been investigated in 
clinical trials. LB-100 (Lixte, Biotechnology), a therapeutic PP2A inhibitor, has 
recently been tested in a Phase I clinical trial in solid tumours and has been shown to 
enhance response to chemotherapy and radiotherapy in pre-clinial studies [196, 258, 
259, 264]. Both lapatinib resistant cell lines and their parental cell lines were tested 
for sensitivity to LB-100 (Figure 3-15). Similar to PP2A inhibition with okadaic acid, 
SKBR3-L and HCC1954-L cell lines were significantly more sensitive to LB-100 
compared to their respective parental cell lines. The LB-100 IC50 value for SKBR3-L 
cells was 2.13 ± 0.20 µM compared to 5.38 ± 0.60 µM for SKBR3-Par cells. The LB-
100 IC50 values for HCC1954-L and HCC1954-Par cells were 2.31 ± 0.19 µM and 
5.32 ± 0.82, respectively. Furthermore, lapatinib plus LB-100 was synergistic in the 
HCC1954-L and SKBR3-L cells (CI value at ED50 = 0.68 ± 0.26 and 0.56 ± 0.13, 
respectively) (Figure 3-16).  
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Figure 3-15: Proliferation of (A) SKBR3-Par and SKBR3-L and (B) HCC1954-
Par and HCC1954-L treated with LB-100 for 5 days was measured by acid 
phosphatase assay. Error bars represent standard deviation of biological 
triplicate experiments. 
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Figure 3-16: Proliferation of (A) SKBR3-L and (B) HCC1954-L treated with 
lapatinib, LB-100, or lapatinib plus LB-100 for 5 days was measured by acid 
phosphatase assay. Error bars represent standard deviation of biological 
triplicate experiments. 
 
3.11 Assessment of sensitivity to LB-100 in 3D growth assays 
 
In addition to examining the effect of LB-100 alone and in combination with lapatinib 
in 2D adherent culture, SKBR3-L and HCC1954-L cells were tested in 3D Matrigel 
growth assays (Figure 3-17). This is more representative of the in vivo tumour 
environment. 
Both cells lines maintained lapatinib resistance in 3D conditions following 7-day 
treatment. The lapatinib IC50 values for SKBR3-L and HCC1954-L cells were 1.02 ± 
0.21 µM and 1.68 ± 0.37 µM. SKBR3-L displayed altered response to LB-100. 
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SKBR3-L cells were significantly less sensitive to LB-100 compared to adherent 
conditions (LB-100 IC50 value = 11.6 ± 0.46 µM versus 2.13 ± 0.2 µM in 2D assay). 
Lapatinib and LB-100 did not enhance response to lapatinib (CI value at ED50 = 0.95 
± 0.49). The LB-100 IC50 value was also reduced in HCC1954-L cells, 5.00 ± 0.12 
µM compared to 2.31 ± 0.19 µM. However, lapatinib plus LB-100 was synergistic in 
HCC1954-L cells in 3D (CI value at ED50 = 0.51 ± 0.07). LB-100 IC50 values and CI 
at ED50 values are summarised in Table 3-5. 
 
 
 
Figure 3-17: Proliferation of (A) SKBR3-L and (B) HCC1954-L treated with 
lapatinib, LB-100, or lapatinib plus LB-100 for 7 days in 3D growth conditions 
was measured by Presto blue assay. Error bars represent standard deviation of 
triplicate experiments. 
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Table 3-5: LB-100 response in SKBR3-L and HCC1954-L cells 
 SKBR3-L SKBR3-Par HCC1954-L HCC1954-Par 
LB-100 IC50 
2D assay (µM) 
2.12 ± 0.20 5.38 ± 0.60 2.31 ± 0.19 5.32 ± 0.82 
Lapatinib + 
LB-100 
CI 2D assay 
0.56 ± 0.13 - 0.68 ± 0.26 - 
LB-100 IC50  
3D assay (µM) 
11.6 ± .046 - 5.0 ± 0.12 - 
Lapatinib + 
LB-100 
CI 3D assay 
0.95 ± 0.49 - 0.51 ± 0.07 - 
 
 
3.12 The effect of lapatinib and LB-100 on cell cycle progression 
 
SKBR3-L and HCC1954-L cells were treated with lapatinib, LB-100, and lapatinib 
plus LB-100 for 48 h and cell cycle progression was analysed by flow cytometry 
(Figure 3-18 and Figure 3-19). Lapatinib alone caused G1 arrest in SKBR3-L (41.8 ± 
2.5% versus 55.3 ± 8.7%)  (p = 0.01) and HCC1954-L cells (28.2 ± 0.6% versus 37.2 
± 0.3%) (p = 1.6 x 10-5). LB-100 increased the SubG1 population of SKBR3-L cells 
(p = 0.019). The combination of lapatinib and LB-100 did not significantly increase 
the Sub G1, apoptotic population compared to LB-100 alone (23/8 ± 8.5% versus 22.6 
± 6.1%)  (p = 0.82). In the HCC1954-L cell line model, LB-100 significantly induced 
apoptosis (p = 0.046), which was enhanced in combination with LB-100 (Sub G1 
with LB-100 = 10.7 ± 1.6% compared to 15.3 ± 2.2% with combination) (p = 0.046). 
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Figure 3-18: Percentage population of SKBR3-L cells treated with 1 µM 
lapatinib, 5 µM LB-100, lapatinib plus LB-100 in SubG1, G1, S, and G2 phases 
of the cell cycle. Cell cycle analysis was performed using the Guava EasyCyte 
and analysed using ModFit LT software. Error bars represent standard 
deviation of triplicate experiments. The Student’s t test was used to determine 
statistical significance. * denotes p < 0.05, ** denotes p < 0.01. 
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Figure 3-19: Percentage population of HCC1954-L cells treated with 1 µM 
lapatinib, 5 µM LB-100, lapatinib plus LB-100 in SubG1, G1, S, and G2 phases 
of the cell cycle. Cell cycle analysis was performed using the Guava EasyCyte 
and analysed using ModFit LT software. Error bars represent standard 
deviation of triplicate experiments. The Student’s t test was used to determine 
statistical significance.  * denotes p < 0.05, ** denotes p < 0.01, *** denotes p < 
0.001. 
 
3.13 The effect of LB-100 plus neratinib on lapatinib resistant cells 
As discussed in Section 3.2.1, lapatinib resistant cell lines have reduced sensitivity to 
neratinib; and LB-100 has been shown to enhance response to lapatinib. It was 
hypothesised that LB-100 may enhance the effect of neratinib in lapatinib resistant 
breast cancer. Proliferation assays showed that neratinib plus LB-100 is synergistic in 
HCC1954-L cells with a CI value at ED50 of 0.61 ± 0.04 (Figure 3-20). Similar to 
lapatinib plus LB-100, neratinib plus LB-100 did not show an additive effect in the 
SKBR3-L cells (Figure 3-21). 
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Figure 3-20: Proliferation of HCC1954-L treated with 0-5 µM neratinib, 20 µM 
LB-100, or neratinib plus LB-100 (1:4 ratio) for 5 days was measured by acid 
phosphatase assay. Error bars represent standard deviation of biological 
triplicate experiments. 
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Figure 3-21: Proliferation of SKBR3-L treated with 0-2.5 µM neratinib, 10 µM 
LB-100, or neratinib plus LB-100 (1:4 ratio) for 5 days was measured by acid 
phosphatase assay. Error bars represent standard deviation of biological 
triplicate experiments. 
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3.15 Summary 
 
Both acquired lapatinib resistant cell lines, SKBR3-L and HCC1954-L, were cross-
resistant to the pan HER irreversible inhibitors, neratinib and afatinib, and to both 
monoclonal antibodies, trastuzumab and pertuzumab. This suggests that another 
therapeutic strategy other than targeting HER2 may be required to overcome 
resistance.  
PP2A represents a potential novel therapeutic target to overcome lapatinib resistance. 
Previous work in our lab and the data generated in this study suggest that the 
development of lapatinib resistance may increase PP2A activity [154]. This increased 
PP2A activity contributes to the lapatinib resistant phenotype, as activating PP2A 
decreased lapatinib sensitivity in both parental cell lines. Lapatinib resistant cell lines 
were more sensitive to PP2A inhibition by okadaic acid and LB-100, compared to the 
parental cells. RPPA analysis showed that inhibition with lapatinib plus okadaic acid 
significantly reduced cell survival signalling in HCC1954-L cells, with down-
regulation of EGFR, HER2 and HER3 phosphorylation and downstream signalling 
components such as phosphorylated Shc, GAB1, MEK 1/2, MAPK, and Src. LB-100 
enhanced the effect of lapatinib in HCC1954-L cells in adherent and 3D conditions. 
LB-100 caused induction of apoptosis in both SKBR3-L and HCC1954-L cells, which 
was further enhanced with lapatinib in the HCC1954-L cell line. The combination of 
lapatinib and PP2A inhibition was also able to prevent the development of lapatinib 
resistance in short-term resistance assays. These data taken together suggest that the 
combination of lapatinib and LB-100 may be effective in both lapatinib resistant and 
lapatinib naive HER2-positive breast cancer.  
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4 Assessment of LB-100 in lapatinib 
resistant breast cancer in vivo 
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4.1 Introduction 
 
The efficacy of LB-100 alone and in combination with lapatinib was assessed in vitro 
in 2D and 3D conditions in two lapatinib resistant cell lines (Section 3.10 and 3.11). 
The HCC1954-L cell line showed in vitro sensitivity to LB-100 and had a synergistic 
response to lapatinib plus LB-100. Similar responses were observed in 3D growth 
conditions. HCC1954 and HCC1954-L cells have been demonstrated to grow in vivo 
[283]. Therefore, HCC1954-L cells were chosen as the cell line model to progress to 
in vivo assessment of LB-100 in combination with lapatinib. LB-100 has been tested 
in vivo alone and in combination with chemotherapy and radiotherapy [259, 264, 
265]. However, LB-100 has not been previously administered with HER2-targeted 
therapies. 
The objectives of this study were (i) to optimise tumour growth conditions for the 
HCC1954-L cells in mice; (ii) to examine the safety of lapatinib and LB-100 in vivo;  
(iii) to determine if HCC1954-L cells retain the therapeutic targets of LB-100 and 
lapatinib; (iv) to determine if HCC1954-L cells maintain lapatinib resistance in vivo; 
and (v) to investigate the effect of LB-100 and lapatinib on HCC1954-L xenograft 
tumour growth in vivo. 
 
4.2 Optimisation of HCC1954-L tumour growth 
4.2.1 Pilot study to determine optimum cell number 
 
In order to assess the optimum cell number for tumour growth, six 8-week old, female 
SCID mice were subcutaneously inoculated bilaterally with HCC1954-L cells, with 1 
x 107 cells (higher cell number) injected on the left side and 5 x 106 cells (lower cell 
number) on the right. Cells were injected in a 1:1 ratio with extracellular matrix. Mice 
were 17.5 ± 0.5 g in weight at the time of tumour inoculation.  
Tumours were allowed to develop and, when of sufficient size, were measured with 
calipers. Both cell numbers caused tumour growth (Figure 4-1). Individual tumour 
growth is represented in Figure 4-2 A and B. After 10 days, four of six mice had 
palpable tumours but were too small to measure. Mice implanted with the higher cell 
number had measurable tumours by day 21 (21.8 ± 7.6 mm3, n = 5) and, after an 
additional 6 days, three of the lower cell number implant tumours were measurable 
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(16.7 ± 5.1 mm3). The average tumour volume 49 days after implantation was 248.3 ± 
25.6 mm3 and 169.8 ± 34.1 mm3 for the higher and lower cell number, respectively. 
The take rate for both cell numbers was 5 out of 6 (83.3%). Although, the higher cell 
number implant tumours developed earlier and were larger by day 49, the lower cell 
number implant tumours surprisingly had a shorter doubling time. The tumour 
doubling time for the tumours implanted at higher cell number was 7.56 ± 0.99 days. 
The tumour doubling time for the lower cell number was 6.01 ± 1.01 days (Figure 4-
3Figure 4-3). Doubling time was caluclated for each individual tumour as described 
in Section 2.16. 
 
 
Figure 4-1: Average tumour growth of HCC1954-L cells in mice (n=5) bilaterally 
implanted with 1 x 107 cell implant (blue) and 5 x 106 cell implant (red). Tumour 
dimensions were measured by calipers and tumour volume was calculated as 
(Height x Width x Depth)/1.9. Error bars represent standard error of the mean 
of at least four tumours. 
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Figure 4-2: Individual growth rate of HCC1954-L cells in SCID mice implanted 
with (A) 1 x 107 and (B) 5 x 106 cells/mouse. Tumour dimensions were measured 
by calipers and tumour volume was calculated as (Height x Width x Depth)/1.9. 
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Figure 4-3: Tumour doubling time for 1 x 107 and 5 x 106 cell implant tumours. 
Doubling time was calculated as described in Section 2. Error bars represent 
standard deviation of five tumours. The Student’s t test was used to determine 
statistical significance. * denotes p ≤ 0.05. 
 
4.2.2 The effect of tumour burden on general health 
 
The health of all mice was monitored daily and mouse body weight was used as an 
indicator of overall health of the animal. Mice with bilateral tumour implantation 
were weighed twice weekly and no significant effect of implantation of cells and 
growth on mouse weight was observed. Mice were 17.5 ± 0.5 g at implantation and 
19.1 ± 1.0 g at day 47 (Figure 4-4).  
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Figure 4-4: The weight of each mouse was normalised to its weight at tumour 
implantation and measured throughout the study. Error bars represent standard 
deviation (n = 5). 
To assess the safety of the combination of lapatinib plus LB-100 six mice on study 
were randomized into two groups; group A were untreated and group B were 
administered lapatinib daily Monday to Friday and LB-100 Monday, Wednesday, and 
Friday (Table 4-1). Treatment began on day 47.  
 
Table 4-1: Randomisation of animals for treatment groups. 
Groups for pilot study of 
combination 
Control Treatment 
M1 M3 
M5 M4 
M6 M2 
 
However, due to skin ulceration which occurred predominantly in the mice implanted 
with 1 x107 cells (Figure 4-5), the pilot study had to be terminated early and treatment 
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was stopped after just 6 days. Skin ulceration can occur when tumour cells or tissue 
are implanted subcutaneously. This is seen by a loss of skin integrity, hair loss over 
the tumour, and skin breakage. This can be due to large tumour size, fast tumour 
growth, or changes in internal tumour pressure [284]. 
Skin ulceration began on Day 36 post implantation in M3. All of the higher cell 
number tumours and one of the lower cell number tumours developed skin ulceration. 
When the skin broke over the tumours, the animal was culled for humane reasons. 
The first mouse culled due to ulceration was on day 52 (M2) and three more were 
culled on day 53. The study was terminated on day 70 with one animal remaining.  
 
Figure 4-5: Images of skin ulceration and hair loss on mice implanted with 1 x 
107 cells (A and C) and 5 x 106 cells (B and D). A and B are images of M4, C and 
D are of M2. 
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This pilot study confirmed the tumorigenesis of the HCC1954-L cells but suggested 
that 5 x 106 cells may be a better cell number for implantation due to the skin 
ulceration occurring in of all the mice implanted with 1 x 107 cells. However, the 
average tumour volume achieved at day 53, in the five mice with measurable tumours, 
was 178.7 ± 29.3 mm3. This would be too small to assess any differences in tumour 
size with treatment in a drug efficacy study. Therefore, an additional pilot study was 
proposed to further assess implantation of 5 x 106 cells and to determine if skin 
ulceration would occur at a larger tumour size in mice implanted with 5 x 106 cells. 
 
4.2.3 Pilot study to test 5 x 106 cell subcutaneous implantation 
 
Six female SCID mice were injected subcutaneously in the flank, with 5 x 106 
HCC1954-L cells, in a 1:1 ratio with extracellular matrix. At implantation, the 
animals were on average 21.5 ± 0.5 g in weight. 15 days after implantation, 
measurable tumours developed (Figure 4-6). The average volume of these tumours 
was 80.9 ± 8.5 mm3. Unfortunately, skin ulceration again occurred. This time after 21 
days, ulceration occurred in three of the six mice inoculated, with a further mouse 
developing ulceration on day 22. Therefore, this pilot study was ended as humane 
endpoints were reached in 4 of 6 animals, with final average tumour volumes of 128.0 
± 38.8 mm3. 
It was concluded from these two pilot studies that subcutaneous injection of 
HCC1954-L cells at either 1 x 107 or 5 x 106 cells/implant was not recommended for 
drug efficacy testing. 
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Figure 4-6: Individual growth rate of HCC1954-L cells in SCID mice (n=5) 
unilaterally implanted with 5 x 106 cells/mouse. Tumour dimensions were 
measured by calipers and tumour volume was calculated as (Height x Width x 
Depth)/1.9. 
 
4.2.4 Mammary fat pad implantation of HCC1954-L cells 
 
As skin ulceration limited the achievable tumour volumes in the previous pilot 
studies, the site of implantation, the cell number, and the strain of mouse were altered. 
The site of implantation was changed to the mammary fat pad. It was hypothesised 
that moving the site of implantation further from the skin would reduce the 
occurrence of skin ulceration. The mammary fat pad also provides a milieu more 
reflective of the tumour microenvironment in patients [285].  As the change of 
implantation involved injection of cells directly into a small organ, the cell number 
and injection volumes were decreased to 5 x 105/50 µL per injection. The strain of 
mouse was changed from SCID to BALB/c nude mice. This was due to a 
recommendation from collaborators who reported a lower frequency of skin 
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ulcerations when HCC1954 cells were implanted in the mammary fat pad of BALB/c 
nude (personal communication, Dr Ian Miller and Prof Annette Byrne, Royal College 
of Surgeons in Ireland).  
Mice implanted with HCC1954-L in the mammary fat pad developed xenograft 
tumours (Figure 4-7 and 4-8), with measurable tumours after 13 days (M1 and M3, 
average tumour volume = 2.9 ± 1.2 mm3). By day 59, four of six mice were tumour 
bearing (Figure 4-9 and 4-10). Therefore, the tumour take rate was 66.7%. One 
additional tumour developed at day 90 (tumour volume = 40.4 mm3). However, this 
tumour was not located in the mammary fat pad and was subcutaneous. This was most 
likely due to inaccurate injection. This tumour was excluded in mammary fat pad 
tumour growth analysis. The maximum average achieved was 545.0 ± 190.1 mm3 at 
day 85. This includes the largest tumour achieved, 1074.5 mm3, in M6. This mouse 
was culled as the tumour height (14.7 mm) approached the maximum allowed limit of 
15 mm. Individual mammary fat pad HCC1954-L tumour growth is represented in 
Figure 4-10. The average tumour doubling time was 7.6 ± 2.6 days. 
Skin ulceration did not occur on any tumours. However, hemorrhagic areas occurred 
on the largest tumour (M6) (Figure 4-11), which occurred at day 83 as the tumour 
approached size limits. These tumours were highly vascularised. This can especially 
be observed in Figure 4-11.  
 
 
Figure 4-7: Images of individual mammary fat pad tumours on day 76. 
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Figure 4-8: Image of HCC1954-L tumour that developed subcutaneously rather 
than in the mammary fat pad. 
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Figure 4-9: Average tumour volume of mammary fat pad implanted HCC1954-L 
cells measured by calipers. Error bars represent standard error of the mean, n = 
4 up to day 85; n = 3 from day 87 to 92. 
 
 
 
 122 
 
Figure 4-10: Individual tumour volumes of mammary fat pad implanted 
HCC1954-L cells. 
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Figure 4-11: Image of HCC1954-L mammary fat pad tumour of M6, 83 days 
post-implantation. Hemorrhagic areas observed in black regions on tumour.  
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4.3 HCC1954-L cells maintain lapatinib resistance ex vivo 
 
After euthanasia, tumours were retrieved and part of the tumour was taken for 
primary cell culture. Two of the four tumours taken for primary culture, continued to 
grow ex vivo (M1 and M3) (Figure 4-12). Both samples were tested by 5-day acid 
phosphatase assay for sensitivity to lapatinib, LB-100, and the combination of 
lapatinib and LB-100 (Figure 4-13Figure 4-13). Both cell populations maintained 
resistance to lapatinib. The IC50 values for M1 and M3 were 2.23 µM and 1.39 µM, 
respectively. This is similar to IC50 values achieved in previous 2D and 3D assays of 
HCC1954-L cells. Similarly, ex vivo HCC1954-L cells maintained a similar response 
to LB-100. LB-100 IC50 values were 5.28 µM and 3.81 µM. Importantly, the synergy 
previously observed with lapatinib and LB-100 was replicated with the ex vivo 
HCC1954-L cells, with CI values of 0.67 and 0.79. 
 
 
Figure 4-12: Representative images of ex vivo HCC1954-L cells in culture after 
tumour retrieval. Images were taken at 200X magnification. 
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Figure 4-13: Sensitivity of the ex vivo HCC1954-L cells to lapatinib, LB-100, and 
lapatinib plus LB-100 was assessed by 5-day acid phosphatase assay. The data 
shown is an average of two ex vivo samples. 
 
4.4 Assessment of the side effects of LB-100 and lapatinib in vivo 
 
Due to the problems with ulceration and the requirement to change mouse strain and 
implantation site a decision was made to perform a separate toxicity study using six 
BALB/c nude mice, which were divided into two groups (untreated control and 
lapatinib plus LB-100 treatment group). The three mice on treatment received 
lapatinib and LB-100 for 45 days. All six mice were checked for adverse events and 
weighed three times per week. The lapatinib plus LB-100 did not have a significant 
effect on body weight (p = 0.42) (Figure 4-14 and Figure 4-15). As lapatinib inhibits 
both HER2 and EGFR, it has been shown to cause skin rashes, redness or peeling of 
skin, and hair loss [286, 287]. Repeated intra-peritoneal injection can also cause skin 
necrosis at the site of injection [288]. Therefore, mice were monitored for signs of 
skin damage. To minimise damage from repeated intra-peritoneal injection, the 
injection site was alternated between left and right sides for each injection. All mice 
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on treatment had no signs of necrosis or skin rashes (Figure 4-16). LB-100 has been 
shown to cause dyspnea (shortness of breath) in humans. No breathing difficulties 
were observed in mice treated with LB-100 and lapatinib.   
 
 
Figure 4-14: Relative weight change of BALB/c nude mice treated Monday – 
Friday with LB-100 and Monday, Wednesday, and Friday with lapatinib (Red) 
or untreated (Blue). Error bars represent standard error of the mean with three 
animals per group. The Student’s t test was used to determine statistical 
significance. 
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Figure 4-15: Relative weight change of individual BALB/c nude mice treated 
Monday – Friday with LB-100 and Monday, Wednesday, and Friday with 
lapatinib (Red) or untreated (Blue). 
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Figure 4-16: Images representative of the abdomen of control and treated mice 
taken after 39 days on treatment.  
 
4.5 Pharmacodynamic effects of lapatinib and LB-100 on HCC1954-L cells in 
vivo 
 
Prior to the early termination of the first pilot study of subcutaneous implantation of 
HCC1954-L cells, animals were divided into two groups of three with one group 
receiving lapatinib plus LB-100. Treatment was ended after six days and no effect on 
tumour growth was observed. However, tumours were retrieved post-mortem and 
analysed for changes in total and phosphorylated levels of eEF2, as a marker for 
PP2A activity. This was also compared to basal levels in HCC1954-L cells grown in 
vitro (Figure 4-17). Total levels of eEF2 were unchanged between in vitro grown 
HCC1954-L and HCC1954-L cells in vivo. Phosphorylated eEF2 was slightly 
decreased in in vivo cells. The tumour from a mouse treated with lapatinib and LB-
100 showed a significant increase in phospho-eEF2 levels compared to an untreated 
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HCC1954-L tumour sample. In order to to ensure that the protein expression in vivo 
was due to HCC1954-L cells, the expression of human mitochondria was examined 
by immunohistochemistry (Figure 4-18). HCC1954-L tumour tested positive for 
human mitochondria similar to cells grown in vitro. In vivo samples showed some 
positive staining in negative controls, which was due to sample preparation. 
 
 
Figure 4-17: Western blotting of total and phosphorylated eEF2 levels in 
HCC1954-L cells grown in vitro, in vivo, and in vivo with lapatinib plus LB-100 
treatment. Tubulin was used as a loading control. Blot shown representative of 
individual in vivo tumours. 
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Figure 4-18: Immunohistochemistry of HCC1954-L cells grown in vitro and in 
vivo in SCID mice for human mitochondria (200X magnification). 
 
4.6 Summary 
 
HCC1954-L cells were demonstrated to grow in vivo following both subcutaneous 
and mammary fat pad implantation. However, skin ulceration limited the length of 
study and achievable tumour volumes following subcutaneous implantation. All mice 
implanted with 1 x 107 cells and one mouse implanted with 5 x 106 cells ulcerated in 
the bilateral pilot study. The 5 x 106 cell implantation was repeated. However, 
ulceration also occurred before tumour volumes, which would allow for the 
observation of drug effect changes, were reached. Importantly, implantation in the 
mammary fat pad of BALB/c nude mice did not result in the development of skin 
ulceration. 
The combination of lapatinib and LB-100 was shown to be safe in BALB/c nude mice 
on long-term treatment, with no significant side effects observed. Preliminary data 
suggest that LB-100 is active in vivo and inhibits PP2A activity in HCC1954-L 
tumours. 
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Thus the conditions for evaluating the efficacy of lapatinib plus LB-100 in vivo have 
been optimised and this will be performed using HCC1954-L cells mammary fat pad 
xenografts in BALB/c nude mice.  
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5 PP2A in innate resistance to HER2-
targeted therapy 
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5.1 Introduction  
 
As Chapter 3 showed, PP2A is a potential mediator of lapatinib resistance in two 
lapatinib-resistant HER2-positive breast cancer cell lines. Clinically, lapatinib 
resistance can emerge after an initial response to lapatinib. However, HER2-positive 
breast cancer tumours can also have de novo resistance to lapatinib. Therefore, the 
possible role for PP2A in innate lapatinib resistance merited investigation. In this 
study, a panel of HER2-positive breast cancer cell lines with varying sensitivities to 
HER2-targeted therapies were examined for sensitivity to okadaic acid and LB-100 
and expression levels of PP2A subunits. 
 
5.2 HER2-positive breast cancer cell line panel response to lapatinib and 
trastuzumab 
 
A panel of HER2-positive breast cancer cell lines was assessed for lapatinib by 5-day 
acid phosphatase proliferation assay (Table 5-1). Of the 10 cell lines tested, three cell 
lines were classified as lapatinib resistant, with an IC50 value greater than 1 µM. 
Trastuzumab sensitivity was taken from [184] (Table 5-2). Six of the 11 cell lines 
were classified as trastuzumab resistant using the fold change cut-off of ≤ 1.2. 
Response to lapatinib was shown to correlate with response to trastuzumab (p = 
0.004) (Figure 5-1).  
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Table 5-1: Lapatinib IC50 values of a panel of HER2-positive breast cancer cell 
lines.  
Lapatinib IC50 values (nM) 
EFM192A 20.2 ± 18.6 
BT474 23.9 ± 19.6 
SKBR3 25.9 ± 2.9 
HCC1419 63.1 ± 29.7 
HCC1569 242.0 ± 8.7 
MDA-MB-361 323.5 ± 50.8 
HCC1954 582.0 ± 31.0 
JIMT-1 1416.0 ± 371.9 
UACC732 3180.0 ± 939.0 
MDA-MB-453 5186.3 ± 1542.8 
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Table 5-2: Trastuzumab response in panel of HER2-positive breast cancer cell 
lines taken from [184]. Fold change was calculated from the ratio of doubling 
time in the presence of trastuzumab divided by the doubling time in the absence 
of drug. 
 
Fold change with 10 µg/mL 
trastuzumab 
 Average StDev 
BT474 5.00 1.05 
EFM192A 1.86 0.54 
UACC812 1.49 0.27 
SKBR3 1.45 0.09 
MDA-MB-361 1.21 0.22 
HCC1419 1.18 0.02 
UACC732 1.17 0.01 
JIMT-1 1.15 0.1 
HCC1954 1.08 0.1 
MDA-MB-453 1.04 0.04 
HCC1569 1.04 0.06 
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Figure 5-1: Lapatinib IC50 values versus growth fold change with 10 µg/mL 
trastuzumab of HER2-positive breast cancer cell lines. R values and p values 
were calculated using Spearman rank correlation. 
 
5.3 Okadaic acid sensitivity in HER2-positive breast cancer panel 
 
In order to determine the relationship between HER2-targeted therapy resistance and 
sensitivity to PP2A inhibition, the panel of HER2-positive breast cancer cell lines was 
assessed for sensitivity to 5 nM okadaic acid (Figure 5-2). Okadaic acid caused 
growth inhibition in all cell lines tested, which indicates that PP2A may not be 
playing a tumour suppressor role in these cell lines. Correlation between response to 
okadaic acid and lapatinib or trastuzumab sensitivity was examined using Spearman 
rank correlation analysis. Sensitivity to okadaic acid was found to positively correlate 
with resistance to both lapatinib (p = 0.01) and trastuzumab (p = 0.01) (Figure 5-3 A 
and B).  
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Figure 5-2: Proliferation of cell lines following 5-days of 5 nM okadaic acid 
treatment. Cell lines were ranked by lapatinib sensitivity. Percentage growth was 
calculated relative to untreated control and error bars represent standard 
deviation of biological triplicate experiments. 
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Figure 5-3: Relationship between (A) lapatinib IC50 values or (B) trastuzumab 
response and growth response with 5 nM okadaic acid treatment. Blue dots 
indicate cell lines sensitive to trastuzumab or lapatinib and red dots indicate 
resistance. R values and p values were calculated using Spearman rank 
correlation. 
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5.3.1.1 The effect of lapatinib plus okadaic acid on innately resistant cell lines 
 
The combination of lapatinib and okadaic acid had an additive effect in both the 
SKBR3-L and HCC1954-L cells (Section 3.3). The three cell lines innately resistant 
to both trastuzumab and lapatinib were tested for sensitivity to 500 nM lapatinib, 5 
nM okadaic acid, and lapatinib plus okadaic acid. Two of the three cell lines showed a 
significant enhancement in growth inhibition, the MDA-MB-453 cells (p value = 
0.0001) and the UACC-732 cells (p value = 0.02) (Figure 5-4). The combination had 
a slight but significant antagonistic effect in the JIMT-1 cells, with a 6.3% increase in 
percentage growth with the combination compared to okadaic acid alone (p value = 
0.015). A selection of five lapatinib sensitive cell lines was assessed for their 
sensitivity to lapatinib plus okadaic acid. The combination of lapatinib plus okadaic 
acid significantly decreased cellular proliferation in one of the five cell lines, 
HCC1569 cells (p = 0.0005) (Figure 5-5). In summary, lapatinib plus okadaic acid 
had an additive effect in three of eight cell lines and an antagonistic effect was only 
observed in one cell line. 
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Figure 5-4: Proliferation of JIMT-1, UACC-732, and MDA-MB-453 cells 
following 5-day treatment with 500 nM lapatinib, 5 nM okadaic acid, and 
lapatinib plus okadaic acid. Error bars represent standard deviation of 
biological triplicate experiments. Percentage growth is relative to untreated 
control cells. The Student’s t test was used to determine statistical significance. * 
denotes a p value of < 0.05, *** denotes a p value of < 0.001.  
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Figure 5-5: Proliferation of SKBR3, BT474, and HCC1419 treated with 50 nM 
lapatinib, 5 nM okadaic acid, and lapatinib plus okadaic acid, and HCC1569 and 
HCC1954 treated with 250 nM lapatinib, 5 nM okadaic acid, and lapatinib plus 
okadaic acid. Error bars represent standard deviation of biological triplicate 
experiments. Percentage growth is relative to untreated control cells. The 
Student’s t test was used to determine statistical significance.  *** denotes p < 
0.001. 
 
5.4 LB-100 sensitivity in HER2-positive breast cancer panel 
 
LB-100 is the PP2A inhibitor that has made the most clinical progression and is the 
chosen candidate PP2A inhibitor for acquired lapatinib resistance. Therefore, LB-100 
was also tested in the panel of HER2-positive breast cancer cell lines; this would 
indicate the sensitivities of the cell lines to a more clinically relevant inhibitor (Figure 
5-6). Unexpectedly, LB-100 sensitivity did not correlate with sensitivity to okadaic 
acid (Figure 5-7 and Table 5-3). This may be due to differences in phosphatase 
inhibitory potency, chemical structure, or off-target effects [289]. LB-100 is a 
cantharidin derivative. Although both okadaic acid and cantharidin most selectively 
inhibit PP2A, they also inhibit other phosphatases at high concentrations. LB-100 
response also did not correlate with either lapatinib or trastuzumab sensitivity (Figure 
5-8 and 5-9).  
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Figure 5-6: Proliferation of 11 HER2-positive breast cancer cell lines treated 
with 0-10 µM LB-100. Error bars represent standard deviation of biological 
triplicate experiments. Lighter series are more resistant to lapatinib. 
Table 5-3: LB-100 IC50 values for HER2-positive breast cancer cell lines. 
LB-100 IC50 value (µM) 
EFM192A > 20 
BT474 7.04 ± 3.56 
SKBR3 5.38 ± 0.46 
HCC1419 > 20 
HCC1569 5.28 ± 0.46 
MDA-MB-361 8.22 ± 2.26 
HCC1954 5.32 ± 0.82 
JIMT-1 4.96 ± 0.68 
UACC732 19.34 ± 3.68 
MDA-MB-453 6.87 ± 0.39 
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Figure 5-7: Relationship between percentage growth with 5 nM okadaic acid 
relative to untreated controls and LB-100 IC50 values of the panel of HER2-
positive breast cancer cell lines. R values and p values were calculated using 
Spearman rank correlation. 
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Figure 5-8: Relationship between LB-100 IC50 values and (A) lapatinib IC50 
values and (B) trastuzumab-induced fold change in growth rate of the panel of 
HER2-positive breast cancer cell lines. R values and p values were calculated 
using Spearman rank correlation. 
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5.4.1.1 The effect of lapatinib plus LB-100 
 
 
Although LB-100 sensitivity did not correlate with innate resistance to HER2-targeted 
therapies, we hypothesised that LB-100 may enhance lapatinib treatment in innately 
resistant cell lines. The three lapatinib resistant cell lines were evaluated for 
sensitivity to the combination therapy (Figure 5-9). Synergy was observed in one of 
the three cell lines tested, the MDA-MB-453 cells (CI value = 0.65 ± 0.16). An 
additive effect was not observed in either JIMT-1 or UACC732 cells (CI values = 
1.21 ± 0.29 and 1.25 ± 0.21 respectively).  
 
 
Figure 5-9: Proliferation of MDA-MB-453, JIMT-1, and UACC732 with 
lapatinib, LB-100, and lapatinib plus LB-100. Error bars represent standard 
deviation of biological triplicate experiments. 
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5.5 PP2A subunit expression in HER2-positive breast cancer cell lines 
 
Alterations in PP2A subunit expression occurs in several cancer types [290, 291]. In 
order to examine if PP2A subunit expression is altered in HER2-positive breast 
cancer cell lines, both isoforms of the catalytic and structural subunits were assessed 
in the panel of cell lines (n=10). The catalytic subunits PPP2CA and PPP2CB did not 
correlate with sensitivity to either lapatinib or trastuzumab (p = 0.33 and 0.16 
respectively) (Figure 5-10). Likewise, the expression levels of PPP2R1A and 
PPP2R1B also did not correlate with lapatinib (p = 0.244 and 0.96) or trastuzumab 
sensitivity (p = 0.185 and 0.444) (Figure 5-11).  
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Figure 5-10: (A) Western blotting of PPP2CA, phospho-PPP2CA, and PPP2CB 
levels in a panel of HER2-positive breast cancer cell lines. Tubulin was used as a 
loading control. Blots shown are representative of triplicate blots. (B) R values 
and p values were calculated using Spearman rank correlation.to determine the 
relationship between total/phospho-PPP2CA, PPP2CB and lapatinib or 
trastuzumab sensitivity. 
B 
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Figure 5-11: (A) Western blotting of PPP2R1A and PPP2R1B levels in a panel of 
HER2-positive breast cancer cell lines. Tubulin was used as a loading control. 
Blots shown are representative of triplicate blots. (B) R values and p values were 
calculated using Spearman rank correlation to determine the relationship 
between PPP2R1A or PPP2R1B and lapatinib or trastuzumab sensitivity. 
  
B 
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5.6 Analysis of PP2A subunit expression in HER2-positive breast cancer 
patients 
5.6.1.1 Correlation between PP2A subunit expression and survival 
 
The expression of the PP2A catalytic and structural subunit isoforms was assessed in 
HER2-positive breast cancer patients and the association with overall and disease-free 
survival was examined. This analysis was done using the publicly available database 
BreastMark (http://glados.ucd.ie/BreastMark) [292]. This was carried out to validate 
the lack of correlation between PP2A subunit levels and HER2-targeted therapy 
response in the panel of HER2-positive cell lines. This database uses gene expression 
and survival data from 26 datasets, corresponding to approximately 17,000 genes and 
4,738 breast cancer patients. In this study, the patient cohort was restricted to HER2-
positive breast cancer patients. For each PP2A subunit, a Kaplan Meier curve was 
plotted. Patient samples with high and low expression of each subunit were stratified 
using the median and the 25th and 75th percentiles.  
The mRNA expression of the α and β subunits of both the catalytic and structural 
subunits did not show a positive or negative correlation with survival outcomes 
(Figure 5-12 – 5-15). The p values for each PP2A subunit and survival outcome are 
summarised in Table 5-4. This is in agreement with the analysis of PP2A catalytic and 
structural subunit expression and the lack of a relationship with trastuzumab or 
lapatinib sensitivity. 
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Figure 5-12: Kaplan Meier survival curves based on PAM50 classifier for OS 
and DFS with high and low expression of PPP2CA. 
 
 
Figure 5-13: Kaplan Meier survival curves based on PAM50 classifier for OS 
and DFS with high and low expression of PPP2CB. 
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Figure 5-14: Kaplan Meier survival curves based on PAM50 classifier for OS 
and DFS with high and low expression of PPP2R1A. 
 
 
 
Figure 5-15: Kaplan Meier survival curves based on PAM50 classifier for OS 
and DFS with high and low expression of PPP2CA. 
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5.6.1.2 Correlation between PP2A endogenous inhibitor expression and survival 
 
As PP2A catalytic and structural subunit expression did not correlate with survival, 
the gene expression levels of the PP2A inhibitor proteins CIP2A and SET were 
assessed. CIP2A and SET both interact with PP2A and reduce its phosphatase 
activity. Increased expression of both of these proteins has been previously associated 
with cancer progression [293]. However, in the BreastMark HER2-positive breast 
cancer dataset, high level expression of SET did not impact survival outcome (p for 
OS = 0.134 and DFS = 0.353) and high levels of CIP2A levels correlated with 
improved overall survival (p = 0.005) (Figure 5-16 and 5-17). CIP2A expression did 
not significantly impact DFS (p = 0.129). In contrast, in another breast cancer survival 
analysis, CIP2A was correlated with positive lymph node status and higher levels of 
proliferation markers. The correlation between low expression of CIP2A and 
improved OS in the BreastMark dataset may indicate that PP2A activity is increased 
in the patient tumours with poorer survival outcomes.  
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Figure 5-16: Kaplan Meier survival curves based on PAM50 classifier for OS 
and DFS with high and low expression of CIP2A. 
 
 
 
Figure 5-17: Kaplan Meier survival curves based on PAM50 classifier for OS 
and DFS with high and low expression of SET. 
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Table 5-4: Significance levels of correlation between PP2A catalytic and 
structural subunits/PP2A inhibitors and OS and DFS. 
Gene Overall survival 
(p value) 
Disease-free survival 
(p value) 
PPP2CA 0.448 0.525 
PPP2CB 0.713 0.923 
PPP2R1A 0.321 0.134 
PPP2R1B 0.537 0.920 
SET 0.134 0.353 
CIP2A 0.005 0.129 
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5.7 Summary 
 
Not all HER2-positive breast cancers have an initial response to HER2-targeted 
therapies and de novo resistance is a common clinical occurrence. This is also 
reflected in immortalised HER2-positive breast cancer cell lines. The panel of cell 
lines assessed had a variety of sensitivities to trastuzumab and lapatinib, with three 
cell lines displaying innate resistance to lapatinib and five cell lines resistant to 
trastuzumab. Okadaic acid caused varying some level of growth inhibition in all cell 
lines tested, indicating that PP2A is not playing a tumour suppressor role in these cell 
lines. The sensitivity to okadaic acid positively correlated with both trastuzumab and 
lapatinib resistance.  
LB-100 was also examined in the panel of HER2-positive breast cancer cell lines. 
Interestingly LB-100 sensitivity did not correlate with response to okadaic acid or 
lapatinib or trastuzumab sensitivity.  
There was no relationship observed between PP2A catalytic and structural subunit 
expression levels in the HER2-positive breast cancer cell lines and their HER2-
targeted therapy sensitivity. Likewise, mRNA levels of the catalytic and structural 
isoforms did not correlate with survival outcomes in the HER2-positive breast cancer 
patients. However, high levels of the PP2A inhibitor protein CIP2A did correlate with 
positive patient outcomes.  
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6 The role of Src in resistance to 
afatinib and neratinib 
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6.1 Introduction 
 
Despite advances in the treatment of HER2-positive breast cancer with HER2-
targeted therapies, the majority of patients with metastatic HER2-positive breast 
cancer develop progressive disease with resistance to HER2 targeted therapies. 
Irreversible HER family inhibitors are in various stages of clinical development and 
represent novel HER2-targeting strategy for these patients. 
Afatinib (Giotrif) is an anilinoquinazoline-derivative which functions as an 
irreversible pan-HER inhibitor, covalently binding to Cys797 of EGFR, Cys805 of 
HER2 and Cys803 of HER4, and rendering the receptors inactive [118]. Afatinib was 
FDA-approved for the treatment of non-small cell lung cancer in 2014 and is 
currently in phase III clinical trials in breast cancer [129]. Afatinib has shown efficacy 
in HER2-positive breast cancer in vitro and in vivo [123]. Canonici et al. showed an 
additive effect for the combination of trastuzumab and afatinib in trastuzumab-
sensitive cell lines [123]. This study also showed that a cell line model of acquired 
trastuzumab resistance was sensitive to afatinib, with afatinib also restoring sensitivity 
to trastuzumab. 
Likewise, neratinib (Nerlynx) is an irreversible HER family tyrosine kinase inhibitor 
that has shown activity in HER2-positive breast cancer in the pre-clinical and clinical 
setting [108]. In addition, following the phase III ExteNET trial, in which neratinib 
improved invasive disease free survival after relapse on trastuzumab, neratinib is 
FDA approved for the treatment of early stage HER2-positive breast cancer [294].  
 
Using afatinib and neratinib resistant cell line models of HER2-positive breast cancer, 
the aim of this study was to examine the mechanisms by which these cells develop 
resistance, and to determine a therapeutic strategy to overcome or prevent resistance 
to irreversible pan-HER inhibitors.  
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6.2 Development of the afatinib-resistant SKBR3-A cell line 
 
The afatinib resistant cell line model, SKBR3-A, was developed by Dr. Alexandra 
Canonici through continuous long-term exposure of the HER2-positive breast cancer 
cell line SKBR3 to afatinib. The SKBR3 cells were treated twice weekly with 150 nM 
afatinib until resistance developed (Figure 6-1 A). An age-matched, parental cell line 
(SKBR3-Par) was cultured alongside the treated cells. No significant morphological 
changes were observed in the afatinib resistant cell line compared to the parental cell 
line (Figure 6-1 B and C). SKBR3-A cells were significantly less sensitive to afatinib, 
with an afatinib IC50 value of 197.7 ± 53.8 nM compared to 10.9 ± 3.4 nM in the 
parental cell line. Pharmacokinetic studies of afatinib dosed at 40 mg per day show a 
peak plasma concentration of 38 ng/mL or 78.2 nM nM [128, 295]. Therefore, the 
cut-off concentration for afatinib sensitivity for this study was set at 80 nM. SKBR3-
A cells are resistant to afatinib at clinically relevant concentrations.  
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Figure 6-1: Proliferation of SKBR3-Par and SKBR3-A cells following 5-day 
treatment with afatinib (0 – 625 nM). Percentage growth was calculated relative 
to untreated control and error bars represent standard deviation of biological 
triplicate experiments. Images taken of SKBR3-A cells and SKBR3-Par cells at 
400X magnification. 
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6.2.1 Effect of HER2-targeted therapies on SKBR3-A and SKBR3-Par 
 
The SKBR3-A cells were also tested for cross-resistance to other HER2-targeted 
therapies. Parental SKBR3 cells are highly sensitive to the HER2-specific monoclonal 
antibody trastuzumab, the dual-targeting (EGFR/HER2) reversible TKI lapatinib, and 
the irreversible pan-HER TKIs afatinib and neratinib. SKBR3-A cells displayed 
cross-resistance to lapatinib and neratinib after five days of treatment (Figure 6-2 A 
and B). The SKBR3-A lapatinib IC50 was 1530.0 ± 380.0 nM compared to 51.0 ± 
23.0 nM for SKBR3-Par cells (30-fold resistance) and the neratinib IC50 value was 
114.0 ± 31.1 nM compared to 3.4 ± 1.1 nM (38-fold resistance). SKBR3-A cells were 
also assessed for altered sensitivity to trastuzumab, pertuzumab and the combination 
of monoclonal antibodies (Figure 6-3). The SKBR3-Par cell line showed 28.9 ± 2.1% 
growth inhibition following five days of trastuzumab treatment (10 µg/mL). In 
contrast, SKBR3-A cell growth was inhibited by 9.7 ± 2.1% (p = 0.0003). 
Pertuzumab also had a reduced anti-proliferative effect on SKBR3-A cells compared 
to the parental cell line, -3.1 ± 6.3% compared to 14.2 ± 1% (p = 0.009). The 
enhanced combination effect observed in SKBR3-Par cells (42.2 ± 2.2% growth 
inhibition) was also not seen in the SKBR3-A cells (-10.7% ± 8.9% growth 
inhibition) (p = 0.0005). Sensitivity of the SKBR3-A and SKBR3-Par cells to each of 
the HER2-targeted therapies is summarised in Table 6-1.  
 
 
Figure 6-2: Proliferation of SKBR3-Par and SKBR3-A cells following 5-day 
treatment with A) 0 – 10 µM lapatinib and B) 0 – 1.25 µM neratinib. Percentage 
growth was calculated relative to untreated control and error bars represent 
standard deviation of biological triplicate experiments. 
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Figure 6-3: Proliferation of SKBR3-Par and SKBR3-A cells following 5-day 
treatment with 10 µg/mL trastuzumab, 10 µg/mL pertuzumab, trastuzumab plus 
pertuzumab. Percentage growth was calculated relative to untreated control and 
error bars represent standard deviation of biological triplicate experiments. The 
Student’s t test was used to determine statistical significance. ** denotes a p 
value of < 0.01, *** denotes P < 0.001. 
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Table 6-1: SKBR3-A versus SKBR3-Par TKI IC50 values and % growth 
inhibition following treatment with 10 µg/mL trastuzumab and/or pertuzumab. 
Cell line SKBR3-Par SKBR3-A 
Afatinib IC50 (nM) 10.9 ± 3.4 nM 197.7 ± 53.8 
Lapatinib IC50 (nM) 51.0 ± 23.0 1530.0 ± 380.0 
Neratinib IC50 (nM) 3.4 ± 1.1 114.0 ± 31.1 
% Growth inhibition  
10 µg/mL trastuzumab 
28.9 ± 2.1 9.7 ± 2.1 
% Growth inhibition  
10 µg/mL pertuzumab 
14.2 ± 1 -3.1 ± 6.3 
% Growth inhibition 
trast + pert 
42.2 ± 2.2 -10.7 ± 8.9 
 
6.3 Molecular characterisation of SKBR3-A cell line 
6.3.1 Genetic profiling of SKBR3-A cells versus SKBR3-Par cells 
 
Cancers that have become resistant to HER2-targeted therapy have been shown to 
develop genetic mutations, which cause oncogenic signalling changes [170, 198, 
208]. In order to assess genetic alterations between the resistant and parental cells, 
both SKBR3-A and SKBR3-Par cell lines underwent whole exome sequencing, 
performed by Beijing Genomic Institute [271] (as described in Section 2.14). This 
analysis provided copy number variations (CNVs), single nucleotide variations 
(SNVs), and insertions and deletions (InDels). In SKBR3-A cells, 19 InDels were 
observed conpared to the parental cells. Only one of these indels caused a frameshift 
in the protein coding sequence (Table 6-2). This was a frameshift in the lactase (LCT) 
gene. There were 150 unique SNVs observed, 48 of which occurred within genes and 
34 with structural implications on proteins (Table 6-3).  SKBR3-A cells had 168 
unique CNVs compared to SKBR3-Par cells, with four significant deletions and 205 
amplifications. A significant alteration was deemed as a copy number ratio greater 
than 1.4 and less than 0.4 (Table 6-4). The InDel changes did not indicate any 
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possible oncogenic changes. Interestingly, SKBR3-A cells did not display mutations 
or gene amplification of HER family members, which has been shown as a 
mechanism of resistance to HER2-targeted therapies [170, 296]. However, the CNV 
analysis showed alterations in several signalling pathways. A number of genes 
associated with EMT, which has been implicated in lapatinib resistance, had 
significantly increased copy number, including PDE4A, PDE4D, ITGB4, SPHK1, 
S100A9, and NR4A1 [297–301]. SKBR3-A cells also showed gene copy number 
amplification of ITPR4 and TNIK, which are involved in autophagy induction [302]. 
Autophagy can act as a mechanism of cell death and also cell survival and afatinib has 
been shown to induce autophagy [303].  Pathway analysis using PANTHER also 
showed changes in several signalling pathways (Figure 6-4). These pathway 
alterations include inflammation related signalling such as inflammation mediated by 
chemokine and cytokine signalling, CCKR pathway, and T cell activation. Growth 
factor signalling was altered including insulin/IGF, VEGF, and PDGF signalling. 
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Table 6-2: Somatic insertions and deletion in SKBR3-A compared to SKBR3-Par 
cells. 
Insertions/Deletions 
Gene name Gene description Region 
CEP104 Centrosomal protein 104 3' UTR 
FBXO28 Centromere protein 30 Intron 
FBXO28 Centromere protein 30 Intron 
ACMSD Aminocarboxymuconate semialdehyde decarboxylase Intron 
LCT Lactase Frameshift 
SESTD1 SEC14 and spectrin domain containing 1 Intron 
USP49 Ubiquitin specific peptidase 49 Downstream 
gene 
KIAA1244 Protein phosphatase 1, regulatory subunit 33 Intron 
NMBR Neuromedin B receptor Intron 
LRCH4 Leucine rich repeats and calponin homology domain 
containing 4 
Intron 
ST7 Suppression of tumorigenicity 7 Intron 
DYRK4 Dual specificity tyrosine phosphorylation regulated kinase 
4 
Intron 
LEMD3 LEM domain containing 3 Intron 
ANP32A Acidic nuclear phosphoprotein 32 family member A 3' UTR 
AKAP13 A-kinase anchoring protein 13 Intron 
DNAH17 Dynein axonemal heavy chain 17 Intron 
ZNF791 Zinc finger protein 791 Intron 
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PRPF31 Pre-mRNA processing factor 31 Intron 
OFD1 Centriole and centriolar satellite protein Intron 
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Table 6-3: Single nucleotide variants in SKBR3-A compared to SKBR3-Par cells. 
Gene Gene description Mutation Nucleotide 
change 
CA6 Carbonic anhydrase 6 Missense  
HIVEP3 Human Immunodeficiency Virus Type I 
Enhancer Binding Protein 3 
Silent  
NCF2 Neutrophil cytosolic factor 2 Missense  
CFH Complement factor H Missense G  
NUP133 Nucleoporin 133 Missense  
LRPPRC Leucine Rich Pentatricopeptide Repeat 
Containing 
Silent  
FER1L5 Fer-1 Like Family Member 5 Missense  
GORASP2 Golgi Reassembly Stacking Protein 2 Silent  
ICOS Inducible T-Cell Costimulator Missense  
PRKAG3 Protein Kinase AMP-Activated Non-
Catalytic Subunit Gamma 3 
Missense  
ARPP21 CAMP Regulated Phosphoprotein 21 Missense  
LZTFL1 Leucine Zipper Transcription Factor Like 
1 
Silent  
CHRD Chordin Silent  
TNK2 Tyrosine Kinase Non Receptor 2 Missense  
KIAA1211 KIAA1211 Missense  
TCOF1 Treacle Ribosome Biogenesis Factor 1 Missense  
ZNF454 Zinc Finger Protein 454 Missense  
HIST1H3A Histone Cluster 1 H3 Family Member A Missense  
HIST1H2AD Histone Cluster 1 H2A Family Member D Missense  
FILIP1 Filamin A Interacting Protein 1 Missense  
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MUC12 Mucin 12, Cell Surface Associated Silent  
GPR22 G Protein-Coupled Receptor 22 Silent  
CNBD1 Cyclic Nucleotide Binding Domain 
Containing 1 
Missense  
MPDZ Multiple PDZ Domain Crumbs Cell 
Polarity Complex Component 
Missense  
ZBTB6 Zinc Finger and BTB Domain Containing 
6 
Missense  
ADARB2 Adenosine Deaminase, RNA Specific B2 Silent  
ASAH2 Neutral Ceramidase Missense  
JMJD1C Jumonji Domain Containing 1C Missense  
OR52B2 Olfactory Receptor Family 52 Subfamily 
B Member 2 
Missense  
OR9G4 Olfactory Receptor Family 9 Subfamily 
G Member 4 
Missense  
AHNAK Neuroblast Differentiation-Associated 
Protein AHNAK 
Missense  
CCDC88B Coiled-Coil Domain Containing 88B Silent  
GLB1L3 Galactosidase Beta 1 Like 3 Silent  
METTL25 Methyltransferase Like 25 Missense  
C14orf119 Chromosome 14 Open Reading Frame 
119  
Missense  
PCNXL4 Pecanex-Like Protein 4 Missense  
ZNF839 Zinc Finger Protein 839 Missense  
AHNAK2 AHNAK Nucleoprotein 2 Missense  
ZNF774 Zinc Finger Protein 774 Missense  
STAT3 Signal Transducer And Activator Of 
Transcription 3 
Silent  
FASN Fatty Acid Synthase Missense  
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ATP8B1 ATPase Phospholipid Transporting 8B1 Missense  
HMHA1 Rho GTPase Activating Protein 45 Missense  
CACTIN Cactin, Spliceosome C Complex Subunit Missense  
ZNF845 Zinc Finger Protein 845 Missense  
THBD Thrombomodulin Silent  
ZNF341 Zinc Finger Protein 341 Missense  
SOGA1 Suppressor Of Glucose, Autophagy-
Associated Protein 1 
Silent  
DIAPH2 Diaphanous Related Formin  Silent  
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Table 6-4: Copy number variations in SKBR3-A compared to SKBR3-Par cells. 
Copy number ratio is given as a relative number of gene copies in SKBR3-A cells 
to SKBR3-Par cells. A cut of >1.5 and < 0.35 copy ratio was used. Complete table 
of significant copy ratio changes in Appendix. 
Gene Gene description Copy 
ratio 
LSM5 LSM5 Homolog, U6 Small Nuclear RNA And MRNA 
Degradation Associated 
0.350 
STS Steroid Sulfatase 0.394 
STAC SH3 And Cysteine Rich Domain 0.527 
ITGA9 Integrin Subunit Alpha 9 0.581 
TRPS1 Transcriptional Repressor GATA Binding 1 1.501 
TFAP2C Transcription Factor AP-2 Gamma 1.501 
ZBTB33 Zinc Finger And BTB Domain Containing 33 1.502 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.506 
QRICH2 Glutamine Rich 2 1.511 
ZNFX1 Zinc Finger NFX1-Type Containing 1 1.514 
EIF4G2 Eukaryotic Translation Initiation Factor 4 Gamma 2 1.520 
TPD52L2 Tumor Protein D52 Like 2 1.524 
F8 Coagulation Factor VIII 1.524 
USP26 Ubiquitin Specific Peptidase 26 1.528 
EPM2AIP1 EPM2A Interacting Protein 1 1.530 
CASKIN2 CASK Interacting Protein 2 1.531 
DCLK3 Doublecortin Like Kinase 3 1.531 
TRANK1 Tetratricopeptide Repeat And Ankyrin Repeat Containing 1 1.531 
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MLH1 MutL Homolog 1 1.531 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.538 
ATP6V0D2 ATPase H+ Transporting V0 Subunit D2 1.539 
CNGB3 yclic Nucleotide Gated Channel Beta 3 1.539 
ITPR1 Inositol 1,4,5-Trisphosphate Receptor Type 1 1.541 
GRM7 Glutamate Metabotropic Receptor 7 1.541 
DSCC1 DNA Replication And Sister Chromatid Cohesion 1 1.542 
MSC Musculin 1.542 
TRPA1 Transient Receptor Potential Cation Channel Subfamily A 
Member 1 
1.542 
TERF1 Telomeric Repeat Binding Factor 1 1.542 
STAU2 Staufen Double-Stranded RNA Binding Protein 2 1.542 
TCEB1 Transcription elongation factor B polypeptide 1 1.542 
JPH1 Junctophilin 1 1.542 
PEX2 Peroxisomal Biogenesis Factor 2 1.542 
STMN2 Stathmin 2 1.542 
MRPS28 Mitochondrial Ribosomal Protein S28 1.542 
TPD52 Tumor Protein D52 1.542 
KCNB2 Potassium Voltage-Gated Channel Subfamily B Member 2 1.543 
KCNB2 Potassium Voltage-Gated Channel Subfamily B Member 2 1.551 
S100A9 S100 Calcium Binding Protein A9 1.551 
BHLHE40 Basic Helix-Loop-Helix Family Member E40 1.553 
RHBDF2 Rhomboid 5 Homolog 2 1.554 
RDH10 Retinol Dehydrogenase 10 1.556 
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KIAA1210 KIAA1210 1.559 
FLNA Filamin A 1.560 
STAU2 Staufen Double-Stranded RNA Binding Protein 2 1.565 
HERPUD1 Homocysteine Inducible ER Protein With Ubiquitin Like 
Domain 1 
1.565 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.567 
MRPL13 Mitochondrial Ribosomal Protein L13 1.567 
MTBP MDM2 Binding Protein 1.567 
ZACN Zinc Activated Ion Channel 1.569 
C17orf80 Chromosome 17 Open Reading Frame 80 1.570 
MYO15B Myosin XVB 1.574 
MTBP MDM2 Binding Protein 1.577 
SEC16B SEC16 Homolog B, Endoplasmic Reticulum Export Factor 1.579 
PDE4D Phosphodiesterase 4D 1.584 
GPR112 G protein-coupled receptor 112 1.590 
FOXK2 Forkhead Box K2 1.598 
JPH1 Junctophilin 1 1.617 
DLEC1 Deleted In Lung And Esophageal Cancer 1 1.628 
SCN5A Sodium Voltage-Gated Channel Alpha Subunit 5 1.628 
SCN10A Sodium Voltage-Gated Channel Alpha Subunit 10 1.628 
CSRNP1 Cysteine And Serine Rich Nuclear Protein 1 1.628 
CX3CR1 C-X3-C Motif Chemokine Receptor 1 1.628 
RPSA Ribosomal Protein SA 1.628 
FAM104A Family With Sequence Similarity 104 Member A 1.631 
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GPRC5C G Protein-Coupled Receptor Class C Group 5 Member C 1.631 
MYO15B Myosin XVB 1.631 
ITGB4 Integrin Subunit Beta 4 1.631 
EXOC7 Exocyst Complex Component 7 1.631 
SPHK1 Sphingosine Kinase 1 1.631 
CYTH1 Cytohesin 1 1.631 
RPTOR Regulatory Associated Protein Of MTOR Complex 1 1.631 
NPB Neuropeptide B 1.631 
TUFT1 Tuftelin 1 1.649 
SCYL1 SCY1 Like Pseudokinase 1 1.670 
TAF2 TATA-Box Binding Protein Associated Factor 2 1.682 
DEPTOR DEP Domain Containing MTOR Interacting Protein 1.682 
PRKDC Protein Kinase, DNA-Activated, Catalytic Polypeptide 1.712 
NR4A1 Nuclear Receptor Subfamily 4 Group A Member 1 1.751 
REEP2 Receptor Accessory Protein 2 1.834 
HIST1H2BD Histone Cluster 1 H2B Family Member D 1.866 
TNIK TRAF2 And NCK Interacting Kinase 1.892 
KRT7 Keratin 7 1.921 
HIST2H3A Histone Cluster 2 H3 Family Member A 1.950 
FLJ42969 Uncharacterized LOC441374 1.966 
TXNRD1 Thioredoxin Reductase 1 2.055 
CCDC57 Coiled-Coil Domain Containing 57 2.160 
AADACL2 Arylacetamide Deacetylase Like 2 2.217 
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Figure 6-4: PANTHER pathway analysis of CNVs in SKBR3-A cells. 
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6.3.2 RPPA analysis of SKBR3-A cells versus SKBR3-Par 
 
The levels of 73 proteins and phospho-proteins involved in key signalling pathways 
were examined in the SKBR3-A and SKBR3-Par cells by RPPA analysis. Applying a 
p-value of ≤ 0.05, the levels of five proteins/ phospho-proteins were significantly 
decreased and nine significantly increased in the SKBR3-A cells (Table 6-5Table 6-5).  
SKBR3-A displayed changes in the levels of some members of the HER family and 
HER-family-related signalling proteins. SKBR3-A cells had decreased phospho-
HER3 (Y1289) (fold change = 0.4, p = 0.0026), but had significantly increased levels 
of total EGFR (fold change = 2.02, p = 0.043). Phospho- and total-HER2 and HER4 
levels were not significantly affected, although, several phospho-proteins downstream 
of HER family signalling were down-regulated. Levels of phospho-Akt (T308 and 
S473) (fold change = 0.44, p = 0.028, and fold change = 0.01, p = 0.022, respectively) 
were decreased compared to parental cells. However, total levels of the Akt isoform, 
Akt2, (fold change = 2.31, p = 0.0017) were significantly increased. The 
phosphorylated levels of the receptor scaffolding protein, Shc, (fold change = 0.41, p 
= 0.025) and MEK 1/2 (fold change = 0.19, p = 8 x 10-4), a protein involved in the 
ERK signalling cascade, were decreased. The levels of the anti-apoptotic protein Bcl-
2 (fold change = 4.14, p = 0.003) were significantly elevated, along with its activating 
phosphorylated from (S70) (fold change = 1.78, p = 0.027). Interestingly, the NR4A1 
gene, which was found to be amplified in SKBR3-A cells by whole exome 
sequencing, can increase levels of EGFR and Bcl-2 levels [304]. 
The highest fold change (fold change = 4.41, p = 0.028) observed in the RPPA 
analysis was in levels of phosphorylated Src (Y416). Src is an oncogenic kinase that 
has been implicated in trastuzumab and lapatinib resistance in breast cancer and 
afatinib resistance in lung cancer [160, 204, 305]. Src is also a druggable target; 
dasatinib is an FDA-approved Src inhibitor used in the treatment of chronic 
myelogenous leukaemia and acute lymphoblastic leukaemia [220]. Therefore, Src was 
chosen as a candidate drug target to overcome afatinib resistance in HER2-positive 
breast cancer. 
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Table 6-5: Statistically significant alterations in SKBR3-A compared to SKBR3-
Par cells by RPPA analysis. 
Decreased protein level 
Antibody Phosphorylation 
site 
Fold change p value 
p-Akt T308 0.44 2.8 x 10-2 
p-Shc Y317 0.41 2.5 x 10-2 
p-HER3 Y1289 0.40 2.6 x 10-3 
p-MEK1/2 S217/221 0.19 8.0 x 10-4 
p-Akt S473 0.01 2.2 x 10-4 
 
Increased protein level 
Antibody Phosphorylation 
site 
Fold change p value 
p-Src Y416 4.41 2.8 x 10-2 
Bcl-2 - 4.14 3.0 x 10-3 
p53 - 2.46 2.0 x 10-3 
Akt2 - 2.31 1.7 x 10-3 
EGFR - 2.02 4.3 x 10-2 
p-Bcl-2 S70 1.78 2.7 x 10-2 
p27 - 1.46 4.6 x 10-2 
p-AMPK T172 1.40 1.5 x 10-2 
p38 MAPK - 1.38 2.1 x 10-2 
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6.3.2.1 Validation of phospho-Src and total EGFR levels in SKBR3-A cells 
 
The increased levels of phospho-Src (Y416) and EGFR in SKBR3-A cells, which 
were observed by RPPA, were validated by Western blotting (Figure 6-5). Total Src 
levels were unchanged between the SKBR3-A and parental cell lines (p = 0.51). 
However, there was a significant increase in phosphorylated Src (Y416) levels (fold 
change = 2.38, p = 0.04). EGFR levels showed an increase but did not achieve 
statistical significance (fold change = 3.39, p = 0.08).  
 
 
Figure 6-5 (A) Western blotting of SKBR3-Par and SKBR3-A cells for Src and 
phospho-Src (Y416) and EGFR. Blots shown are representative of triplicate 
blots. (B) Densitometry analysis of immunoblots of SKBR3-Par and SKBR3-A 
cells for total and phospho-Src and EGFR. Error bars represent standard 
deviation of biological triplicate experiments. 
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6.4 Assessment of SKBR3-A sensitivity to Src inhibition 
 
The effect of the Src inhibitor dasatinib was assessed using a proliferation assay. 
SKBR3-A cells were moderately more sensitive to dasatinib compared to SKBR3-Par 
cells, with IC50 values of 1718.8 ± 901.8 nM and 2948.7 ± 441.7 nM respectively 
(Figure 6-6). 
 
 
Figure 6-6: Proliferation of SKBR3-Par and SKBR3-A cells following 5-day 
treatment with dasatinib (0 – 1.25 µM). Percentage growth was calculated 
relative to untreated control and error bars represent standard deviation of 
biological triplicate experiments. 
 
6.5 The effect of afatinib and dasatinib on SKBR3-A cells 
 
In order to establish if the addition of Src inhibition would enhance the effect of 
afatinib, SKBR3-A cells were assessed for sensitivity to afatinib, dasatinib and 
afatinib plus dasatinib at a 1:2 ratio, in proliferation assays. The combination of 
afatinib and dasatinib was highly synergistic in SKBR3-A cells (CI value = 0.09 ± 
0.06) (Figure 6-7).  
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Figure 6-7: A) Proliferation of SKBR3-A cells following 5-day treatment with 
afatinib (0 – 625 nM), dasatinib (0 – 1250 nM) and 1:2 afatinib:dasatinib 
combination. Percentage growth was calculated relative to untreated control and 
error bars represent standard deviation of biological triplicate experiments.  
 
6.5.1 Mechanism of action of afatinib and dasatinib combination in SKBR3-A 
cells 
 
The anti-cancer effect of afatinib and dasatinib as single agents can occur through cell 
cycle arrest, apoptosis and/or autophagy [122, 303, 306–309]. Therefore, the 
combination was tested in SKBR3-A cells using assays for cell cycle apoptosis and 
autophagy. 
 
6.5.1.1 The effect on cell cycle progression 
 
SKBR3-A cells were treated with afatinib, dasatinib, and the combination to 
investigate alterations in cell cycle progression, using propidium iodide staining and 
flow cytometry. There was no significant induction of cell cycle arrest with either 
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inhibitor, alone or in combination (p values for G1: control v afatinib = 0.51, control v 
dasatinib = 0.41, control versus combination = 0.09, afatinib versus the combination = 
0.36, dasatinib versus combination = 0.08) (Figure 6-8). Likewise, the subG1 
population was not significantly changed following treatment. However, afatinib plus 
dasatinib increased the combined population of SubG1 and G1 (63.8 ± 2.7%) 
compared to either afatinib (56.5 ± 1.0%, p = 0.03) or dasatinib (48.3 ± 0.7%, p = 
0.007) alone.  
 
 
Figure 6-8: Cell cycle assays of SKBR3-A cells treated with afatinib, and/or 
dasatinib were examined by propidium iodide staining and flow cytometry. 
Error bars represent standard deviation of biological triplicate assays. The 
Student’s t test was used to determine statistical significance. 
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6.5.1.2 Apoptosis induction 
 
In order to determine if the combination of afatinib and dasatinib induces apoptosis, 
SKBR3-A cells treated with afatinib, dasatinib, or the combination were assessed for 
caspase 3/7 activation after 48 h of drug treatment using the Caspase-Glo 3/7 assay. 
Afatinib treatment alone resulted in decreased levels of caspase 3/7 activation (p = 
0.004 compared to DMSO control). The combination of afatinib and dasatinib also 
decreased caspase 3/7 activation (p = 0.007 relative to DMSO), but did not 
significantly alter caspase 3/7 activity compared to afatinib treatment (p = 0.3) (Figure 
6-9). The lack of subG1 population increase and caspase 3/7 activation, suggest that 
afatinib plus dasatinib does not induce apoptotic cell death. 
 
 
Figure 6-9: Caspase 3/7 activation in SKBR3-A cells following 48 h treatment 
with 150 nM afatinib, 300 nM dasatinib, or afatinib plus dasatinib. Error bars 
represent standard deviation of biological triplicate assays. Student’s t test was 
used to determine statistical significance. 
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6.5.1.3 Autophagy induction 
 
Both afatinib and dasatinib individually, have been shown to induce autophagy in 
other cell line models [303, 308]. Induction of autophagy was examined by treating 
SKBR3-A cells with 150 nM afatinib, 300 nM dasatinib or the combination for 2 
days. Evidence of autophagy was then examined by fluorescent microscopy and 
fluorescent photospectrometry. Afatinib treatment alone stimulated a 13% increase in 
autophagy activity (p = 0.04). However, there was no increase in autophagy levels 
with the combination of afatinib plus dasatinib compared to afatinib alone (p = 0.21) 
(Figure 6-10). 
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Figure 6-10: Autophagy levels in SKBR3-A cells treated with DMSO, 150 nM 
afatinib, 300 nM dasatinib, or the combination for 48 h, or 50 µM chloroquine 
for 24 h measured by fluorescent spectroscopy and immunofluorescence images. 
Error bars represent standard deviation of triplicate experiments. The Student’s 
t test was used to determine statistical significance. * denotes p < 0.05. 
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6.5.1.4 Necrosis 
 
Cells undergoing necrosis have been shown to secrete the nuclear protein HMGB1. 
Apoptotic cells can also passively release HMGB1; however, this is cell line 
dependent and may rely on DNA deacetylation [310, 311]. Extracellular HMGB1 was 
found to be elevated 3-fold in conditioned medium of SKBR3-A cells treated with 
afatinib and dasatinib for 48 h (p = 0.039) (Figure 6-11). Secreted HMGB1 levels 
were not significantly increased by either afatinib or dasatinib alone. This result 
suggests that afatinib in combination with dasatinib induces necrosis rather than 
apoptosis or autophagy. 
 
 
Figure 6-11: Western blotting of extracellular and intracellular HMGB1 in 
SKBR3-A cells treated with 150 nM afatinib, 300 nM dasatinib, afatinib plus 
dasatinib. Densitometry was carried out on triplicate assays. Blots shown are 
representative of triplicate blots. Tubulin was used as a loading control. The 
Student’s t test was used to determine statistical significance. Error bars 
represent standard deviation of biological triplicate experiments. * denotes p < 
0.05. 
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6.6 Assessment of afatinib plus dasatinib in other HER2-targeted therapy 
resistant cell lines 
6.6.1 Afatinib plus dasatinib in trastuzumab-resistant cell lines 
 
We have shown that Src is a potential mediator of afatinib resistance. Src has 
previously been implicated in trastuzumab and lapatinib resistance [160, 305]. 
Therefore, we hypothesised that afatinib-sensitive HER2-targeted therapy-naïve and 
trastuzumab-resistant cells may have an improved response to the combination of 
afatinib and dasatinib. A panel of trastuzumab-resistant cell lines (SKBR3-T, BT474-
T, EFM192A-T) and their parental cells (SKBR3-Par, BT474, EFM192A) were 
assessed for sensitivity to afatinib and dasatinib. All six cell lines were highly 
sensitive to afatinib, with IC50 values < 20 nM (Table 6-6). Dasatinib was ineffective 
as a single agent; an IC50 value was not reached at 160 nM dasatinib in any of the six 
cell lines. Three of the six cell lines showed no growth inhibition with 160 nM 
dasatinib alone. BT474 cells were most sensitive to dasatinib with 68.2 ± 7% growth 
following treatment with 160 nM dasatinib. The trastuzumab resistant variant, 
BT474-T, was less sensitive to 160 nM dasatinib, with 91.5 ± 10.1% growth. The 
combination of afatinib and dasatinib did not enhance response to afatinib in the cell 
lines tested (Figure 6-12). However, SKBR3-T cell did show a small additive effect at 
40 and 80 nM (p = 0.008 and 0.001, respectively). 
 
Table 6-6: Afatinib IC50 values for trastuzumab-resistant and parental cell lines. 
Afatinib IC50 values (nM) 
SKBR3-Par SKBR3-T BT474 BT474-T EFM192A EFM192A-T 
6.6 ± 0.4 14.4 ± 1.9 4.3 ± 1.4 2.8 ± 1.5 8.4 ± 6.2 12.9 ± 5.1 
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Figure 6-12: Proliferation of SKBR3-Par, SKBR3-T, BT474, BT474-T, 
EFM192A, and EFM192A-T with afatinib, dasatinib, and afatinib plus dasatinib 
treatment. Error bars represent standard deviation of biological triplicate 
experiments. 
 
6.6.2 Afatinib plus dasatinib in lapatinib-resistant cell lines 
 
As was previously shown, SKBR3-L cells are 13.9-fold less sensitive to afatinib 
compared to controls (Table 3-1). SKBR3-L cells are resistant to dasatinib (IC50 value 
> 10 µM). However, SKBR3-L cells showed enhanced response to the combination of 
afatinib and dasatinib similar to SKBR3-A cells (CI value = 0.12 ± 0.4) (Figure 6-13). 
This suggests the afatinib plus dasatinib combination could also be effective in 
lapatinib-refractory breast cancer. 
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Figure 6-13: Proliferation of SKBR3-L cells treated with afatinib, dasatinib, or 
afatinib plus dasatinib. Error bars represent standard deviation of triplicate 
experiments. 
 
6.7 Afatinib plus dasatinib in the prevention of afatinib resistance development 
 
Although afatinib plus dasatinib did not enhance the effect of afatinib alone in the 
SKBR3, BT474, or EFM192A cell lines or the trastuzumab-resistant variants, the 
combination may have longer-term anti-cancer effects. Therefore, in order to assess if 
afatinib plus dasatinib can improve long term response to afatinib and prevent the 
development of afatinib resistance, the parental and resistant cell lines were treated 
twice weekly with 75 nM afatinib, 150 nM dasatinib, or the combination (as described 
in Section 2.9) (Figure 6-14 and 6-15). The concentrations chosen for afatinib and 
dasatinib are close to peak plasma levels [295, 312] and follow the 1:2 ratio that was 
used in five-day proliferation assays. 
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All cell lines were highly sensitive to 75 nM afatinib, with   all but the HCC1954 cell 
line achieving greater than 80% growth inhibition after two weeks. Untreated SKBR3, 
BT474, EFM192A, SKBR3-T and BT474-T cells became confluent at 14 days. At 
this point, the afatinib plus dasatinib treatment did not enhance growth inhibition 
compared to afatinib alone. Likewise, after 28 days when dasatinib treated cells 
became confluent, no difference was observed between afatinib alone and the 
combination. However, after 70 days of treatment, EFM192A, SKBR3, and SKBR3-T 
cells developed resistance to afatinib (% growth with afatinib = 20.5 ± 1.0%, 20.5 ± 
6.2%, 14.3 ± 4.3% compared to 1.6 ± 1.7%, 2.4 ± 2.0%, and 3.2 ± 2.1%, 
respectively). The BT474 cell lines did not develop resistance after 70 days. The % 
growth with afatinib was 3.9 ± 0.6% and 3.8 ± 0.5% with afatinib plus dasatinib in the 
BT474-T cell line. 
HCC1954 cells displayed a synergistic response to afatinib plus dasatinib in 5-day 
proliferation assays. Therefore, these cells were also treated twice weekly with 
afatinib and dasatinib for longer-term treatment (Figure 6-14). Control cells became 
confluent after 7 days, with afatinib treatment causing a 58.3 ± 6.9% growth 
reduction. The second plate was treated for a further 7 days. The afatinib-treated cells 
were spread out, however, were at 38.9 ± 13.7% growth level of the untreated control 
cells at day 7. Importantly, afatinib plus dasatinib treated cells had 8.4 ± 5.9% growth 
relative to control at day 7, and this growth level was maintained until day 14 (3.7 ± 
1.5%). 
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Figure 6-14: SKBR3, BT474, EFM192A, and HCC1954 cells were treated with 
75 nM afatinib, 150 nM dasatinib, or afatinib plus dasatinib twice weekly until 
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untreated control cells became confluent (Plate 1) [each row represents one 
plate], dasatinib-treated cells became confluent (Plate 2), and afatinib-treated 
cells became confluent (Plate 3). Each image is representative of three biological 
assays.  
  
 
Figure 6-15: SKBR3-T and BT474-T cells were treated with 75 nM afatinib, 150 
nM dasatinib, or afatinib plus dasatinib twice weekly until untreated control 
cells became confluent (Plate 1), dasatinib-treated cells became confluent (Plate 
2) and afatinib-treated cells became confluent (Plate 3). Each image is 
representative of three biological triplicate assays. 
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6.8 The role of Src in neratinib resistance 
6.8.1.1 Acquired neratinib resistant cell line 
 
In order to test if the combination effect of afatinib and dasatinib was specific to 
afatinib, and as neratinib has now been approved for early-stage HER2-positive 
disease, the combination of neratinib and dasatinib was examined in a neratinib 
resistant model. The HCC1954-N cell line was developed by Dr. Susan Breslin and 
Prof. Lorraine O’Driscoll, Trinity College Dublin, by treating HCC1954 cells with 
250 nM neratinib three times per week for 6 months, and gifted to the NICB. 
HCC1954-N cells were resistant to neratinib with an IC50 value of 781.8 ± 142.7 nM 
compared to 26.1 ± 1.2 nM for HCC1954-Par (Figure 6-16 A). Similar to the lapatinib 
and afatinib resistant cell lines, HCC1954-N cells were cross-resistant to the other 
tyrosine kinase inhibitors (Figure 6-16 B and C). 
 
 
Figure 6-16: Proliferation of HCC1954-Par and HCC1954-N cells following 5 
days of treatment with A) neratinib (0 – 2.5 µM), B) 0-2.5 µM afatinib, and C) 0-
10 µM lapatinib. Error bars indicate standard deviation of triplicate biological 
experiments. 
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6.8.2 Dasatinib sensitivity in HCC1954-Par and HCC1954-N cells 
 
The effect of dasatinib on HCC1954-Par and HCC1954-N cells was assessed by 5-
day proliferation assays using the acid phosphatase method. HCC1954-N cells were 
less sensitive to dasatinib compared to HCC1954-Par cells. The dasatinib IC50 value 
for the HCC1954-N cells was 2086.2 ± 2324.9 nM and was 681.3 ± 170.8 nM for 
HCC1954-Par cells. However, dasatinib in combination with neratinib was highly 
synergistic in both parental (CI value = 0.09 ± 0.1) and resistant (CI value = 0.1 ± 
0.03) cells (Figure 6-17 and Figure 6-18). 
Neratinib and dasatinib were also assessed, as single agents and in combination, in 
HCC1954-N cells under 3D growth conditions. HCC1954-N cells were significantly 
more sensitive to neratinib in 3D conditions compared to 2D assays (IC50 value in 3D 
= 29.6 ± 3.9 versus 781.8 ± 142.7 nM in 2D).  HCC1954-N cells were slightly more 
resistant to dasatinib in 3D culture (IC50 value in 3D = 3.1 ± 0.4 µM compared to 2.1 
± 2.3 µM in 2D). However, the combination of neratinib and dasatinib was also 
synergistic in 3D (CI value = 0.36 ± 0.02) (Figure 6-19). 
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Figure 6-17: 2D acid phosphatase proliferation assays of HCC1954-N cells 
following 5 days of treatment with neratinib (0 – 625 nM), dasatinib (0 – 1250 
nM), and 1:2 neratinib plus dasatinib. Error bars indicate standard deviation of 
triplicate biological experiments. 
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Figure 6-18: 2D acid phosphatase proliferation of HCC1954-Par cells following 5 
days of treatment with neratinib (0 – 625 nM), dasatinib (0 – 1250 nM), and 1:2 
neratinib plus dasatinib. Error bars indicate standard deviation of triplicate 
biological experiments. 
 
 194 
 
Figure 6-19: Proliferation of HCC1954-N cells, grown in 3D suspension in 4% 
Matrigel, following 7 days of treatment with neratinib (0 – 625 nM), dasatinib (0 
– 1250 nM), and 1:2 neratinib plus dasatinib. Error bars indicate standard 
deviation of triplicate biological experiments. 
 
6.8.3 Mechanism of cell death by neratinib and dasatinib 
 
The induction of apoptosis by neratinib and dasatinib was examined in the HCC1954-
N cells by investigating caspase 3/7 activation and by cell cycle analysis. Cell cycle 
analysis showed a highly significant increase in the sub G1 population in cells treated 
with the combination (61.7 ± 8.3%) compared to neratinib (11.4 ± 1.3%, p = 0.018) 
and dasatinib (11.9 ± 1.3%, p value = 0.013) (Figure 6-20). Both neratinib and 
dasatinib increased caspase 3/7 activity compared to control cells (p = 0.04 and 0.006, 
respectively). Neratinib plus dasatinib caused a significant increase in caspase 3/7 
activation compared to both single agents (p = 7 x 10-5 relative to neratinib treatment, 
and 0.015 compared to dasatinib) (Figure 6-21). 
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Figure 6-20: Cell cycle analysis was carried out on HCC1954-N cells treated with 
150 nM neratinib, 300 nM dasatinib, and neratinib plus dasatinib for 72 h. Error 
bars represent standard deviation of biological triplicate experiments. The 
Student’s t test was used to determine statistical significance. *** denotes a p 
value of < 0.001. 
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Figure 6-21: Caspase 3/7 activation in HCC1954-N cells treated with 150 nM 
neratinib, 300 nM dasatinib, and neratinib plus dasatinib. Error bars represent 
standard deviation of triplicate experiments. The Student’s t test was used to 
determine statistical significance. * denotes p < 0.05. 
 
6.9 Summary 
 
Afatinib-sensitive cells developed resistance to afatinib following long-term 
treatment. SKBR3-A cells were cross-resistant to the HER2-targeted therapies 
trastuzumab, pertuzumab, lapatinib and neratinib. The SKBR3-A cell line showed 
alterations in key signalling pathways including down-regulation of Akt and MEK 1/2 
activity and an up-regulation of EGFR levels and Src activity. The SKBR3-A cell line 
displayed multiple genetic changes. There were 168 unique CNVs, 34 SNVs with 
protein structural implications, and 1 frameshift InDel in a protein-coding region. 
These adaptations indicate the possibility of EMT and an increase in autophagy-
related proteins. Interestingly, afatinib treatment increased levels of autophagy in 
SKBR3-A cells.  
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Src was selected as a therapeutic target to overcome afatinib resistance, as Src has 
previously been implicated in trastuzumab and lapatinib resistance and can be 
inhibited by the FDA-approved drug dasatinib. SKBR3-A cells were modestly more 
sensitive to dasatinib than the SKBR3-Par cells. Afatinib plus dasatinib was strongly 
synergistic in SKBR3-A cells. The effect of afatinib plus dasatinib was independent 
of apoptosis and autophagy and may be due to induction of necrosis. 
The combination of afatinib plus dasatinib was tested in other models of HER2-
targeted therapy resistance. SKBR3-L cells had reduced sensitivity to afatinib and 
were innately resistant to dasatinib. Nonetheless, strong synergy was observed with 
the combination. The trastuzumab-resistant cell lines, SKBR3-T, BT474-T, and 
EFM192A-T cells, were exquisitely sensitive to afatinib and did not show 
enhancement with five-day combination treatment. However, longer term treatment 
with afatinib and dasatinib prevented afatinib resistance development in SKBR3-T 
cells. This was also observed in SKBR3, EFM192A, and HCC1954 cells. 
The synergy of pan-HER inhibition and Src inhibition was also replicated in the 
neratinib resistant HCC1954-N model. HCC1954-N cells were highly sensitive to 
neratinib plus dasatinib in 2D acid phosphatase assays and 3D growth assays.  
The combination of afatinib or neratinib plus dasatinib showed promise in HER2-
positive breast cancer in vitro, in both HER2-targeted therapy naive and resistant cell 
lines. Afatinib plus dasatinib overcame afatinib resistance, prevented afatinib 
resistance development in three of four treatment naive and one of two trastuzumab 
resistant cell lines, and showed efficacy against lapatinib resistant cells.   
 198 
 
 
 
 
 
 
 
 
 
 
 
7 Discussion
 199 
7.1 Introduction 
 
There are five HER2-targeted therapies approved for the treatment of HER2-positive 
breast cancer [34–36, 39, 313]. However, the optimal treatment window and order of 
HER2-targeted therapies has been a much debated topic and the emergence of 
resistance to these therapies is a significant issue. HER2-targeted therapy has 
dramatically improved the prognosis of patients with HER2-positive breast cancer, 
especially in early-stage disease. The disease-free survival rate after three years for 
patients with early-stage HER2-positive breast cancer treated with trastuzumab and 
pertuzumab is 92%, and for patients with node negative disease that increases to 
97.5% [314]. The addition of neratinib to this setting may also further improve the 
disease-free survival of those patients [294]. There have also been incredible 
advances in the metastatic setting; median survival for patients with metastatic HER2-
positive breast cancer with trastuzumab plus pertuzumab in the CLEOPATRA trial 
was 56.5 months [67]. The use of lapatinib plus capecitabine or T-DM1 provides 
additional second- or third-line therapy for these patients. Nonetheless, unfortunately, 
the majority of these patients still die of their disease. Therefore, there is a clinical 
need for novel treatment options for metastatic HER2-positive breast cancer patients. 
The aim of this study was to examine the mechanisms of resistance to currently 
approved HER2-targeted therapies and to identify novel therapies for those patients 
whose disease no longer respond to HER2-targeted agents. 
 
7.2 Cross-resistance to HER2-targeted therapies 
 
In vitro assessment of the sensitivity of cell line models of HER2-targeted therapy 
resistant breast cancer to HER-family targeting monoclonal antibodies (trastuzumab 
and pertuzumab), and TKIs (lapatinib, afatinib and neratinib) provides pre-clinical 
evidence that may inform the order in which HER2-targeted therapies should be 
administered and also allows evaluation of cross-resistance that may emerge 
following specific HER2 targeted therapies. The three trastuzumab-resistant cell lines 
tested in this study were sensitive to afatinib, with IC50 values < 20 nM (Figure 6-12). 
Trastuzumab-resistant cell lines have previously been shown to be sensitive to the 
irreversible pan-HER inhibitors afatinib neratinib, and dacomitinib [108, 123, 315] 
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The TKI sensitivity in trastuzumab-resistant cells indicates that the irreversible TKIs 
could be active as a second-line therapy in metastatic disease after cells become 
refractory to trastuzumab, similar to lapatinib. Clinical examination of neratinib in the 
ExteNET trial showed that neratinib enhanced the clinical benefit when given after 
adjuvant trastuzumab in early-stage HER2-positive breast cancer and showed a 2.3% 
improvement in 2-year iDFS in a sub-population that had developed trastuzumab 
resistance [294]. Likewise, afatinib showed some single agent clinical benefit in a 
trastuzumab-refractory setting. In a phase II clinical trial afatinib monotherapy 46% 
of patients achieved clinical benefit, with 10% PR [128]. 
Trastuzumab is given as first-line therapy for metastatic breast cancer and, following 
the results of the CLEOPATRA trial, pertuzumab may soon be added to first-line 
trastuzumab as standard-of-care [275, 316]. In this study, the effectiveness of 
trastuzumab, pertuzumab or the dual combination was assessed in HER2-targeted 
therapy naive cells and cells with acquired lapatinib or afatinib resistance. The 
combination of the HER2 antibodies can have an additive anti-proliferative effect, 
which was seen in the SKBR3-Par cells (Figure 3-3). This was previously observed in 
BT474 cells, which are also innately sensitive to trastuzumab alone [66].  Notably, 
however, the combination had no effect on the innately trastuzumab-resistant cell line 
HCC1954-Par. This was also found in both the SKBR3-L and HCC1954-L cell lines 
(Figures 3-3 and 3-4). A caveat to this observation is that only the anti-proliferative 
effect of the antibody combination was assessed here. In another study, the innately 
trastuzumab- and lapatinib-resistant JIMT-1 cells were shown to be more sensitive to 
trastuzumab plus pertuzumab due to an increase in NK cell mediated ADCC [317].  
Both acquired lapatinib resistant cell lines also had reduced sensitivity to the 
irreversible pan-HER inhibitors afatinib and neratinib (Figure 3-2). The HCC1954-L 
cell line was cross-resistant to afatinib and neratinib at reported maximum plasma 
concentrations (80 nM and 150 nM respectively). The SKBR3-L cells achieved an 
afatinib IC50 value greater than the resistance cut-off. However, the neratinib IC50 
value was below the cut-off but was still 22.7-fold less sensitive to neratinib (Table 7-
1). This result is also consistent with the clinical evidence of reduced effectiveness of 
neratinib in lapatinib-refractory breast cancer compared to lapatinib-naive disease 
[114]. In a phase I/II clinical trial, the ORR with neratinib treatment was 64% for the 
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lapatinib-naïve and 57% for the lapatinib pre-treated patients, with median PFS of 
40.3 and 35.9 weeks, respectively. Likewise, in clinical investigation of afatinib plus 
vinorelbine versus trastuzumab plus vinorelbine, the afatinib-containing regimen did 
not show superiority in trastuzumab- or lapatinib-refractory breast cancers [318]. The 
LUX-Breast 3 clinical trial of afatinib plus vinorelbine versus the investigator’s 
choice of therapy demonstrated the investigator’s choice had a higher PFS and patient 
benefit rate [129].  
Despite the clinical potential of the irreversible pan-HER inhibitors in HER2-positive 
breast cancer, resistance may develop. For example, afatinib resistance commonly 
occurs in lung cancer. In a small trial of 24 NSCLC patients, 23 patients developed 
progressive disease [319]. The SKBR3-A cells developed cross-resistance to 
trastuzumab alone, pertuzumab alone, and the combination of the antibodies, similar 
to the SKBR3-L cells (Figure 6-3). However, afatinib resistance also conferred 
resistance to lapatinib (IC50 value > 1 µM) (Figure 6-2). Afatinib is approved in 
NSCLC and, although lapatinib is not approved in this setting, the EGFR-targeted 
TKIs, gefitinib and erlotinib are [320, 321]. Reduced sensitivity to afatinib was also 
observed in lung cancer after progression following gefitinib or erlotinib in the LUX-
Lung 1 trial [322]. Similar to the lapatinib resistant SKBR3-L, SKBR3-A cells had a 
significant reduction in neratinib sensitivity reflected in a 33.5-fold increase in IC50 
value (Figure 6-2). Nevertheless, this was still just below the maximum plasma 
concentration of neratinib. Similarly, the HCC1954-N cell line was cross-resistant to 
both lapatinib and afatinib (Figure 6-16). The results from this study suggest that 
HER2-targeted TKIs should be given after trastuzumab treatment and that treatment 
with a HER-targeted TKI might have reduced efficacy after other HER2-targeted TKI 
treatment. Other pre-clinical studies have also observed cross-resistance in HER2-
targeted TKI resistant cell lines. Using the irreversible pan-HER inhibitor 
dacomitinib, Kalous et al. showed that an SKBR3-L cell line was less sensitive to 
dacomitinib than the parental cells. Interestingly, SKBR3-T cells were as sensitive to 
dacomitinib as their parental cells [315], mirroring the results observed with afatinib 
in this study and in that of Canonici, et al. [123]. 
 
 
 202 
Table 7-1: Fold change of HER2-targeted therapy response in SKBR3-L, 
HCC1954-L, and SKBR3-A cell lines. 
Fold change relative 
to parental cell lines 
SKBR3-L HCC1954-L SKBR3-A 
10 µg/mL 
trastuzumab 
1.2 1.0 1.3 
10 µg/mL 
pertuzumab 
1.1 1.0 1.2 
Trastuzumab plus 
pertuzumab 
1.7 1.1 1.9 
Lapatinib IC50 47.4 5.2 30.6 
Neratinib IC50 22.8 10.4 33.5 
Afatinib IC50 13.9 75.3 58.1 
 
In summary, HER2-targeted therapy treatment affects future sensitivity to other 
HER2-targeted therapy agents. These results suggest that there is a role for HER2-
targeted TKIs as a second-line therapy following progression on monoclonal antibody 
therapies, which is consistent with the approved use of lapatinib in this setting. 
However, the data indicates that irreversible TKIs might have reduced impact 
following lapatinib or other irreversible TKI treatment. Future work should examine 
the possible sensitivity of resistant models to T-DM1, the only other approved HER2-
targeted therapy not examined in this study. The cytotoxic component of this 
trastuzumab-based antibody drug conjugate could offer a potential treatment strategy 
for both monoclonal antibody- and TKI-refractory disease.  
The reduced sensitivity of HER2-targeted TKI resistant breast cancer cell lines to 
other HER2-targeted therapies indicates that a novel therapeutic target is required for 
these patients with metastatic disease that has acquired resistance to the TKIs. That 
led us to examine the lapatinib, afatinib and neratinib resistant cell lines for targetable 
alterations. PP2A was selected as the potential target in lapatinib resistance and Src 
was assessed in afatinib and neratinib resistance. 
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7.3 PP2A in acquired lapatinib resistance 
 
We have previously shown that lapatinib treatment elevated phosphorylated (p-) eEF2 
levels in SKBR3-Par cells, but not in SKBR3-L cells [154]. Both SKBR3-L and 
HCC1954-L cells showed decreased p-eEF2 levels and increased PP2A activity 
compared to parental cells. eEF2 is a phosphatase substrate of PP2A [323]. Thr56 
phosphorylation of eEF2 prevents ribosomal binding, thereby preventing global 
protein translation within the cell [323, 324]. Another study has also shown that 
lapatinib treatment stimulated an increase in PP2A activity in a lapatinib-sensitive 
HER2-positive breast cancer cell line [193]. Therefore, increased PP2A activity may 
be a stress response to lapatinib treatment. 
 
PP2A plays a critical role in cell growth and development and several studies indicate 
PP2A may have a tumour suppressor role [226, 228, 290]. Contrary to this, other 
studies have shown an anti-apoptotic and anti-proliferative effect, suggesting the 
phosphatase has an oncogenic function [325–327]. This starkly contrasting behaviour 
may be due to the multi-faceted activity of PP2A in the cell, the complexity of its 
trimeric holoenzyme composition, or cell line variations [190, 328].  
 
Compared to their parental cell lines, both SKBR3-L and HCC1954-L cells were 
more sensitive to PP2A inhibitors, okadaic acid and LB-100 (Figures 3-5 and 3-14). 
Importantly, PP2A inhibition enhanced the anti-proliferative effect of lapatinib.  
In order to determine if the growth inhibition with okadaic acid and LB-100 was 
inhibitor-specific, siRNA knockdown was employed (Section 3.6). Knockdown of the 
PP2A catalytic subunit PPP2CA, which carries out the majority of the holoenzyme’s 
phosphatase activity [225], resulted in a significant reduction of HCC1954-L 
proliferation. The combination of siRNA PPP2CA knockdown and lapatinib also 
caused a minor enhancement, although not statistically significant compared to the 
siRNA alone (Section 3.6). Another study examining the effect of PP2A inhibition in 
HER2-positive breast cancer showed that PPP2CA knockdown in both BT474 and 
SKBR3 cells caused apoptosis [325]. These results combined give further evidence 
that inhibiting PP2A can suppress HER2-positive breast cancer cell growth. 
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To further validate the role of PP2A and lapatinib resistance, PP2A activity was 
increased in lapatinib sensitive cells using FTY720 (Section 3.7). FTY720 is a 
sphingosine derivative that activates PP2A [329]. FTY720 activates PP2A through 
several mechanisms; it can inhibit SET-PP2A binding, down-regulate CIP2A and 
cause de-phosphorylation of PP2A Tyr307 [231, 330, 331]. FTY720 (2.5 µM) has 
previously been shown to increase PP2A activity and disrupt SET:PP2A binding in 
cancer cell lines and was therefore chosen as the concentration to be used [332, 333]. 
Activation of PP2A in the SKBR3-Par and HCC1954-Par cells using FTY720 
reduced lapatinib sensitivity by 5.4- and 2.1-fold. Conversely, another study of 
lapatinib resistance showed that knockdown of CIP2A increased sensitivity to 
lapatinib [197]. In this study, a BT474-L cell line was generated by lapatinib 
treatment for 5 months up to a concentration of 5 µM lapatinib. This cell line had up-
regulation of CIP2A, along with increased phosphorylated levels of HER2, Akt, and 
mTOR. Increased CIP2A, in the BT474-L cell line and CIP2A-transfected SKBR3 
cells, reduced sensitivity to lapatinib [197]. The discrepancy in the effect of PP2A 
activation on lapatinib response between the Zhao et al. study and the results 
described herein (Section 3.7) may be due to variations in the cell lines used or 
differences in the mechanism of PP2A activation employed. The lapatinib resistant 
model of their study used BT474-L cells. The BT474 cell lines are ER-positive and 
this may impact the role PP2A is playing in the cells. Increased ER can increase 
expression of the PP2A inhibitor SET [334]. FTY720 activates PP2A by several 
mechanisms and can directly bind to the PP2A inhibitors SET, CIP2A, and ANP32A 
[330, 335]. Therefore, the effect of FTY720 may be due to interactions with PP2A 
inhibitors other than CIP2A. In addition, the experiment in this PhD project used pre-
treatment with FTY720 rather than combinatorial treatment, which may prevent 
antagonistic effects of lapatinib plus FTY720. Future work could examine the binding 
affinity of SET:PP2A in lapatinib resistant cell lines and in lapatinib-treated parental 
cell lines. The relationship between PP2A and CIP2A and ANP32A should also be 
examined. 
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7.3.1 Mechanism of action of lapatinib plus PP2A inhibition 
 
As PP2A can affect the activity of a myriad of proteins [190, 192], RPPA analysis 
was used to determine the pathway alterations in the HCC1954-L cells treated with 3 
nM okadaic acid with or without 500 nM lapatinib (Section 3.9) (Figure 7-1). RPPA 
allows for ~80 proteins to be analysed in samples simultaneously. The concentration 
of okadaic acid used (3 nM) was chosen to ensure phosphatase inhibition was specific 
to PP2A [289]. The combination of okadaic acid and lapatinib increased phospho-
eEF2 levels most at 18 h, compared to 4, 6, and 24 h treatment. Treatment with 3 nM 
okadaic acid for 18 h showed minimal changes to key signalling pathways, including 
HER family signalling, Bcl-2 family members, STAT3 signalling, and caspase/PARP 
cleavage. The phosphorylation states of two proteins were altered: Src (Y416) and 
p38 MAPK (T180). The decreased levels of phosphorylated Src was unexpected as 
PP2A inhibition by okadaic acid has been shown to increase phosphorylated Src 
(Y416) in cell-free experiments [336]. However, higher concentrations of okadaic 
acid were used in that study, which may be a reason for the different effect in the 
lapatinib-resistant cells. The two cell lines may also have different levels of the 
regulatory subunits. It is possible that further alteration to PP2A substrates would be 
seen at a later timepoint. PP2A is a known regulator of p38 MAPK phosphorylation 
[337]. Previous studies demonstrated that chemical inhibition of PP2A caused p38 
MAPK phosphorylation, which inhibited apoptosis induction. This anti-apoptotic 
effect was not observed in the HCC1954-L cells as okadaic acid and LB-100 
treatment decreased cell proliferation and induced apoptosis (Sections 3.3, 3.10 and 
3.12). The apoptotic effect of PP2A inhibition may be due to the inhibition of eEF2 
and, therefore, the down-regulation of protein synthesis. Inhibition of eEF2 has 
previously been shown to inhibit cell growth in colon cancer cell lines and eEF2 is 
over-expressed in colon cancer and head and neck squamous cell carcinoma [338, 
339].  
RPPA analysis of 18 h 500 nM lapatinib treatment showed inactivation of HER2 and 
HER3 and down-regulation of total levels of EGFR in HCC1954-L cells. This is 
consistent with previous reporting of the HER family inhibitory activity of lapatinib 
[88, 340]. Interestingly, lapatinib also induced increased activation of NFκB p65 and 
MET. NFκB p65 has previously been shown to be up-regulated by lapatinib in breast 
cancer [341] and activation of NFκB can confer lapatinib resistance [342]. MET has 
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also been previously implicated in lapatinib resistance [343]. These increases may be 
a stress response by the resistant cells to overcome the effect of lapatinib.  
Importantly, the combination of okadaic acid and lapatinib caused a significant 
increase in inhibition of survival signalling pathways. The inhibition of EGFR, HER2, 
and HER3 activity, along with inactivation of downstream signalling components 
such as mTOR, ERK 1/2, MEK 1/2, and Src was observed. PP2A, with B56 
regulatory subunit composition, negatively regulates ERK phosphorylation [344], but 
inhibition of PP2A in combination with lapatinib inhibited ERK 1/2 phosphorylation. 
The down-regulation of MEK 1/2 and ERK 1/2 acitivity may be due to the up-stream 
inhibition of Src or decreased total levels of RAF, which activates MEK1/2, which 
was also observed in the RPPA analysis [345]. 
Notably, HCC1954-L cells are more sensitive to lapatinib plus okadaic acid than 
SKBR3-L cells (Figure 3-6) and previous investigations in our lab showed that 
HCC1954-L cells had increased levels of phosphorylated Akt and ERK compared to 
HCC1954-Par cells [346]. The opposite trend is observed in SKBR3-L cells. The 
enhanced growth inhibition observed with the combination of lapatinib and okadaic 
acid in HCC1954-L cells may be due to the additional inhibition of Akt and ERK 
signalling. 
Lapatinib plus okadaic acid did not abrogate the increased activation of NFκB p65 
that was seen with lapatinib alone treatment. As NFκB p65 can stimulate cell 
proliferation and prevent apoptosis [341, 347], this may be a potential mechanism of 
resistance to treatment. Conversely, okadaic acid treatment of PANC-1 cells induced 
apoptosis by activating NFκB. NFκB caused up-regulation of the pro-apoptotic genes 
TNF-α, TRAILR1, and TRAILR2 [348]. Further work should examine the role of 
NFκB p65 in lapatinib and PP2A inhibitor response. 
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Figure 7-1: Representation of pathway alterations of HCC1954-L cells observed 
in RPPA analysis. Red arrows indicate lapatinib treatment, green arrows 
indicate okadaic acid treatment, and yellow arrows represent lapatinib plus 
okadaic acid (Pathway adapted from [349]). 
 
7.3.2 PP2A expression in lapatinib resistant cells 
 
The composition of the PP2A holoenzyme governs the localisation and substrate 
specificity of the molecule. The α isoforms of the catalytic subunits are dominant and 
90% of PP2A holoenzymes contain the α isoforms [225, 350]. Changes to subunit 
composition can therefore lead to significantly altered function and could contribute 
to lapatinib resistance. 
Analysis of both lapatinib resistant cell lines by Western blotting showed no alteration 
in total levels of either catalytic subunit isoform (Section 3.5). However, post-
translational modifications of PPP2CA were altered in the HCC1954-L cells. 
Phosphorylation of PPP2CA inhibits the phosphatase activity of the enzyme [351]. As 
PP2A activity was increased in these cells, it was unsurprising that Y309 
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phosphorylation was decreased. Methylation of PPP2CA was also decreased in the 
lapatinib resistant cell line. PPP2CA methylation affects the regulatory subunits that 
can bind to the dimer [352]. Methylation levels were significantly decreased in 
HCC1954-L cells compared to their parental cells. Phosphorylation and methylation 
of PP2A catalytic subunit may be a marker of lapatinib resistance and, therefore, 
future work should examine phospho- and methyl-PPP2CA in lapatinib-resistant 
HER2-positive breast cancer patient samples. 
 
7.3.3 LB-100 in lapatinib resistance 
 
Although there are several chemical inhibitors of PP2A, including okadaic acid, 
fostriecin, and cantharidin [353–355], many of these inhibitors cannot be used 
clinically due to severe toxicities. However, LB-100 shows promise as a clinical 
PP2A inhibitor. A phase I clinical trial of LB-100 showed that the drug was safe and 
tolerable [268]. Pre-clinical studies demonstrated that LB-100 enhances response to 
chemotherapy and radiotherapy [262, 263]. LB-100 has also shown some efficacy in 
overcoming resistance to the EGFR-targeted therapy, gefitinib, in pre-clinical models 
of EGFR-mutant NSCLC. Two acquired gefitinib-resistant cell lines showed 
improved response to gefitinib in combination with LB-100, which was also 
replicated in in vivo examination [267]. In this study, SKBR3-L and HCC1954-L cells 
were 2.5- and 2.3-fold more sensitive to LB-100 than their respective parental cell 
lines. The IC50 values achieved in the lapatinib resistant cell lines are similar to those 
observed in other cancer cell line models [265, 266, 356]. Both cell lines showed 
reduced LB-100 sensitivity in 3D conditions. However, synergy with lapatinib was 
maintained in the HCC1954-L cell line. Interestingly, a similar effect was also 
observed with LB-100 in combination with neratinib, as synergy was observed in the 
HCC1954-L cells. This is of particular interest as neratinib is now approved for the 
treatment of early-stage HER2-positive breast cancer [39]. To provide clinically 
relevant pre-clinical data, future work should examine the efficacy of LB-100 in 
trastuzumab resistant cell lines and the potential of LB-100 with lapatinib or neratinib 
in acquired trastuzumab resistant models. Future studies should also attempt to 
understand why there is a reduced response to LB-100 in 3D conditions. Cantharidin 
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efficacy has been shown to be influenced by calcium and phosphate transporters 
[357], these may be altered in 3D conditions.  
Previous studies by other groups have shown that LB-100 can induce apoptosis, 
mitotic catastrophe, G1 cell cycle arrest, and G2/M cell cycle arrest [260, 266, 356]. 
LB-100 in combination with DNA-chelating chemotherapy enhances DNA damage 
by preventing cell cycle arrest. This forced cell cycle progression allows for 
additional DNA damage by DNA-chelating agents [260, 265, 356]. Combination 
treatment of LB-100 with cisplatin showed an induction of apoptosis [260]. This was 
also observed in hepatocellular carcinoma in combination with the VEGFR inhibitor 
sorafenib [266]. In the lapatinib-resistant cell lines, LB-100 alone significantly 
induced apoptosis, evident from cell cycle analysis (Section 3.12), and the 
combination with lapatinib further enhanced this effect in the HCC1954-L cells. 
Lapatinib alone instigated G1 cell cycle arrest in both SKBR3-L and HCC1954-L 
cells. This G1 cell cycle arrest was down-regulated by the combination with LB-100 
in both cell lines. This suggests LB-100 was driving the arrested cells into apoptosis, 
similar to that observed in previous studies by other laboratories [260, 266].  
 
7.3.4 PP2A inhibition prevented lapatinib resistance development 
 
Although short-term growth assays are a useful tool for screening potential anti-
cancer drugs, longer-term clonogenic assays provide a better insight into what can be 
expected in vivo [358]. Resistance development assays were carried out to examine 
the efficacy of okadaic acid and LB-100 in preventing the development of lapatinib 
resistance (Section 3.8 and 3.14). Twice weekly treatment of SKBR3 and HCC1954 
cells with lapatinib with or without okadaic acid or LB-100 showed that PP2A 
inhibition can prevent the development of lapatinib resistance in vitro. After 2-4 
weeks, growth of SKBR3 and HCC1954 cells continued in the presence of lapatinib, 
but this recommencement of growth did not occur with the addition of a PP2A 
inhibitor. 
 
In summary, PP2A is a mediator of the lapatinib resistant phenotype in both the 
SKBR3-L and HCC1954-L cells. Both cell lines were more sensitive to PP2A 
inhibition with okadaic acid and LB-100. This PP2A inhibition also enhanced 
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lapatinib response, primarily in the HCC1954-L cell line. Lapatinib plus okadaic acid 
significantly inhibited survival signalling; an effect that was not observed with either 
inhibitor alone. 
LB-100 showed pre-clinical efficacy in the lapatinib resistant HER2-positive breast 
cancer, particularly in the HCC1954-L model (Figure 7-2). LB-100 alone and in 
combination with lapatinib or neratinib inhibited HCC1954-L proliferation. From this, 
an in vivo assessment of lapatinib plus LB-100 was proposed to further investigate the 
clinical potential of LB-100 in lapatinib-resistant HER2-positive breast cancer. 
 
 
Figure 7-2: Lapatinib plus PP2A inhibition in HER family member signalling 
(Pathway adapted from [349]). Red X indicates inhibition by lapatinib. Green X 
indicates inhibition by okadaic acid/LB-100.  
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7.4 Lapatinib resistance in vivo 
7.4.1 Maintenance of lapatinib resistance phenotype in vivo 
 
Although numerous acquired lapatinib resistant cell line models have been developed, 
not all of these can be used for in vivo assessment of candidate drugs to overcome 
resistance. This can be due to the low tumourigenicity of the cell lines in mice or loss 
of the resistant phenotype when withdrawn from lapatinib treatment. The SKBR3-L 
cell line is not a good in vivo model for both of these reasons. Previous work from our 
group showed that withdrawal of lapatinib treatment resulted in increased sensitivity 
to lapatinib in SKBR3-L. In contrast, the lapatinib IC50 value of the HCC1954-L did 
not significantly change after three months without lapatinib; the IC50 value following 
one week of lapatinib withdrawal was 2.73 ± 0.05 µM and after 12 weeks it was 2.63 
± 0.16 µM [148]. In comparison, the SKBR3-L cell line had a 7.6-fold decrease in 
lapatinib IC50 value 14 weeks after lapatinib withdrawal, rendering the cells sensitive 
to lapatinib [346]. Although lapatinib resistance in HCC1954-L cells was shown to be 
maintained in vitro, it was not known if the resistant phenotype would be maintained 
in vivo. The ex vivo experiments showed that lapatinib resistance was retained by 
HCC1954-L after 12 weeks in vivo growth in the absence of lapatinib treatment 
(Figure 4-13). Importantly, this work also demonstrated that in vivo conditions did not 
significantly affect the synergy observed between lapatinib and LB-100 in HCC1954-
L.  
Implantation of cancer cell lines into mouse models can impact on the expression of 
RTKs, such as HER2, insulin receptor, and IGF-1R [359]. Therefore, prior to 
assessment of lapatinib plus LB-100 against HCC1954-L, the maintenance of the 
respective targets needed to be confirmed. This was achieved by analysing HER2 and 
phospho-eEF2 levels in HCC1954-L xenografts and comparing them to levels found 
in vitro; no differences were observed between in vitro and in vivo samples (Figure 4-
17). Previously, LB-100 has been shown to inhibit PP2A in a glioblastoma model at a 
dose of 1.5 mg/kg, the same concentration used in this study [356]. In order to 
examine if LB-100 was also effective in the in vivo HCC1954-L model, tumour tissue 
was removed post-mortem from a mouse treated with 75 mg/kg lapatinib plus 1.5 
mg/kg LB-100. Phosphorylated eEF2 levels were up-regulated in a treated sample 
(Figure 4-17). As protein samples were taken from extracted tumours, it is possible 
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mouse cells were also extracted. However, HER2 levels were similar to that of the 
HER2-amplified HCC1954-L cells. In addition, the relative levels of phospho-eEF2 
to both α-tubulin and HER2 levels indicate that the increased phospho-eEF2 is due to 
the effect of LB-100 on the tumour cells.  
 
7.4.2 Lapatinib plus LB-100 is non-toxic in BALB/c nude mice 
 
If the combination of lapatinib plus LB-100 resulted in high levels of toxicity, it 
would be difficult to support the progression of this combination to clinical 
assessment. Although LB-100 has been examined in vivo previously [258, 261, 265, 
356], it has not been tested in combination with HER2-targeted therapy. Assessment 
of LB-100 alone by Lu et al. inhibited PP2A but did not cause systemic toxicities 
after 21 days of consecutive treatment [356]. Likewise, 1.5 mg/kg LB-100 in 
combination with doxorubicin showed no toxicity in animals after 11 days of 
treatment [360]. We tested 75 mg/kg lapatinib plus 1.5 mg/kg LB-100 in non-tumour-
bearing mice for 30 days, with lapatinib given daily Monday-Friday by oral gavage 
and LB-100 administered by IP injection Monday, Wednesday, and Friday (Section 
4.4). The drug regimen scheduled in treatment holidays at weekends to allow for 
recovery from treatments. Thirty days was chosen as the duration of treatment as this 
would allow the establishment and maintenance of long-term peak plasma 
concentration of lapatinib and LB-100. Lapatinib has previously been shown to reach 
peak plasma levels after 5 to 7 days in humans and has a half-life of approximately 24 
h [361]. Despite the short half-like of LB-100, its maximum PP2A inhibition occurs 
2-4 h after infusion [194]. This 30-day treatment regimen was chosen to give an 
indication of the expected adverse events of this combination in vivo. The most 
common adverse events related to lapatinib in humans are diarrhoea and skin rashes 
[362] and LB-100 has been shown to impair renal function [268]. These side effects, 
along with the adverse effects of the drug administration, were monitored by weight 
measurement and observation for skin damage. The absence of such side effects 
suggest that the combination of lapatinib and LB-100 could be tolerated in a pre-
clinical model, which adds support to the rationale for testing this combination in a 
phase I clinical trial. 
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7.4.3 Mammary fat pad is optimal for HCC1954-L cells in vivo 
 
The first objective of the in vivo assessment of lapatinib plus LB-100 in a model of 
lapatinib resistance was to optimise the tumour growth conditions for HCC1954-L 
cells in mice. The two pilot studies examining HCC1954-L growth in SCID mice with 
sub-cutaneous implantation (Sections 4.2.1 and 4.2.2) confirmed that HCC1954-L 
cells form tumours in vivo. However, best practice and adherence to animal welfare 
regulation meant that the occurrences of skin ulceration on the tumours terminated 
these studies prior to any investigation of the effect of the drug combination on 
xenograft tumour growth. Skin ulceration can occur due to rapid tumour expansion, 
haemorrhagic development, continuous abrasion, tumour type, or cell line 
predisposition to cause ulceration [363]. This has been observed in several cell line 
models when implanted sub-cutaneously including the ovarian cancer cell line A2780 
and the pancreatic cancer cell line AR42J [284]. This skin ulceration can be painful to 
the animal and cause loss of skin integrity and injection. Therefore, extensive skin 
ulceration requires humane termination [284, 363].  
Mammary fat pad implantation allowed for greater maximum tumour volume 
compared to the sub-cutaneous injections (545.0 ± 190.1 mm3 compared to 248.3 ± 
25.6 mm3) without incidence of skin ulceration. Although sub-cutaneous injection is a 
more simple procedure and avoids the need for anaesthetic, mammary fat pad 
implantation allows for a more accurate recreation of the tumour microenvironment, 
increases the metastatic potential of the developing tumours, and reduces the 
likelihood of skin ulceration [285, 364, 365]. One disadvantage of the procedure is the 
accuracy and technical proficiency required to inject cells into the murine mammary 
fat pad. In this mammary fat pad implant pilot study, the take rate was 66.7%, with an 
additional tumour developing subcutaneously (Section 4.2.4). Importantly, skin 
ulceration did not occur in any of the six mice tested. The only tumour-related side 
effect was haemorrhagic areas developing at a large tumour volume in one mouse 
(Figure 4-11). Adverse haemorrhagic events at this volume should not interfere with a 
drug efficacy study of lapatinib plus LB-100 as expected tumour volume differences 
between treatment arms would be expected below the volume at which the 
haemorrhagic necrosis occurred. 
There is little information in the literature relating to the occurrence of skin ulceration 
with implanted HCC1954 cells. Some studies briefly mention the development of 
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tumour ulceration but do not give details of percentage occurrences or the size of 
tumours at ulceration [366, 367].  
 
In summary, the HCC1954-L cell line showed high tumourigenic potential both in 
sub-cutaneous and mammary fat pad injection. The lapatinib resistant cell line 
maintained its HER2 and phospho-eEF2 levels in vivo and lapatinib resistance was 
preserved despite the absence of lapatinib treatment for over three months. 
Unfortunately, skin ulceration of sub-cutaneous implanted tumours hampered the 
further study of lapatinib plus LB-100 in vivo. As skin ulceration did not occur in the 
mammary fat pad model, future work should use this model to test the efficacy of the 
drug combination. This study should also examine the metastatic potential of the 
HCC1954-L cell line and evaluate the in vivo mechanisms of lapatinib plus LB-100. 
 
7.5 PP2A in innate lapatinib resistance 
 
As the acquired lapatinib resistant cells were more sensitive to okadaic acid and LB-
100 than their parental cell lines (Sections 3.2 and 3-10), the role of PP2A in innate 
lapatinib resistance was examined (Section 5.3). Previous work in our research group 
showed that there was a relationship between lower levels of phospho-eEF2 and 
innate lapatinib resistance in a panel of HER2-positive breast cancer cell lines [346]. 
In this study, the sensitivity of the HER2-positive cell lines to okadaic acid was 
shown to correlate with both lapatinib and trastuzumab sensitivity (Figure 5-3). The 
cytotoxic effect of okadaic acid in cancer cell lines has been examined in a number of 
studies. Okadaic acid has shown anti-proliferative activity in osteosarcoma, pancreatic 
cancer, and breast cancer cell lines [327, 368, 369]. Okadaic acid induced apoptosis 
and cell differentiation in three breast cancer cell lines: MDA-MB-231, MCF7, and 
AU565 [368, 370]. Okadaic acid may also induce increased expression of Fas 
receptor and ligand and also affects sensitivity to TRAIL [239, 371]. In contrast, 
okadaic acid has also demonstrated pro-growth activity in prostate and pancreatic cell 
lines [331, 372]. In this study, okadaic acid enhanced the anti-proliferative effect of 
lapatinib in two of three lapatinib-resistant cell lines (Figure 5-4).  
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As discussed earlier, LB-100 has been examined in a phase I clinical trial and was 
shown to be safe and tolerable [268] and, in this study, has shown efficacy in acquired 
lapatinib resistant HER2-positive breast cancer [154]. However, when LB-100 
sensitivity was assessed in a panel of HER2-positive cell lines naive to any HER2-
targeted therapy, sensitivity to LB-100 did not correlate with either lapatinib or 
trastuzumab resistance (Figure 5-8). The difference in okadaic acid and LB-100 
sensitivity may be due to the differences in potency and selectivitiy of the molecules. 
LB-100 is a cantharidin derivative and therefore has different selectivity to PP2A 
[289]. The associated transporter proteins of LB-100 have not yet been investigated. 
Okadaic acid uptake is regulated by OATP1B3 and p-glycoprotein [373, 374]. LB-
100 may be regulated by different transporter molecules. 
LB-100 enhanced lapatinib in the HCC1954-L cells and synergy was also observed in 
the innately lapatinib and trastuzumab resistant MDA-MB-453 cell line (Figure 5-9), 
but slight antagonism was observed in the JIMT-1 and UACC732 cell lines. The 
MDA-MB-453 cells showed a similar enhancement with okadaic acid. However, the 
additive effect observed with okadaic acid plus lapatinib was lost with LB-100.  
 
Alterations in PP2A subunit levels have been observed in several cancer types [277]. 
This may occur through mutation of the structural subunit, which decreases 
holoenzyme assembly [375]. This study showed that there was no relationship 
between PP2A catalytic and structural subunit expression and sensitivity to lapatinib 
or trastuzumab (Figure 5-10). This indicates that the mediator of okadaic acid and 
HER2-targeted therapy response is independent from PP2A expression in HER2-
positive breast cancer cell lines. The lack of a relationship between PP2A expression 
and HER2-targeted therapy response was mirrored by the absence of a correlation 
between high expression of PP2A catalytic or structural subunits and HER2-positive 
breast cancer patient survival response (Figure 5-12 – 5-17). Interestingly, low levels 
of the PP2A inhibitor protein CIP2A were associated with improved overall survival. 
CIP2A levels has previously been reported to correlate with poor prognosis in breast 
cancer [231]. Future work should examine the expression of CIP2A in the panel of 
HER2-positive breast cancer cell lines and evaluate the relationship between CIP2A 
levels and HER2-targeted therapy response. Methylation levels of PP2A and PP2A 
activity should also be evaluated in the HER2-positive breast cancer cell lines. 
 
 216 
7.6 Analysis of afatinib resistant cell line model 
 
In addition to evaluating the potential of PP2A as a novel target for the treatment of 
HER2-positive breast cancer, the afatinib resistant SKBR3-A cells, which were 
generated by Dr. Alexandra Canonici in our research group, were examined in order 
to identify additional novel targets in the treatment of HER-targeted TKI resistance. 
Acquired resistance to afatinib has not previously been investigated in HER2-positive 
breast cancer. All pre-clinical investigations of afatinib resistance have focused on the 
emergence of resistance in NSCLC using cell lines to develop resistant models to 
afatinib in vitro and in vivo [170, 198, 204, 319, 376–378]. 
An afatinib resistant breast cancer cell line model, SKBR3-A was developed in our 
lab by Dr Alexandra Canonici. In order to investigate the mechanisms by which the 
SKBR3-A cells become resistant to afatinib and the other HER2-targeted therapies 
tested, the afatinib-resistant and parental cells were analysed by whole exome 
sequencing and RPPA.  
 
7.6.1 HER family member alterations 
 
The acquisition of EGFR- or HER2-mutations is the most commonly occurring 
resistance mechanism in afatinib-resistant NSCLC models. EGFR L858R, V843I and 
T790M mutations and EGFR exon insertions have all been associated with afatinib 
resistance [201, 378, 379]. However, the SKBR3-A cell line did not develop 
secondary HER family member mutations (Table 6-3), insertions or deletions (Table 
6-2), or gene copy number alterations (Table 6-4); indicating afatinib resistance in a 
HER2-positive breast cancer model utilises alternative mechanisms to those described 
in lung cancer. Other previously reported afatinib resistance mechanisms were also 
examined in the SKBR3-A cells by RPPA and whole exome sequencing analysis. The 
SKBR3-A cells did not display MET amplification, which has been shown to occur in 
afatinib-resistant lung cancer (Table 6-5) [380]. RPPA analysis showed changes in 
HER family members. Total levels of EGFR were significantly increased and 
phosphorylated levels of HER3 (Y1289) were decreased in SKBR3-A cells. The 
results suggest that EGFR has a role to play in circumventing afatinib resistance in 
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lapatinib-resistant SKBR3-L cell line model [154]. Levels of HER2 were also slightly 
decreased in the SKBR3-A cells but this was not statistically significant. Increased 
EGFR levels, through amplification or mutation, is a common mechanism of 
resistance to HER2-targeted therapies and has been observed in our SKBR3-L, 
SKBR3-T, and SKBR3-TL cell lines [169, 198]. Alterations to EGFR, through 
increased levels or by mutation, has been shown to drive afatinib resistance in a lung 
cancer cell line model [377].  
 
7.6.2 Downstream signalling changes 
 
Reactivated signalling downstream of EGFR and HER2 can compensate for the effect 
of HER2-targeted therapies and several downstream kinases have been associated 
with afatinib, lapatinib, and trastuzumab resistance [153, 199, 202, 377]. RPPA 
analysis showed no significant increase in mTOR levels or S2448 phosphorylation. 
Likewise, phosphorylation of AKT (S473 and T308) and phosphorylated MEK 1/2 
(S217/221) were down-regulated. This suggests that the afatinib resistant cells have 
become less dependent on Akt and ERK signalling. As discussed, total levels of 
EGFR were significantly increased, despite the absence of EGFR amplification 
(Figure 6-5 and Table 6-3). Phosphorylation of EGFR was increased but not 
statistically significantly. EGFR up-regulation has been observed in afatinib-resistant 
NSCLC cell lines [198]. However, this increase in EGFR caused constitutive 
activation of PI3K/Akt signalling, which was not observed in RPPA analysis of our 
afatinib-resistant HER2-positive breast cancer model. This is possible due to the lack 
of a similar increase in phospho-EGFR levels.  
However, the RPPA data indicated increased activation of other signalling pathways. 
Despite down-regulation of PI3K/AKT and ERK signalling, SKBR3-A cells had 
increased total p38 MAPK, phosphorylated AMPK (T172), AKT2, and 
phosphorylated Src (Y416) levels. All of these proteins are involved with EGFR 
activity, which may be driving compensatory signalling networks. P38 MAPK can act 
independently of EGFR and HER2 signalling and can act as an internal activator of 
EGFR, by phosphorylating EGFR Y845 [381, 382]. AKT2 activity is driven by EGFR 
signalling [383], which may account for the increased AKT2 in the SKBR3-A cells. 
Src kinase cross-talks with EGFR and has been associated with a variety of HER-
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targeted therapies [157, 204, 305, 384, 385]. Src can be activated by EGFR through 
phosphorylation of Y416. Activated Src can then interact with EGFR and 
phosphorylate EGFR Y845 [386] and Src activation is more dependent on EGFR than 
HER2 signalling [160].  
The gene copy number of nuclear receptor subfamily 4 group 1 (NR4A1) was 
significantly amplified in the SKBR3-A cells. NR4A1 is a transcription factor that has 
been implicated in several cancer types and is now being pursued as a potential anti-
cancer drug target [301, 387–389]. Importantly, knockdown of NR4A1 caused 
decreased levels of EGFR and Bcl-2 and an increase in cleaved caspase-3 and PARP 
[387]. Thus increased expression of NR4A1 in the SKBR3-A cells may contribute to 
the increased levels of EGFR observed. Future work should further investigate the 
role of NR4A1 in afatinib resistance and in regulating EGFR in afatinib resistant 
cells.  
 
7.6.3 Epithelial-mesenchymal transition 
 
The development of a stem cell-like phenotype has previously been observed in 
afatinib resistant lung cancer cell lines [376]. In that study, 10 afatinib resistant cell 
lines were developed. Of those cell lines, three afatinib-resistant cell lines, (two 
originating from HCC4011 and one from HCC827) and a dual afatinib and crizotinib 
resistant HCC827 cell line showed increased vimentin, a mesenchymal marker, and 
down-regulated E-cadherin, an epithelial marker. In our study, whole exome 
sequencing showed amplification of several genes associated with EMT. The EMT-
associated amplified genes include NR4A1, SPHK1, ITGB4, S100A9, and PDE4A 
[297–301]. The emergence of an EMT phenotype has also been observed in both 
trastuzumab and lapatinib resistance [189, 390]. Further investigation into the 
possible stem-like properties of afatinib resistant HER2-positive breast cancer cells 
may be warranted. This should be done by examining the protein levels of the EMT-
associated genes altered in the exome sequencing and by assessing the mammosphere 
formation ability of the SKBR3-A and SKBR3-Par cell lines. Mammosphere assays 
indicate the stem cell potential of tumour cells. In this assay, cells are cultured in 
suspension in mammosphere medium (DMEM/F12, B27 supplement, and EGF). The 
number of spheroids > 50 µm formed after five days, relative to the cell seeding 
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density, indicates the stem cell progenitor activity. Disaggregation and reseeding of 
these spheroids for a secondary mammosphere assays then gives the self-renewal 
potential of the cells [391, 392]. 
 
7.6.4 Integrin level alterations 
 
Integrin proteins are cell adhesion molecules that are involved in cancer progression, 
proliferation, and metastasis [393]. Whole exome sequencing of SKBR3-A cells show 
significant changes in the gene copy number of two integrins, integrin subunit alpha 9 
(ITGA9) and integrin subunit beta 4 (ITGB4). 
ITGA9 is a suspected tumour suppressor and its copy number ratio is decreased in 
SKBR3-A cells. ITGA9 has been shown to be down-regulated or hyper-methylated in 
lung, breast and nasopharyngeal cancer [394–396].  
ITGB4 is an oncogenic integrin that has been shown to increase invasion of cancer 
cells [298, 397–399]. This gene was significantly amplified in SKBR3-A cells. 
ITGB4 promoted EMT and metastasis in pancreatic cancer and was a negative 
prognostic marker [298]. In hepatocellular carcinoma, ITGB4 is often over-expressed 
and has been demonstrated to induce an invasive and migratory phenotype. ITGB4 
can also interact with EGFR, thereby activating FAK and AKT signalling [397]. As 
the SKBR3-A cells have over-expression of EGFR, ITGB4 may stimulate cell 
survival through interaction with EGFR. Levels of both integrin proteins should be 
evaluated in order to determine if they are having an effect on afatinib response. 
 
7.6.5 Bcl-2 expression and activation 
 
Bcl-2 is an anti-apoptotic protein found on the mitochondrial membrane. Bcl-2 family 
member proteins regulate intrinsic apoptosis. The eponymous Bcl-2 prevents 
apoptosis induction by blocking caspase 9 activation. Inhibition of Bcl-2 family 
members, MCL-1 and BIM, has been shown to overcome lapatinib resistance in cell 
line models of acquired resistance [91, 93, 400]. SKBR3-L and SKBR3-TL cells were 
previously shown in our lab to have decreased levels of the pro-apoptotic Bcl-2 
family member BAX and increased levels of MCL-1 [401]. RPPA analysis of the 
SKBR3-A cells showed no significant alterations to BAX, MCL-1, the anti-apoptotic 
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Bcl-xL, or pro-apoptotic BIM. However, SKBR3-A cells had increased total and 
phosphorylated (S70) Bcl-2 levels.  
Like the increase observed in EGFR levels, this up-regulation of Bcl-2 could be 
related to amplification of the transcription factor NR4A1, as NR4A1 has been shown 
to increase Bcl-2 expression [402]. Interestingly, when NR4A1 is exported out of the 
nucleus it binds to Bcl-2 to form a pro-apoptotic complex [403]. This has led to the 
development of NR4A1 mimetics and drugs that induce nuclear export [387, 404, 
405]. This may be a therapeutic strategy to examine in this SKBR3-A cell line. 
 
7.7 Dasatinib in afatinib resistant HER2-positive breast cancer 
 
Src kinase was chosen as the best candidate target to overcome afatinib resistance, as 
phosphorylated Src (Y416) had a 4-fold increase in the RPPA data and a 2-fold 
increase by Western blotting. Src has been implicated in cell line models of lapatinib 
and trastuzumab resistance in HER2-positive breast cancer and afatinib resistance in 
NSCLC [160, 204, 305]. Dasatinib plus afatinib has also shown some potential in 
triple negative breast cancer in pre-clinical studies [406]. Dasatinib was chosen as the 
Src inhibitor for this study as saracatinib is not being further pursued for novel 
oncological use. In addition, afatinib plus dasatinib has completed phase I clinical 
testing to examine safety and tolerability in NSCLC at 30 mg afatinib plus 100 mg 
dasatinib [205]. Dasatinib has shown little activity in pre-clinical testing in HER2-
positive breast cancer [210]. The triple negative breast cancer subtype proved more 
sensitive to dasatinib in pre-clinical models but did not show clinical efficacy in triple 
negative breast cancer patients as a single agent [312]. Following this outcome, 
further investigation of the clinical potential of dasatinib has been in combination 
with chemotherapy or another targeted therapy, with some positive results. For 
example, dasatinib showed an enhancing effect in combination with doxorubicin in 
triple negative breast cancer cells [407] and is currently being investigated in 
combination with trastuzumab and paclitaxel as first-line therapy in HER2-positive 
breast cancer [408]. 
In our study, SKBR3-A cells were more sensitive to the Src inhibitor dasatinib than 
the parental cell line (Figure 6-6). However, single agent dasatinib still had only 
modest activity in SKBR3-A cells. Our results suggest the therapeutic potential is in 
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the combination of afatinib plus dasatinib, which was strongly synergistic in the 
afatinib resistant model (Section 6.2.4). This anti-proliferative enhancement of Src 
inhibition and HER2-targeted therapies has been reported in both breast and lung 
cancer cell lines. Lapatinib plus saracatinib had a greater than additive effect in the 
innately lapatinib resistant JIMT-1 cell line [160]. One study showed that lapatinib 
plus dasatinib or afatinib plus dasatinib can act synergistically in the 
lapatinib/trastuzumab resistant MDA-MB-453 cell line, but showed antagonism in 
SKBR3 cells [409]. This antagonism was not observed in the SKBR3-Par or the 
trastuzumab- and lapatinib-resistant variants in our lab. However, the combination of 
afatinib plus dasatinib showed a slight enhancement in SKBR3-T cells and synergism 
in SKBR3-L cells. 
 
This study shows that the combination of afatinib and dasatinib may also be a 
therapeutic approach to overcome and prevent the development of afatinib resistance 
in HER2-positive breast cancer.  Interestingly, the synergistic growth inhibitory effect 
of the combination was apoptosis-independent (Figure 6-8 and 6-9). Dasatinib plus 
afatinib at concentrations causing approximately 80% growth inhibition caused no 
significant change in caspase 3/7 activation or increase in the subG1, apoptotic 
population. Both agents have been shown to cause cell cycle arrest and apoptosis in 
other cancer types [306, 309]. They are also known to stimulate autophagy [303, 308]. 
This led us to examine if the combination of afatinib and dasatinib caused induction 
of autophagy. Although afatinib treatment alone caused an increase in autophagy, the 
combination did not significantly enhance this effect (Figure 6-10). However, the 
RPPA data showed that the SKBR3-A cells had an increase in total and 
phosphorylated (activating) Bcl-2 levels. Bcl-2 has been implicated in cell death 
mechanism switching. In a study using Bcl-2 transfected HeLa cells, Bcl-2 prevented 
apoptotic cell death at low concentrations of H2O2 that caused apoptosis in control 
vector cells. Notably, at higher H2O2 concentrations, Bcl-2 transfected cells died at a 
greater rate than control cells as Bcl-2 prevented apoptosis induction but stimulated 
necrosis [410].  
As the combination of afatinib and dasatinib did not result in increased levels of 
apoptosis or autophagy, necrosis was considered as a possible mechanism. Afatinib 
has been shown to induce apoptosis and necrosis in a retinoblastoma cell line, RB116 
[411]. Afatinib in combination with paclitaxel has also caused tumour necrosis in vivo 
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[412]. We examined if afatinib plus dasatinib causes necrotic death in SKBR3-A cells 
by assaying the levels of secreted HMGB1 (Figure 6-11). HMGB1 is a chromatin 
protein that is bound to chromatin during apoptosis, but, when a cell undergoes 
necrosis, it is released into the extracellular matrix and signals to surrounding cells to 
elicit an inflammatory response [310, 413]. Extracellular HMGB1 was found to be 
elevated in afatinib plus dasatinib treated SKBR3-A cells relative to untreated 
controls and single agent treatment. A limitation of this experiment was that in order 
to distinguish HMGB1 through Western blotting, SKBR3-A cells were grown in 
serum-free conditions, which may alter the growth of the cells. However, this result 
combined with the cell cycle and caspase 3/7 activation experiments suggest that 
afatinib plus dasatinib induces non-apoptotic, necrotic cell death in this afatinib-
resistant cell model. As HMGB1 release can cause immune cell activation [310], 
future work should examine the effect of extracellular HMGB1 on natural killer cell 
cytotoxicity against SKBR3-A cells. This would give insight into the possible 
advantageous immunological effect of afatinib plus dasatinib.  
 
As well as looking for therapeutic strategies to overcome afatinib resistance, we also 
investigated ways of preventing the development of resistance. As HER2-positive 
breast cancer patients that could potentially receive afatinib would most likely have 
received previous HER2-targeted therapy, we examined the efficacy of afatinib alone 
and in combination with dasatinib in acquired trastuzumab resistant cell lines and a 
lapatinib resistant cell line model. A panel of HER2-targeted therapy-naive cell lines 
were also examined as representatives of patients without prior HER2-targeted 
intervention. All HER2-targeted therapy-naive cell lines and the three trastuzumab 
resistant cell lines were exquisitely sensitive to afatinib alone (IC50 values < 15 nM) 
(Figure 6-12), while the lapatinib resistant model, as previously discussed in Section 
7.2, was resistant to afatinib alone at clinically relevant concentrations. Similar to 
literature reports, the HER2-positive breast cancer cells tested with dasatinib alone in 
this study showed minimal to no growth inhibition [210].  
Afatinib plus dasatinib was strongly synergistic in SKBR3-L cells (Figure 6-13). In 
contrast, the combination only slightly improved afatinib response in one HER2-
targeting TKI-naive cell line, the SKBR3-T cells and had a non-antagonistic but non-
additive effect in the other cell lines tested. It is possible that in a five day assay, 
afatinib causes such growth inhibition that dasatinib cannot enhance growth inhibition 
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further in such a short timeframe. Thus, we then used a longer-term treatment format 
to assess growth response (Section 6.4). By treating cells twice weekly until cells 
become treatment refractory, the drug response can be measured across time as well 
as by growth inhibition. The benefit of addition of dasatinib was observed in four of 
the six cell lines tested. For example, SKBR3 cells, which showed no improvement in 
the five-day assay, began to actively grow again after approximately 70 days of 
afatinib treatment. In contrast, SKBR3 cells treated with afatinib plus dasatinib did 
not develop resistance by this point. This was also observed in the SKBR3-T, 
EFM192A and HCC1954 cell lines. Importantly, the HCC1954 cells, which showed 
an initial synergistic response to afatinib plus dasatinib, maintained their response in 
this repeated treatment assay over a longer timescale. BT474 and BT474-T cells did 
not show emergence of afatinib resistance following treatment with 80 nM afatinib. 
Unfortunately, SKBR3 cells show a low tumourigenic potential in vivo [414] and 
therefore the effect of afatinib plus dasatinib on the SKBR3-A cell line cannot be 
investigated in vivo. In order to further examine the potential of afatinib plus dasatinib 
an in vivo model should be generated.  
 
The HCC1954-N cell line may provide an appropriately model for studying the 
combination of a pan-HER inhibitor and dasatinib in vivo; HCC1954 cells are 
tumourigenic and the combination of neratinib and dasatinib was synergistic in this 
model. However, there are a number of differences between the HCC1954-N and 
SKBR3-A. The HCC1954-N cells displayed a different mechanism of cell death to 
the SKBR3-A cells. Both cell cycle and caspase 3/7 activation showed that neratinib 
plus dasatinib significantly induces apoptosis (Figure 6-20 and 6-21). Notably, 
previous work by another group showed that the HCC1954-N have decreased levels 
of EGFR, HER2 and HER3 and had increased IGF-1R, which is unlike the SKBR3-A 
cells [151, 206]. This would indicate that alternate resistance mechanisms are being 
exploited in the HCC1954-N cell line. However, the response to neratinib plus 
dasatinib in both the resistant and parental cell lines suggests that this is a viable 
therapeutic combination (Figure 6-17 and 6-18). The synergy observed in the 
HCC1954-N cell model was also observed in a 3D environment (Figure 6-19). 
Previous investigations into the mechanism of neratinib resistance in the HCC1954-N 
cell line model by the group that developed the cell line have implicated CYP3A4 
activity, over-expression of Neuromedin U, and down-regulation of miR-630 [151, 
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165, 206]. CYP3A4 is a cytochrome P450 that metabolises approximately half of all 
marketed drugs, including neratinib [415]. Therefore, the elevated CYP3A4 activity 
in HCC1954-N cells may decrease intracellular neratinib accumulation. 
Pharmacokinetic analysis of neratinib in combination with the CYP3A inhibitor 
ketoconazole showed a 3.2-fold increase in neratinib Cmax [416]. CYP3A4 may also 
be relevant to the potential of neratinib plus dasatinib. Dasatinib is also a substrate 
and weak inhibitor of CYP3A4 and dasatinib levels are increased by co-
administration of ketoconazole [417]. This may explain the reduced inhibition of 
neratinib or dasatinib alone in HCC1954-N cells compared to HCC1954-Par cells 
(Figures 6-17 and 6-18). Neuromedin U confers neratinib resistance by interacting 
with Hsp27, which stabilises HER2. Neuromedin U can increase HER2 and EGFR 
expression and reduce sensitivity to HER2-targeted therapy [165]. As the neratinib 
and dasatinib are acting downstream of HER2, the combination may overcoming this 
resistance mechanism.  
 
In summary, the combination of afatinib or neratinib plus dasatinib shows potential 
for the treatment of pan-HER inhibitor resistant HER2-positive breast cancer (Figure 
7-3). The combination of afatinib and dasatinib was strongly synergistic in SKBR3-A 
cells and cell death was due to necrosis and independent of apoptosis and autophagy. 
Neratinib plus dasatinib was also highly synergistic in HCC1954-N cells and, in 
contrast to the afatinib resistant model, stimulated a significant induction of apoptosis. 
The addition of dasatinib to afatinib does not enhance response in cell lines highly 
sensitive to afatinib, in short-term treatment experiments. However, the combination 
can delay or block the emergence of afatinib resistance. One cell line model of 
afatinib resistance and one model of neratinib resistance were tested in this study. 
This should be expanded in order to ensure that this is not a cell line-dependent 
phenomenon. Further in vivo investigations are necessary to determine the potential 
therapeutic benefit of afatinib or neratinib in combination with dasatinib.  
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Figure 7-3: Afatinib/neratinib plus dasatinib in HER family member signalling 
(Pathway adapted from [349]). Red X indicates inhibition by afainib/neratinib. 
Green X indicates inhibition by dasatinib. 
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7.8 Summary 
 
Acquired HER2-targeted therapy resistant cell lines represent a valid model of 
resistance observed in the clinic [148]. This study utilised seven HER2-targeted 
therapy resistant cell lines: three trastuzumab resistant, two lapatinib resistant, one 
afatinib resistant and one neratinib resistant cell line. These cell lines showed that the 
irreversible inhibitors afatinib and neratinib had a better efficacy against trastuzumab 
resistant cell lines than lapatinib resistant cell lines. Afatinib and neratinib resistant 
cell lines were insensitive to trastuzumab, pertuzumab, lapatinib and either pan-HER 
inhibitor, highlighting the need for novel targets for treatment-refractory HER2 
positive breast cancer. 
Both SKBR3-L and HCC1954-L cell lines were more sensitive to PP2A inhibition 
with okadaic acid and LB-100 compared to their parental cell lines. Okadaic acid and 
LB-100 in combination with lapatinib were both synergistic in HCC1954-L cells. 
PP2A inhibition and lapatinib caused apoptosis in both lapatinib-resistant cell lines. 
Importantly, combining PP2A inhibition with lapatinib in both SKBR3-Par and 
HCC1954-Par cell lines prevented the development of lapatinib resistance. Activation 
of PP2A using FTY720 also generated a less lapatinib sensitive phenotype in both 
parental cell lines. The proteomic analysis of HCC1954-L cells treated with okadaic 
acid and lapatinib by RPPA gave an insight into the molecular mechanism of action 
as combination therapy significantly inhibited downstream survival signalling 
compared to either single agent. 
The optimal xenograft model of the HCC1954-L cell line was found to be mammary 
fat pad implantation. HCC1954-L cells caused skin ulceration on the tumour surface 
when implanted subcutaneously. This limited the size of the tumours and ultimately 
both subcutaneous implantation pilot studies were ended early for humane reasons. 
The mammary fat pad implantation did not display skin ulceration and will be the 
chosen model for future efficacy studies of LB-100 plus lapatinib. Preliminary study 
of the activity of LB-100 and lapatinib in vivo shows that the treatment can increase 
phospho-eEF2, indicating decreased PP2A activity, and the combination did not cause 
any adverse events in mice. 
In a panel of HER2-positive breast cancer cell lines, sensitivity to okadaic acid 
correlated with resistance to both lapatinib and trastuzumab. Response to okadaic acid 
did not show any relationship to PP2A catalytic or structural subunit expression. 
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Likewise, PP2A expression had no relationship with lapatinib or trastuzumab 
sensitivity, showing that PP2A inhibition sensitivity is independent of PP2A catalytic 
and structural subunit expression. PP2A inhibition with LB-100 did not relate to 
HER2-targeted therapy or okadaic acid response. This indicates that LB-100 may 
have a different mechanism of action to okadaic acid in the panel of cell lines. 
The SKBR3-A cell line represents an afatinib resistant model in HER2-positive breast 
cancer. This cell line showed increased EGFR and phosphorylated Src levels and -
heightened sensitivity to the combination of afatinib and dasatinib. The combination 
caused a non-apoptotic, necrotic cell death in this model. The combination of afatinib 
and dasatinib prevented the development of afatinib resistance in five of seven cell 
lines tested. 
Similarly, the neratinib resistant HCC1954-N cell line showed a synergistic response 
to the other pan-HER inhibitor neratinib plus dasatinib. In contrast to the SKBR3-A 
cells, the combination significantly induced apoptosis in these cells. 
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7.9 Conclusions 
 
In conclusion, two novel approaches have been identified to overcome resistance to 
HER2-targeted therapies. Firstly, the combination of lapatinib plus LB-100 may be 
effective in acquired lapatinib resistant breast cancer, which will be further evaluated 
in in vivo efficacy testing. Levels of PP2A expression did not correlate with response 
to PP2A inhibition. Therefore, other potential biomarkers of response should be 
investigated, including methylated PP2A and PP2A substrate levels.  
Secondly, afatinib or neratinib in combination with dasatinib has potential as a novel 
treatment strategy to block the emergence of TKI resistance in HER2-positive breast 
cancer. This combination could be evaluated clinically in two different settings: the 
combination may be effective as a second line-therapy in metastatic breast cancer 
after progression on trastuzumab or as a third line-therapy after the subsequent 
development of resistance to lapatinib. 
 
 
 
 
 229 
 
 
 
 
 
 
 
 
8 References  
 230 
1. Hanahan D, Weinberg RA, Francisco S: The Hallmarks of Cancer. 2000, 100:57–
70. 
2. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 
144:646–74. 
3. Cancer trends No. 29 - breast cancer 
[http://www.ncri.ie/sites/ncri/files/pubs/bc_trends_21.pdf] 
4. Linda A, Zuiani C, Girometti R, Londero V, Machin P, Brondani G, Bazzocchi M: 
Unusual malignant tumors of the breast: MRI features and pathologic 
correlation. Eur J Radiol 2010, 75:178–184. 
5. Pourteimoor V, Mohammadi-Yeganeh S, Paryan M: Breast cancer classification 
and prognostication through diverse systems along with recent emerging 
findings in this respect; the dawn of new perspectives in the clinical applications. 
Tumor Biol 2016, 37:14479–14499. 
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, 
Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale 
A-L, Botstein D: Repeated observation of breast tumor subtypes in independent 
gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418–23. 
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, 
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, 
Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene expression 
profiling in breast cancer: understanding the molecular basis of histologic grade 
to improve prognosis. J Natl Cancer Inst 2006, 98:262–72. 
8. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees C a, Pollack JR, 
Ross DT, Johnsen H, Akslen L a, Fluge O, Pergamenschikov  a, Williams C, Zhu SX, 
Lønning PE, Børresen-Dale  a L, Brown PO, Botstein D: Molecular portraits of 
human breast tumours. Nature 2000, 406:747–52. 
9. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen 
MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein 
D, Lønning PE, Børresen-Dale  a L: Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications. Proc Natl 
Acad Sci U S A 2001, 98:10869–74. 
10. Dvorkin-Gheva A, Hassell JA: Identification of a novel luminal molecular 
subtype of breast cancer. PLoS One 2014, 9:e103514. 
 231 
11. Dawson S-J, Rueda OM, Aparicio S, Caldas C: A new genome-driven 
integrated classification of breast cancer and its implications. EMBO J 2013, 
32:617–28. 
12. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann 
B, Senn H-J: Personalizing the treatment of women with early breast cancer: 
highlights of the St Gallen International Expert Consensus on the Primary 
Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206–23. 
13. Kauraniemi P, Kallioniemi A: Activation of multiple cancer-associated genes at 
the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006, 13:39–49. 
14. Schnitt SJ: Classification and prognosis of invasive breast cancer: from 
morphology to molecular taxonomy. Mod Pathol 2010, 23 Suppl 2:S60-4. 
15. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou 
CM: Phenotypic and molecular characterization of the claudin-low intrinsic 
subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 
16. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, 
Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz A-L, Brisken C, 
Fiche M, Delorenzi M, Iggo R: Identification of molecular apocrine breast 
tumours by microarray analysis. Oncogene 2005, 24:4660–71. 
17. Aertgeerts K, Skene R, Yano J, Sang B-C, Zou H, Snell G, Jennings A, Iwamoto 
K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S: 
Structural analysis of the mechanism of inhibition and allosteric activation of the 
kinase domain of HER2 protein. J Biol Chem 2011, 286:18756–65. 
18. Cho H, Mason K, Ramyar KX, Stanley AM: Structure of the extracellular 
region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 
421:756–60. 
19. Roskoski R: ErbB/HER protein-tyrosine kinases: Structures and small 
molecule inhibitors. Pharmacol Res 2014, 87:42–59. 
20. Stein RA, Staros J V: Evolutionary analysis of the ErbB receptor and ligand 
families. J Mol Evol 2000, 50:397–412. 
21. Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 
2003, 284:14–30. 
 232 
22. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev 
Mol Cell Biol 2001, 2:127–37. 
23. Shankaran H, Zhang Y, Tan Y, Resat H: Model-based analysis of HER 
activation in cells co-expressing EGFR, HER2 and HER3. PLoS Comput Biol 
2013, 9:e1003201. 
24. Sliwkowski MX: Ready to partner. Nat Struct Biol 2003, 10:158–9. 
25. Brennan PJ, Kumogai T, Berezov A, Murali R, Greene MI: HER2/Neu: 
mechanisms of dimerization/oligomerization. Oncogene 2000, 19:6093–6101. 
26. Peles E, Lamprecht R, Ben-Levy R, Tzahar E, Yarden Y: Regulated coupling of 
the Neu receptor to phosphatidylinositol 3’-kinase and its release by oncogenic 
activation. J Biol Chem 1992, 267:12266–74. 
27. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, Birchmeier C, 
Riethmacher D: The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, 
are essential for development of the sympathetic nervous system. Genes Dev 
1998, 12:1825–1836. 
28. Moscoso LM, Chu GC, Gautam M, Noakes PG, Merlie JP, Sanes JR: Synapse-
associated expression of an acetylcholine receptor-inducing protein, 
ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing 
mammalian muscle. Dev Biol 1995, 172:158–69. 
29. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and 
oncogenesis: signal diversification through combinatorial ligand-receptor 
interactions. FEBS Lett 1997, 410:83–86. 
30. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, Chien KR, 
Birchmeier C, Garratt AN: Conditional mutation of the ErbB2 (HER2) receptor in 
cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002, 
99:8880–5. 
31. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-
oncogene in normal human adult and fetal tissues. Oncogene 1990, 5:953–62. 
32. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, 
Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, 
Klagsbrun M, Mekada E: Heparin-binding EGF-like growth factor and ErbB 
signaling is essential for heart function. Proc Natl Acad Sci U S A 2003, 100:3221–
6. 
 233 
33. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W: Human breast 
cancer: correlation of relapse and survival with amplification of the HER-2/neu 
oncogene. Science (80- ) 1987, 235:177–182. 
34. Research C for DE and: Therapeutic Biologic Applications (BLA) - 
Trastuzumab Product Approval Information - Licensing Action 9/25/98. . 
35. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko C, Sridhara R, Justice R, Pazdur 
R: FDA drug approval summary: lapatinib in combination with capecitabine for 
previously treated metastatic breast cancer that overexpresses HER-2. 
Oncologist 2008, 13:1114–9. 
36. Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, Liu Q, 
Ringgold K, Pilaro AM, Tilley A, King KE, Graham L, Rellahan BL, Weinberg WC, 
Chi B, Thomas C, Hughes P, Ibrahim A, Justice R, Pazdur R: First FDA approval of 
dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and 
docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 2013, 
19:4911–6. 
37. Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, 
Pazdur R, Cortazar P: First FDA approval of neoadjuvant therapy for breast 
cancer: pertuzumab for the treatment of patients with HER2-positive breast 
cancer. Clin Cancer Res 2014, 20:5359–64. 
38. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, 
Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Pope Miksinski S, 
Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra 
N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, 
Cortazar P: FDA Approval: Ado-trastuzumab Emtansine for the Treatment of 
Patients with HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 2014. 
39. Research AA for C: Neratinib Approved for HER2+ Breast Cancer. Cancer 
Discov 2017. 
40. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia 
BP, Nguyen NT, Hortobagyi GN, Hung M-C, Yu D: PTEN activation contributes 
to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab 
resistance in patients. Cancer Cell 2004, 6:117–27. 
41. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, 
Jensen-Jarolim E, Bergmann M: Trastuzumab mediates antibody-dependent cell-
mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and 
metastatic HER2/neu breast cancer patients. J Transl Med 2013, 11:307. 
 234 
42. Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O’Byrne 
KJ, O’Donovan N, Crown J: Tyrosine kinase inhibitors as modulators of 
trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast 
cancer cell lines. Cell Immunol 2017, 319:35–42. 
43. Ram S, Kim D, Ober RJ, Ward ES: The level of HER2 expression is a predictor 
of antibody-HER2 trafficking behavior in cancer cells. MAbs 2014, 6:1211–9. 
44. Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D: Combined 
trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated 
angiogenesis in breast carcinoma through a more effective inhibition of Akt than 
either treatment alone. Cancer 2003, 98:1377–85. 
45. Le X-F, Claret F-X, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, 
Bast RC: The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 
antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 
2003, 278:23441–50. 
46. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: 
p185HER2 monoclonal antibody has antiproliferative effects in vitro and 
sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989, 
9:1165–72. 
47. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: 
Characterization of murine monoclonal antibodies reactive to either the human 
epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990, 
50:1550–8. 
48. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, 
Shepard HM: Characterization of an anti-p185HER2 monoclonal antibody that 
stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991, 
1:72–82. 
49. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland 
AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 
antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285–9. 
50. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, 
Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the 
efficacy and safety of humanized anti-HER2 monoclonal antibody in women who 
have HER2-overexpressing metastatic breast cancer that has progressed after 
chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639–48. 
 235 
51. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming 
T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy 
plus a monoclonal antibody against HER2 for metastatic breast cancer that 
overexpresses HER2. N Engl J Med 2001, 344:783–92. 
52. Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J: Durable complete 
response following chemotherapy and trastuzumab for metastatic HER2-positive 
breast cancer. Ann Oncol 2012, 23:2204–5. 
53. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in 
the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review 
and Meta-Analysis of Randomized Controlled Trials. Oncologist 2008, 13:620–
630. 
54. O’Sullivan CC, Smith KL: Therapeutic Considerations in Treating HER2-
Positive Metastatic Breast Cancer. Curr Breast Cancer Rep 2014, 6:169–182. 
55. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu 
E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh 
LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, 
Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus 
adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 
2005, 353:1673–84. 
56. Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, Lortholary A, 
Espié M, Fumoleau P, Serin D, Jacquin J-P, Jouannaud C, Rios M, Abadie-
Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar 
A, PHARE trial investigators: 6 months versus 12 months of adjuvant 
trastuzumab for patients with HER2-positive early breast cancer (PHARE): a 
randomised phase 3 trial. Lancet Oncol 2013, 14:741–8. 
57. Gyawali B, Niraula S: Duration of adjuvant trastuzumab in HER2 positive 
breast cancer: Overall and disease free survival results from meta-analyses of 
randomized controlled trials. Cancer Treat Rev 2017, 60:18–23. 
58. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de 
Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, 
McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant 
(HERA) Trial Study Team: 11 years’ follow-up of trastuzumab after adjuvant 
chemotherapy in HER2-positive early breast cancer: final analysis of the 
HERceptin Adjuvant (HERA) trial. Lancet (London, England) 2017, 389:1195–
1205. 
59. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, 
 236 
Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda 
B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, 
Baselga J: Neoadjuvant and adjuvant trastuzumab in patients with HER2-
positive locally advanced breast cancer (NOAH): follow-up of a randomised 
controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 
2014. 
60. Gianni L, Salvatorelli E, Minotti G: Anthracycline cardiotoxicity in breast 
cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 
2007, 7:67–71. 
61. Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA: 
Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using 
Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With 
Breast Cancer. Am J Clin Oncol 2017:1. 
62. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, 
Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von 
Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay M-
A, Riva A, Crown J, Breast Cancer International Research Group TBCIR: Adjuvant 
trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273–83. 
63. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, 
Marschner N, Gluz O, Schrader I, Heinrich G, Untch M, Jackisch C: HER2 
Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast 
Cancer. Breast Care 2013, 8:49–55. 
64. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: 
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab 
complex. Cancer Cell 2004, 5:317–28. 
65. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M: Strongly 
Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination 
Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer Res 
2009, 69:9330–9336. 
66. Nahta R: The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab 
Synergistically Inhibit the Survival of Breast Cancer Cells. Cancer Res 2004, 
64:2343–2346. 
67. Swain SM, Kim S-B, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, 
Ferrero J-M, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J: 
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast 
cancer (CLEOPATRA study): overall survival results from a randomised, 
 237 
double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14:461–471. 
68. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, 
Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM: Pertuzumab 
plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 
2012, 366:109–119. 
69. Sabatier R, Gonçalves A: Pertuzumab (Perjeta®) approval in HER2-positive 
metastatic breast cancers. Bull Cancer 2014, 101:765–771. 
70. Five-year analysis of the phase II NeoSphere trial evaluating four cycles of 
neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). | 
2015 ASCO Annual Meeting | Abstracts | Meeting Library 
[http://meetinglibrary.asco.org/content/147709-156] 
71. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch A, 
Staroslawska E, de la Haba-Rodriguez J, Im S-A, Pedrini JL, Poirier B, Morandi P, 
Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, 
Valagussa P: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in 
women with locally advanced, inflammatory, or early HER2-positive breast 
cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet 
Oncol 2012, 13:25–32. 
72. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler 
WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, 
Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX: Targeting HER2-
positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug 
conjugate. Cancer Res 2008, 68:9280–90. 
73. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX: Trastuzumab-DM1 
(T-DM1) retains all the mechanisms of action of trastuzumab and efficiently 
inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 
2011, 128:347–356. 
74. Barok M, Tanner M, Köninki K, Isola J: Trastuzumab-DM1 causes tumour 
growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer 
cells in vivo. Breast Cancer Res 2011, 13:R46. 
75. Barok M, Tanner M, Köninki K, Isola J: Trastuzumab-DM1 causes tumour 
growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer 
cells in vivo. Breast Cancer Res 2011, 13:R46. 
76. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi 
 238 
J-H, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA: Phase I study of 
trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to 
patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 
28:2698–704. 
77. Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN, Modi S: 
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients 
with advanced human epidermal growth factor 2-positive breast cancer. Cancer 
2012, 118:5733–5740. 
78. Peddi PF, Hurvitz SA: Ado-trastuzumab emtansine (T-DM1) in human 
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: 
latest evidence and clinical potential. Ther Adv Med Oncol 2014, 6:202–9. 
79. Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, 
Blackwell K, Hoersch S, Xu J, Green M, Gianni L: Trastuzumab emtansine versus 
capecitabine plus lapatinib in patients with previously treated HER2-positive 
advanced breast cancer (EMILIA): a descriptive analysis of final overall survival 
results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017, 18:732–
742. 
80. Guerin M, Sabatier R, Gonçalves A: Autorisation de mise sur le marché du 
trastuzumab emtansine (Kadcyla®) dans les cancers du sein métastatiques 
HER2-positifs. Bull Cancer 2015, 102:390–397. 
81. Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, 
Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA: Phase IIa Trial of 
Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal 
Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast 
Cancer. J Clin Oncol 2014. 
82. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, 
Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson 
N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, 
Oliva C, Rubin S, Stein S, Geyer CE: A phase III randomized comparison of 
lapatinib plus capecitabine versus capecitabine alone in women with advanced 
breast cancer that has progressed on trastuzumab: updated efficacy and 
biomarker analyses. Breast Cancer Res Treat 2008, 112:533–43. 
83. Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N’guyen T, 
Vuillemin AT, Demarchi M, Dobi E, Pivot X: Phase II study assessing lapatinib 
added to letrozole in patients with progressive disease under aromatase inhibitor 
in metastatic breast cancer-Study BES 06. Target Oncol 2013, 8:137–43. 
 239 
84. PubChem Compound Database 
85. Nahta R, Yuan LXH, Du Y, Esteva FJ: Lapatinib induces apoptosis in 
trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I 
signaling. Mol Cancer Ther 2007, 6:667–74. 
86. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht 
JR, Slamon DJ, Finn RS: Lapatinib, a dual EGFR and HER2 kinase inhibitor, 
selectively inhibits HER2-amplified human gastric cancer cells and is synergistic 
with trastuzumab in vitro and in vivo. Clin Cancer Res 2010, 16:1509–19. 
87. Zhu X, Wu L, Qiao H, Han T, Chen S, Liu X, Jiang R, Wei Y, Feng D, Zhang Y, 
Ma Y, Zhang S, Zhang J: Autophagy stimulates apoptosis in HER2-
overexpressing breast cancers treated by lapatinib. J Cell Biochem 2013, 
114:2643–53. 
88. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, 
Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, 
Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016) against 
HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 
2006, 66:1630–9. 
89. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, 
Murray DM, Knight WB, Mullin RJ, Gilmer TM: The effects of the novel, 
reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, 
GW2016, on the growth of human normal and tumor-derived cell lines in vitro 
and in vivo. Mol Cancer Ther 2001, 1:85–94. 
90. Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O’Neil B, Marcom 
PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, 
Mangum S, Spector NL: Phase I safety, pharmacokinetics, and clinical activity 
study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth 
factor receptor tyrosine kinases, in heavily pretreated patients with metastatic 
carcinomas. J Clin Oncol 2005, 23:5305–13. 
91. Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K: Roles of 
BIM induction and survivin downregulation in lapatinib-induced apoptosis in 
breast cancer cells with HER2 amplification. Oncogene 2011, 30:4097–106. 
92. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke 
MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL: Regulation of 
survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing 
breast cancers. Cancer Res 2006, 66:1640–7. 
 240 
93. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P: Inhibition of 
MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-
dependent autophagy. Cancer Biol Ther 2009, 8:2084–96. 
94. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, 
Nephew KP, Dent P: Inhibition of MCL-1 in breast cancer cells promotes cell 
death in vitro and in vivo. Cancer Biol Ther 2010, 10:903–17. 
95. Tural D, Akar E, Mutlu H, Kilickap S: P95 HER2 fragments and breast cancer 
outcome. Expert Rev Anticancer Ther 2014, 14:1089–96. 
96. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, 
Landolfi S, Ramon y Cajal S, Arribas J, Baselga J: Lapatinib, a HER2 tyrosine 
kinase inhibitor, induces stabilization and accumulation of HER2 and 
potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28:803–14. 
97. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, 
Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, 
Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, 
Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman J-AW, 
Parulekar WR: Lapatinib or Trastuzumab Plus Taxane Therapy for Human 
Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final 
Results of NCIC CTG MA.31. J Clin Oncol 2015, 33:1574–83. 
98. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-
Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, 
Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for 
HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733–43. 
99. Bian L, Wang T, Zhang S, Jiang Z: Trastuzumab plus capecitabine vs. 
lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-
pretreated metastatic breast cancer. Tumour Biol 2013, 34:3153–8. 
100. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis 
C, Florance A, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J: Overall survival 
benefit with lapatinib in combination with trastuzumab for patients with human 
epidermal growth factor receptor 2-positive metastatic breast cancer: final 
results from the EGF104900 Study. J Clin Oncol 2012, 30:2585–92. 
101. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, 
Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, 
McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck 
N, Tjulandin S, Im Y-H, Huang C-S, Diéras V, Hillman DW, Wolff AC, Jackisch C, 
Lang I, Untch M, Smith I, Boyle F, et al.: Adjuvant Lapatinib and Trastuzumab 
 241 
for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 
Results From the Randomized Phase III Adjuvant Lapatinib and/or 
Trastuzumab Treatment Optimization Trial. J Clin Oncol 2016, 34:1034–42. 
102. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, 
Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang T-W, 
Horváth Z, Coccia-Portugal M, Domont J, Tseng L-M, Kunz G, Sohn JH, Semiglazov 
V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-
Gebhart M: Lapatinib with trastuzumab for HER2-positive early breast cancer 
(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 
379:633–40. 
103. The association between event-free survival and pathological complete 
response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-
positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 
1-06) 
[http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_877&terms=] 
104. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis 
C, Casey M, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J: Randomized study 
of Lapatinib alone or in combination with trastuzumab in women with ErbB2-
positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 
28:1124–30. 
105. Bundred N, Cameron D, Armstrong D, Brunt A, Dodwell D, Evans A, Hanby A, 
Hartup S, Hong A, Horgan K, Khattak I, Morden J, Naik J, Narajan S, Ooi J, Shaaban 
A, Smith R, Webster-Smith M, Bliss J: Effects of perioperative lapatinib and 
trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK 
EPHOS-B trial (CRUK/08/002). In European Breast Cancer Conference 10; 2016. 
106. Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal 
M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, 
Peláez A, Prat A: HER2-enriched subtype as a predictor of pathological complete 
response following trastuzumab and lapatinib without chemotherapy in early-
stage HER2-positive breast cancer (PAMELA): an open-label, single-group, 
multicentre, phase 2 trial. Lancet Oncol 2017, 18:545–554. 
107. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, 
Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou 
H-R, Wang Y-F, Wissner A: Antitumor activity of HKI-272, an orally active, 
irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64:3958–65. 
108. Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, 
O’Brien NA, Roxanis I, Li J-L, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, 
O’Donovan N, Crown J, Kong A: Neratinib overcomes trastuzumab resistance in 
 242 
HER2 amplified breast cancer. Oncotarget 2013, 4:1592–605. 
109. Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti 
M, Andreis D, Haider S, Li J-L, Bridges E, Capala J, Ioannis R, Harris AL, Kong A: 
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated 
with poor outcome in HER2 positive breast cancer. Oncotarget 2014, 5:5934–49. 
110. Wong K-K, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, 
Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, 
Vermette J, Abbas R, Quinn S, Powell C, Burris HA: A phase I study with neratinib 
(HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in 
patients with solid tumors. Clin Cancer Res 2009, 15:2552–8. 
111. Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ: HER2-Mutated Breast 
Cancer Responds to Treatment With Single-Agent Neratinib, a Second-
Generation HER2/EGFR Tyrosine Kinase Inhibitor. J Natl Compr Canc Netw 
2015, 13:1061–4. 
112. Sequist L V., Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, 
Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria J-C: 
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: 
Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung 
Cancer. J Clin Oncol 2010, 28:3076–3083. 
113. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade 
A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, 
Badwe R: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in 
patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 
28:1301–7. 
114. Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortes J, Kiger 
C, Germa C, Wang K, Martin M, Baselga J, Kim S-B: Safety and Efficacy of 
Neratinib in Combination With Capecitabine in Patients With Metastatic 
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin 
Oncol 2014. 
115. Martin M, Bonneterre J, Geyer CE, Ito Y, Ro J, Lang I, Kim S-B, Germa C, 
Vermette J, Wang K, Wang K, Awada A: A phase two randomised trial of 
neratinib monotherapy versus lapatinib plus capecitabine combination therapy 
in patients with HER2+ advanced breast cancer. Eur J Cancer 2013, 49:3763–72. 
116. A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine 
in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or 
More Prior HER2 Directed Regimens in the Metastatic Setting - Full Text View - 
 243 
ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT01808573] 
117. Jankowitz RC, Abraham J, Tan AR, Limentani S a, Tierno MB, Adamson LM, 
Buyse M, Wolmark N, Jacobs S a: Safety and efficacy of neratinib in combination 
with weekly paclitaxel and trastuzumab in women with metastatic 
HER2‑positive breast cancer: an NSABP Foundation Research Program phase I 
study. Cancer Chemother Pharmacol 2013, 72:1205–12. 
118. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera 
RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich 
H, Wong K-K: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective 
in preclinical lung cancer models. Oncogene 2008, 27:4702–11. 
119. Sequist L V, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, 
Orlov S, Tsai C-M, Boyer M, Su W-C, Bennouna J, Kato T, Gorbunova V, Lee KH, 
Shah R, Massey D, Zazulina V, Shahidi M, Schuler M: Phase III study of afatinib 
or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma 
with EGFR mutations. J Clin Oncol 2013, 31:3327–34. 
120. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, 
Himmelsbach F, Haaksma E, Adolf GR: Target binding properties and cellular 
activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J 
Pharmacol Exp Ther 2012, 343:342–50. 
121. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, 
Himmelsbach F, Haaksma E, Adolf GR: Target binding properties and cellular 
activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J 
Pharmacol Exp Ther 2012, 343:342–50. 
122. Ioannou N, Dalgleish AG, Seddon AM, Mackintosh D, Guertler U, Solca F, 
Modjtahedi H: Anti-tumour activity of afatinib, an irreversible ErbB family 
blocker, in human pancreatic tumour cells. Br J Cancer 2011, 105:1554–62. 
123. Effect of afatinib alone and in combination with trastuzumab in HER2-
positive breast cancer cell lines. | 2013 ASCO Annual Meeting | Virtual Meeting | 
Meeting Library 
[http://meetinglibrary.asco.org/content/85383?media=vm&poster=1] 
124. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, 
Zhao Y, Stopfer P, Agus DB: A Phase I, open-label, dose-escalation study of 
continuous once-daily oral treatment with afatinib in patients with advanced 
solid tumors. Invest New Drugs 2013, 31:409–16. 
 244 
125. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell 
S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, 
Plummer R: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor 
BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28:3965–
72. 
126. Eskens FALM, Mom CH, Planting AST, Gietema JA, Amelsberg A, Huisman H, 
van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EGE: A phase I dose 
escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal 
growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 
2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008, 
98:80–5. 
127. Marshall J, Hwang J, Eskens FALM, Burger H, Malik S, Uttenreuther-Fischer 
M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL: A Phase I, open-label, dose 
escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with 
advanced solid tumors. Invest New Drugs 2013, 31:399–408. 
128. Lin NU, Winer EP, Wheatley D, Carey L a, Houston S, Mendelson D, Munster 
P, Frakes L, Kelly S, Garcia A a, Cleator S, Uttenreuther-Fischer M, Jones H, Wind 
S, Vinisko R, Hickish T: A phase II study of afatinib (BIBW 2992), an irreversible 
ErbB family blocker, in patients with HER2-positive metastatic breast cancer 
progressing after trastuzumab. Breast Cancer Res Treat 2012, 133:1057–65. 
129. Harbeck N, Huang C-S, Hurvitz S, Yeh D-C, Shao Z, Im S-A, Jung KH, Shen K, 
Ro J, Jassem J, Zhang Q, Im Y-H, Wojtukiewicz M, Sun Q, Chen S-C, Goeldner R-G, 
Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M, Senkus E, Kyriakides S, Penault-
Llorca F, al.  et, Network NCC, Narayan M, Wilken J, Harris L, Baron A, Kimbler K, 
Maihle N, et al.: Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in 
patients with HER2-overexpressing metastatic breast cancer who had 
progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-
label, randomised, phase 3 trial. Lancet Oncol 2016, 17:357–366. 
130. Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, 
Kim S-B, Schneeweiss A, Sohn JH, Nabholtz J-M, Kellokumpu-Lehtinen P-L, 
Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H: 
Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of 
treatment for HER2-positive breast cancer with progressive brain metastases 
after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, 
multicentre, phase 2 tr. Lancet Oncol 2015, 16:1700–10. 
131. Hickish T, Tseng L-M, Jay M, Tsang J, Kovalenko N, Udovitsa D, Pelling K, 
Ullenreuther-Fischer M, Huang C-S: LUX-breast 2: Phase II, open-label study of 
oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients 
(pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). J Clin Oncol 
2012, 30. 
 245 
132. Rimawi MF, Aleixo SB, Rozas AA, Nunes de Matos Neto J, Caleffi M, Figueira 
AC, Souza SC, Reiriz AB, Gutierrez C, Arantes H, Uttenreuther-Fischer MM, Solca 
F, Osborne CK: A Neoadjuvant, Randomized, Open-Label Phase II Trial of 
Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally 
Advanced HER2-Positive Breast Cancer. Clin Breast Cancer 2015, 15:101–109. 
133. Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kummel S, Jackisch 
C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, 
Engels K, Burchardi N, von Minckwitz G: Dual Blockade with AFatinib and 
Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or 
Operable Breast Cancer Receiving Taxane-Anthracycline Containing 
Chemotherapy--DAFNE (GBG-70). Clin Cancer Res 2015, 21:2924–2931. 
134. Wistuba II, Behrens C, Milchgrub S, Wistuba I, Cunningham H, Minna D: 
Comparison of features of human breast cancer cell lines and their 
corresponding tumors . of Features of Human and. 1998:2931–2938. 
135. Lacroix M, Leclercq G: Relevance of breast cancer cell lines as models for 
breast tumours: an update. Breast Cancer Res Treat 2004, 83:249–89. 
136. Vu T, Claret FX: Trastuzumab: updated mechanisms of action and 
resistance in breast cancer. Front Oncol 2012, 2:62. 
137. Vu T, Sliwkowski MX, Claret FX: Personalized drug combinations to 
overcome trastuzumab resistance in HER2-positive breast cancer. Biochim 
Biophys Acta 2014, 1846:353–65. 
138. Lavaud P, Andre F: Strategies to overcome trastuzumab resistance in HER2-
overexpressing breast cancers: focus on new data from clinical trials. BMC Med 
2014, 12:132. 
139. Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, 
Palacio-Vázquez I: Mechanisms Behind the Resistance to Trastuzumab in HER2-
Amplified Breast Cancer and Strategies to Overcome It. Clin Med Insights Oncol 
2016, 10(Suppl 1):21–30. 
140. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ: 
Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma 
cells. Cancer Res 2009, 69:2191–4. 
141. Shattuck DL, Miller JK, Carraway KL, Sweeney C: Met Receptor Contributes 
to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. Cancer 
Res 2008, 68:1471–1477. 
 246 
142. Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O’Brien T, Mendoza 
AD, Landi L, Biernat W, Czartoryska-Arłukowicz B, Jankowski T, Zuziak D, Zok J, 
Szostakiewicz B, Foszczyńska-Kłoda M, Tempińska-Szałach A, Rossi E, Varella-
Garcia M: Increased MET and HGF gene copy numbers are associated with 
trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 
2012, 107:793–9. 
143. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, 
O’Donovan N: Inhibition of IGF1R activity enhances response to trastuzumab in 
HER-2-positive breast cancer cells. Ann Oncol 2011, 22:68–73. 
144. Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL: 
Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to 
tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 
2002, 99:783–791. 
145. Li G, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai J, Wei H, Guo Y: 
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation 
of MUC1 and MUC4 expression. Oncotarget 2014, 5:8317–8329. 
146. Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, 
Massarweh S, Huang C, Wang Y-C, Batra SK, Gutierrez MC, Osborne CK, Schiff R: 
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer 
xenografts with acquired resistance to endocrine and HER2-targeted therapies. 
Breast Cancer Res Treat 2012, 134:583–93. 
147. Tsé C, Gauchez A-S, Jacot W, Lamy P-J: HER2 shedding and serum HER2 
extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat 
Rev 2012, 38:133–142. 
148. McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, 
O’Donovan N, Stordal B: In vitro Development of Chemotherapy and Targeted 
Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case 
Studies. Front Oncol 2014, 4(March):40. 
149. Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin 
WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL: An heregulin-EGFR-
HER3 autocrine signaling axis can mediate acquired lapatinib resistance in 
HER2+ breast cancer models. Breast Cancer Res 2013, 15:R85. 
150. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, 
Martin A-M, Gilmer TM: Novel mechanism of lapatinib resistance in HER2-
positive breast tumor cells: activation of AXL. Cancer Res 2009, 69:6871–8. 
 247 
151. Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O’Driscoll L: 
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall 
cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 2014, 
13:71. 
152. Ma C, Niu X, Luo J, Shao Z, Shen K: Combined effects of lapatinib and 
bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast 
cancer cells and activity of bortezomib against lapatinib-resistant breast cancer 
cells. Cancer Sci 2010, 101:2220–2226. 
153. Jegg A-M, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, 
Pegram MD: PI3K independent activation of mTORC1 as a target in lapatinib-
resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 2012, 136:683–92. 
154. McDermott MS, Browne BC, Conlon NT, O’Brien NA, Slamon DJ, Henry M, 
Meleady P, Clynes M, Dowling P, Crown J, O’Donovan N: PP2A inhibition 
overcomes acquired resistance to HER2 targeted therapy. Mol Cancer 2014, 
13:157. 
155. Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, 
Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K: Switching 
addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: 
FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys 
Res Commun 2011, 407:219–24. 
156. Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A: Evaluating HER2 
amplification status and acquired drug resistance in breast cancer cells using 
Raman spectroscopy. J Biomed Opt 2014, 19:25001. 
157. Rexer BN, Ham A-JL, Rinehart C, Hill S, Granja-Ingram N de M, González-
Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL: 
Phosphoproteomic mass spectrometry profiling links Src family kinases to 
escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163–74. 
158. Brady SW, Zhang J, Seok D, Wang H, Yu D: Enhanced PI3K p110α signaling 
confers acquired lapatinib resistance that can be effectively reversed by a p110α-
selective PI3K inhibitor. Mol Cancer Ther 2014, 13:60–70. 
159. Chen S, Zhu X, Qiao H, Ye M, Lai X, Yu S, Ding L, Wen A, Zhang J: 
Protective autophagy promotes the resistance of HER2-positive breast cancer 
cells to lapatinib. Tumor Biol 2016, 37:2321–2331. 
160. Formisano L, Nappi L, Rosa R, Marciano R, D Amato C, D Amato V, Damiano 
 248 
V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, 
De Placido S, Bianco R: Epidermal growth factor receptor activation modulates 
Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res 
2014, 16:R45. 
161. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang Y-C, Shou J, 
Bissell MJ, Osborne CK, Schiff R: β1 integrin mediates an alternative survival 
pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011, 
13:R84. 
162. Komurov K, Tseng J-T, Muller M, Seviour EG, Moss TJ, Yang L, Nagrath D, 
Ram PT: The glucose-deprivation network counteracts lapatinib-induced toxicity 
in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012, 8:596. 
163. Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B: 
Spontaneous epithelial-mesenchymal transition and resistance to HER-2-
targeted therapies in HER-2-positive luminal breast cancer. PLoS One 2013, 
8:e71987. 
164. Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú 
B, López-Rodríguez ML, Urruticoechea A, Colomer R: A novel inhibitor of fatty 
acid synthase shows activity against HER2+ breast cancer xenografts and is 
active in anti-HER2 drug-resistant cell lines. Breast Cancer Res 2011, 13:R131. 
165. Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, 
Browne BC, O’Donovan N, Crown J, Gogarty M, Byrne AT, O’Driscoll L: 
Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and 
Overcome Resistance to HER-Tyrosine Kinase Inhibitors. Cancer Res 2014. 
166. Wang Y-C, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy 
NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R: 
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-
positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast 
Cancer Res 2011, 13:R121. 
167. Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L: RON confers lapatinib 
resistance in HER2-positive breast cancer cells. Cancer Lett 2013, 340:43–50. 
168. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk 
P, Hill J, Harris J, Spector NL: A model of acquired autoresistance to a potent 
ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in 
breast cancer. Proc Natl Acad Sci U S A 2006, 103:7795–800. 
 249 
169. Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin 
WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL: An heregulin-EGFR-
HER3 autocrine signaling axis can mediate acquired lapatinib resistance in 
HER2+ breast cancer models. Breast Cancer Res 2013, 15:R85. 
170. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, 
Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda 
S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, 
Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, 
Gray JW, et al.: HER2 Reactivation through Acquisition of the HER2 L755S 
Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in 
HER2 + Breast Cancer. Clin Cancer Res 2017, 23:5123–5134. 
171. Trowe T, Boukouvala S, Calkins K, Cutler RE, Fong R, Funke R, Gendreau SB, 
Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews 
DJ, Lamb P, Heuer TS: EXEL-7647 inhibits mutant forms of ErbB2 associated 
with lapatinib resistance and neoplastic transformation. Clin Cancer Res 2008, 
14:2465–75. 
172. De Leon DD, Wilson DM, Powers M, Rosenfeld RG: Effects of insulin-like 
growth factors (IGFs) and IGF receptor antibodies on the proliferation of 
human breast cancer cells. Growth Factors 1992, 6:327–36. 
173. Grimberg A, Cohen P: Role of insulin-like growth factors and their binding 
proteins in growth control and carcinogenesis. J Cell Physiol 2000, 183:1–9. 
174. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA: 
Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer 
cells by targeting IGF-1R. PLoS One 2013, 8:e61015. 
175. O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa 
R, Le Beau MM, Earp HS, Liu ET: axl, a transforming gene isolated from primary 
human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell 
Biol 1991, 11:5016–31. 
176. Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH, Gelmon K, 
Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, 
Tsao MS, Eisenhauer E, Bradbury P: A phase-I study of lapatinib in combination 
with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor 
inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive 
metastatic breast cancer. Breast Cancer Res 2017, 19:54. 
177. Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast 
growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139–49. 
 250 
178. Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley 
E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, 
Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, 
Baselga J, Piccart M, Sotiriou C, Arteaga CL: HER2-Overexpressing Breast 
Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual 
Therapeutic Blockade of HER2. Clin Cancer Res 2017, 23:4323–4334. 
179. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, 
Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH: The PIK3CA gene 
is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004, 
3:772–5. 
180. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, 
Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, 
Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine 
phosphatase gene mutated in human brain, breast, and prostate cancer. Science 
1997, 275:1943–7. 
181. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter 
G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian Y-W, Zeckner 
DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai 
M-HT, Blanchard KL, Thomas JE: A transforming mutation in the pleckstrin 
homology domain of AKT1 in cancer. Nature 2007, 448:439–44. 
182. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan 
M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso 
S, Neri G, Testa JR: Molecular alterations of the AKT2 oncogene in ovarian and 
breast carcinomas. Int J Cancer 1995, 64:280–5. 
183. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu 
X: PI3K pathway activation results in low efficacy of both trastuzumab and 
lapatinib. BMC Cancer 2011, 11:248. 
184. O’Brien N a, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, 
Crown J, O’Donovan N, Slamon DJ: Activated phosphoinositide 3-kinase/AKT 
signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 
2010, 9:1489–502. 
185. Elster N, Cremona M, Morgan C, Toomey S, Carr A, O’Grady A, Hennessy BT, 
Eustace AJ: A preclinical evaluation of the PI3K alpha/delta dominant inhibitor 
BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to 
the HER2-targeted therapies trastuzumab and lapatinib. Breast Cancer Res Treat 
2015, 149:373–383. 
 251 
186. Ikink GJ, Hilkens J: Insulin receptor substrate 4 (IRS4) is a constitutive 
active oncogenic driver collaborating with HER2 and causing therapeutic 
resistance. Mol Cell Oncol 2017, 4:e1279722. 
187. Gahlaut R, Bennett A, Fatayer H, Dall BJ, Sharma N, Velikova G, Perren T, 
Dodwell D, Lansdown M, Shaaban AM: Effect of neoadjuvant chemotherapy on 
breast cancer phenotype, ER/PR and HER2 expression – Implications for the 
practising oncologist. Eur J Cancer 2016, 60:40–48. 
188. Shibue T, Weinberg RA: EMT, CSCs, and drug resistance: the mechanistic 
link and clinical implications. Nat Rev Clin Oncol 2017, 14:611–629. 
189. Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-
Castillo B, Iglesias JM, López-Bonet E, Martin ÁG, Menendez JA: Epithelial-to-
mesenchymal transition (EMT) confers primary resistance to trastuzumab 
(Herceptin). Cell Cycle 2012, 11:4020–32. 
190. Seshacharyulu P, Pandey P, Datta K, Batra SK: Phosphatase: PP2A structural 
importance, regulation and its aberrant expression in cancer. Cancer Lett 2013, 
335:9–18. 
191. Yang J, Wu J, Tan C, Klein PS: PP2A:B56epsilon is required for Wnt/beta-
catenin signaling during embryonic development. Development 2003, 130:5569–
78. 
192. Westermarck J, Hahn WC: Multiple pathways regulated by the tumor 
suppressor PP2A in transformation. Trends Mol Med 2008, 14:152–60. 
193. Wong LL, Chang CF, Koay ESC, Zhang D: Tyrosine phosphorylation of 
PP2A is regulated by HER-2 signalling and correlates with breast cancer 
progression. Int J Oncol 2009, 34:1291–1301. 
194. Martiniova L, Lu J, Chiang J, Bernardo M, Lonser R, Zhuang Z, Pacak K: 
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes 
PHEO in a MPC cell and mouse model to conventional chemotherapy. PLoS One 
2011, 6:e14678. 
195. Lu J, Zhuang Z, Song DK, Mehta GU, Ikejiri B, Mushlin H, Park DM, Lonser 
RR: The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway 
in glioma. J Neurosurg 2010, 113:225–33. 
196. Wei D, Parsels L a, Karnak D, Davis M a, Parsels JD, Marsh AC, Zhao L, 
Maybaum J, Lawrence TS, Sun Y, Morgan M a: Inhibition of protein phosphatase 
 252 
2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and 
homologous recombination repair. Clin Cancer Res 2013, 19:4422–32. 
197. Zhao M, Howard EW, Parris AB, Guo Z, Zhao Q, Ma Z, Xing Y, Liu B, 
Edgerton SM, Thor AD, Yang X: Activation of cancerous inhibitor of PP2A 
(CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt 
feedback loop in ErbB2-positive breast cancer cells. Oncotarget 2017, 8:58847–
58864. 
198. Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, Ando K, 
Ishida H, Ohnishi T, Sasaki Y: Distinct Afatinib Resistance Mechanisms Identified 
in Lung Adenocarcinoma Harboring an EGFR Mutation. Mol Cancer Res 2017, 
15:915–928. 
199. Wu S-G, Liu Y-N, Tsai M-F, Chang Y-L, Yu C-J, Yang P-C, Yang JC-H, Wen 
Y-F, Shih J-Y: The mechanism of acquired resistance to irreversible EGFR 
tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 
2016, 7:12404–13. 
200. van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, 
Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den 
Berg A, Groen HJM: Overall survival in EGFR mutated non-small-cell lung 
cancer patients treated with afatinib after EGFR TKI and resistant mechanisms 
upon disease progression. PLoS One 2017, 12:e0182885. 
201. V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for 
Resistance to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 2014, 9:1377–
1384. 
202. O’Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz 
SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ: Targeting 
PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of 
feedback activation of AKT. Clin Cancer Res 2014, 20:3507–20. 
203. Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, 
de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, 
Miller V, Gettinger S, Pao W, Politi K: Acquired Resistance of EGFR-Mutant 
Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with 
Activation of mTORC1. Cell Rep 2014, 7:999–1008. 
204. Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, 
Poklepovic A, Dent P: The afatinib resistance of &lt;i&gt;in vivo&lt;/i&gt; 
generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-
MET compensatory survival signaling. Oncotarget 2016, 7:19620–19630. 
 253 
205. Creelan B, Gray J, Lima D, Antonia S, Chiappori A, Tanvetyanon T, DeVane R, 
Williams C, Haura E: Abstract CT060: Efficacy, safety and tolerability of 
dasatinib combined with afatinib: a phase I trial in patients with epidermal 
growth factor receptor mutant (EGFRm) advanced non-small-cell lung cancer 
(NSCLC) after acquired tyrosine kinase inhibitor (TKI) resistance. Cancer Res 
2016, 76(14 Supplement):CT060-CT060. 
206. Breslin S, Lowry MC, O’Driscoll L: Neratinib resistance and cross-resistance 
to other HER2-targeted drugs due to increased activity of metabolism enzyme 
cytochrome P4503A4. Br J Cancer 2017, 116:620–625. 
207. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, 
Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ: Activating HER2 
mutations in HER2 gene amplification negative breast cancer. Cancer Discov 
2013, 3:224–37. 
208. Hanker AB, Red Brewer M, Sheehan JH, Koch JP, Nagy R, Lanman R, Berger 
MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Meiler J, 
Arteaga CL: An acquired HER2 T798I gatekeeper mutation induces resistance to 
neratinib in a patient with HER2 mutant-driven breast cancer. . 
209. Nam S, Kim D, Cheng JQ, Zhang S, Lee J-H, Buettner R, Mirosevich J, Lee FY, 
Jove R: Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on 
Human Prostate Cancer Cells. Cancer Res 2005, 65:9185–9189. 
210. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon 
DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl 
kinases, selectively inhibits growth of basal-type/?triple-negative? breast cancer 
cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319–326. 
211. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, 
Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, 
Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, 
Schmidt RJ, Tokarski J, Wen M-L, Wityak J, Borzilleri RM: Discovery of N -(2-
Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-
methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual 
Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays. J 
Med Chem 2004, 47:6658–6661. 
212. Roskoski R: Src protein–tyrosine kinase structure and regulation. Biochem 
Biophys Res Commun 2004, 324:1155–1164. 
213. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon 
DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl 
 254 
kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer 
cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319–326. 
214. Tai Y-L, Chu P-Y, Lai I-R, Wang M-Y, Tseng H-Y, Guan J-L, Liou J-Y, Shen 
T-L: An EGFR/Src-dependent β4 integrin/FAK complex contributes to 
malignancy of breast cancer. Sci Rep 2015, 5:16408. 
215. Larsen SL, Laenkholm A-V, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, 
Kirkegaard T: Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell 
Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment. PLoS One 
2015, 10:e0118346. 
216. Jain S, Wang X, Chang C-C, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, 
Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK, 
Richards-Kortum R, Jia W, Seewaldt VL, Yu D: Src Inhibition Blocks c-Myc 
Translation and Glucose Metabolism to Prevent the Development of Breast 
Cancer. Cancer Res 2015, 75:4863–4875. 
217. Zhang S, Huang W-C, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, 
Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D: Src Family Kinases as Novel 
Therapeutic Targets to Treat Breast Cancer Brain Metastases. Cancer Res 2013, 
73:5764–5774. 
218. De Luca A, D’Alessio A, Gallo M, Maiello MR, Bode AM, Normanno N: Src 
and CXCR4 are involved in the invasiveness of breast cancer cells with acquired 
resistance to lapatinib. Cell Cycle 2014, 13:148–56. 
219. Nam S, Kim D, Cheng JQ, Zhang S, Lee J-H, Buettner R, Mirosevich J, Lee FY, 
Jove R: Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on 
Human Prostate Cancer Cells. Cancer Res 2005, 65:9185–9. 
220. FDA Approval for Dasatinib - National Cancer Institute 
[https://www.cancer.gov/about-cancer/treatment/drugs/fda-dasatinib] 
221. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS, 
Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA, Papadimitrakopoulou VA: 
Phase 2 study of dasatinib in the treatment of head and neck squamous cell 
carcinoma. Cancer 2011, 117:2112–2119. 
222. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, 
Molinaro A, Sznol M: A phase 2 trial of dasatinib in advanced melanoma. Cancer 
2011, 117:2202–2208. 
 255 
223. Kelley MJ, Jha G, Shoemaker D, Herndon JE, Gu L, Barry WT, Crawford J, 
Ready N: Phase II Study of Dasatinib in Previously Treated Patients with 
Advanced Non-Small Cell Lung Cancer. Cancer Invest 2017, 35:32–35. 
224. Haesen D, Sents W, Lemaire K, Hoorne Y, Janssens V: The Basic Biology of 
PP2A in Hematologic Cells and Malignancies. Front Oncol 2014, 4:347. 
225. Gu P, Qi X, Zhou Y, Wang Y, Gao X: Generation of Ppp2Ca and Ppp2Cb 
conditional null alleles in mouse. genesis 2012, 50:429–436. 
226. Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA: Protein phosphatase 2A 
regulates interleukin-2 receptor complex formation and JAK3/STAT5 
activation. J Biol Chem 2010, 285:3582–91. 
227. Buchert M, Burns CJ, Ernst M: Targeting JAK kinase in solid tumors: 
emerging opportunities and challenges. Oncogene 2016, 35:939–951. 
228. Fukukawa C, Tanuma N, Okada T, Kikuchi K, Shima H: pp32/ I-1PP2A 
negatively regulates the Raf-1/MEK/ERK pathway. Cancer Lett 2005, 226:155–
160. 
229. Arroyo JD, Hahn WC: Involvement of PP2A in viral and cellular 
transformation. Oncogene 2005, 24:7746–55. 
230. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho 
R, Nielsen C, Ivaska J, Taya Y, Lu S-L, Lin S, Chan EKL, Wang X-J, Grènman R, 
Kast J, Kallunki T, Sears R, Kähäri V-M, Westermarck J: CIP2A inhibits PP2A in 
human malignancies. Cell 2007, 130:51–62. 
231. Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles 
P, Rovira A, Albanell J, García-Foncillas J, Madoz-Gúrpide J, Rojo F: PP2A 
inhibition determines poor outcome and doxorubicin resistance in early breast 
cancer and its activation shows promising therapeutic effects. Oncotarget 2015, 
6:4299–314. 
232. Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD: 
PP2A impaired activity is a common event in acute myeloid leukemia and its 
activation by forskolin has a potent anti-leukemic effect. Leukemia 2011, 25:606–
614. 
233. Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, 
Peppelenbosch MP, Hardwick JCH: Effect of aspirin on the Wnt/beta-catenin 
pathway is mediated via protein phosphatase 2A. Oncogene 2006, 25:6447–56. 
 256 
234. Duong FHT, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, 
Ketterer S, Terracciano L, Heim MH: Protein phosphatase 2A promotes 
hepatocellular carcinogenesis in the diethylnitrosamine mouse model through 
inhibition of p53. Carcinogenesis 2014, 35:114–122. 
235. Ruvolo PP, Deng X, May WS: Phosphorylation of Bcl2 and regulation of 
apoptosis. Leukemia 2001, 15:515–22. 
236. Shouse GP, Cai X, Liu X: Serine 15 phosphorylation of p53 directs its 
interaction with B56gamma and the tumor suppressor activity of B56gamma-
specific protein phosphatase 2A. Mol Cell Biol 2008, 28:448–56. 
237. Tachibana K, Scheuer PJ, Tsukitani Y, Kikuchi H, Van Engen D, Clardy J, 
Gopichand Y, Schmitz FJ: Okadaic acid, a cytotoxic polyether from two marine 
sponges of the genus Halichondria. J Am Chem Soc 1981, 103:2469–2471. 
238. Valdiglesias V, Laffon B, Pásaro E, Méndez J: Okadaic acid induces 
morphological changes, apoptosis and cell cycle alterations in different human 
cell types. J Environ Monit 2011, 13:1831. 
239. Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, 
Ruan A, Du Q, Olumi AF, Zhang X: Inhibition of PP2A Activity Confers a 
TRAIL-sensitive Phenotype During Malignant Transformation. Mol Cancer Res 
2013. 
240. Walsh AH, Cheng A, Honkanen RE: Fostriecin, an antitumor antibiotic with 
inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) 
and 2A (PP2A), is highly selective for PP2A. FEBS Lett 1997, 416:230–4. 
241. Lewy DS, Gauss C-M, Soenen DR, Boger DL: Fostriecin: chemistry and 
biology. Curr Med Chem 2002, 9:2005–32. 
242. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW: Inhibition of type 
II topoisomerase by fostriecin. Biochem Pharmacol 1988, 37:4063–8. 
243. Takeuchi T, Takahashi N, Ishi K, Kusayanagi T, Kuramochi K, Sugawara F: 
Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of 
protein phosphatase 2A catalytic subunit in mammalian cells. Bioorg Med Chem 
2009, 17:8113–8122. 
244. Scheithauer W, Von Hoff DD, Clark GM, Shillis JL, Elslager EF: In vitro 
activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor 
cloning assay. Eur J Cancer Clin Oncol 1986, 22:921–6. 
 257 
245. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC: 
Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. 
Cancer Res 1984, 44:1928–32. 
246. Lê LH, Erlichman C, Pillon L, Thiessen JJ, Day A, Wainman N, Eisenhauer EA, 
Moore MJ: Phase I and pharmacokinetic study of fostriecin given as an 
intravenous bolus daily for five consecutive days. Invest New Drugs 2004, 22:159–
67. 
247. Gao D, O’Doherty GA: Total Synthesis of Fostriecin: Via a Regio- and 
Stereoselective Polyene Hydration, Oxidation, and Hydroboration Sequence. Org 
Lett 2010, 12:3752–3755. 
248. Reddy YK, Falck J: Asymmetric Total Synthesis of (+)-Fostriecin†. Org Lett 
2002, 21:961–71. 
249. Kadioglu O, Kermani NS, Kelter G, Schumacher U, Fiebig HH, Greten HJ ET: 
Pharmacogenomics of Cantharidin in Tumor Cells. Biochem Pharmacol 2012, 
doi:pii: S. 
250. Efferth T, Rauh R, Kahl S, Tomicic M, Böchzelt H, Tome ME, Briehl MM, 
Bauer R, Kaina B: Molecular modes of action of cantharidin in tumor cells. 
Biochem Pharmacol 2005, 69:811–818. 
251. Rauh R, Kahl S, Boechzelt H, Bauer R, Kaina B, Efferth T: Molecular biology 
of cantharidin in cancer cells. Chin Med 2007, 2:8. 
252. Chen Y-N, Chen J-C, Yin S-C, Wang G-S, Tsauer W, Hsu S-F, Hsu S-L: 
Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in 
human hepatoma cells. Int J Cancer 2002, 100:158–165. 
253. Gu X-D, Xu L-L, Zhao H, Gu J-Z, Xie X-H: Cantharidin suppressed breast 
cancer MDA-MB-231 cell growth and migration by inhibiting MAPK signaling 
pathway. Brazilian J Med Biol Res = Rev Bras Pesqui medicas e Biol 2017, 
50:e5920. 
254. Su C-C, Lee K-I, Chen M-K, Kuo C-Y, Tang C-H, Liu SH: Cantharidin 
Induced Oral Squamous Cell Carcinoma Cell Apoptosis via the JNK-Regulated 
Mitochondria and Endoplasmic Reticulum Stress-Related Signaling Pathways. 
PLoS One 2016, 11:e0168095. 
255. Shen M, Wu M-Y, Chen L-P, Zhi Q, Gong F-R, Chen K, Li D-M, Wu Y, Tao M, 
Li W: Cantharidin represses invasion of pancreatic cancer cells through 
 258 
accelerated degradation of MMP2 mRNA. Sci Rep 2015, 5:11836. 
256. Xie X, Wu M-Y, Shou L-M, Chen L-P, Gong F-R, Chen K, Li D-M, Duan W-M, 
Xie Y-F, Mao Y-X, Li W, Tao M: Tamoxifen enhances the anticancer effect of 
cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition 
of the protein kinase C signaling pathway. Oncol Lett 2015, 9:837–844. 
257. Coloe Dosal J, Stewart PW, Lin J-A, Williams CS, Morrell DS: Cantharidin for 
the Treatment of Molluscum Contagiosum: A Prospective, Double-Blinded, 
Placebo-Controlled Trial. Pediatr Dermatol 2014, 31:440–449. 
258. Ho WS, Feldman MJ, Maric D, Amable L, Hall MD, Feldman GM, Ray-
Chaudhury A, Lizak MJ, Vera J-C, Robison RA, Zhuang Z, Heiss JD: PP2A 
inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin 
resistance in medulloblastoma cells. Oncotarget 2016. 
259. Hong CS, Ho W, Zhang C, Yang C, Elder JB, Zhuang Z: LB100, a small 
molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. 
Cancer Biol Ther 2015. 
260. Chang K-E, Wei B-R, Madigan JP, Hall MD, Simpson RM, Zhuang Z, 
Gottesman MM: The protein phosphatase 2A inhibitor LB100 sensitizes ovarian 
carcinoma cells to cisplatin-mediated cytotoxicity. Mol Cancer Ther 2015, 14:90–
100. 
261. Zhang C, Hong CS, Hu X, Yang C, Wang H, Zhu D, Moon S, Dmitriev P, Lu J, 
Chiang J, Zhuang Z, Zhou Y: Inhibition of protein phosphatase 2A with the small 
molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin 
treatment. Cell Cycle 2015, 14:2100–8. 
262. Lv P, Wang Y, Ma J, Wang Z, Li J-L, Hong CS, Zhuang Z, Zeng Y-X: 
Inhibition of protein phosphatase 2A with a small molecule LB100 
radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic 
catastrophe and blocking DNA damage repair. Oncotarget 2014, 5:7512–24. 
263. Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, 
Maybaum J, Lawrence TS, Sun Y, Morgan MA: Inhibition of protein phosphatase 
2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and 
homologous recombination repair. Clin Cancer Res 2013, 19:4422–32. 
264. Gordon IK, Lu J, Graves CA, Huntoon K, Frerich JM, Hanson RH, Wang X, 
Hong CS, Ho W, Feldman MJ, Ikejiri B, Bisht K, Chen XS, Tandle A, Yang C, 
Arscott WT, Ye D, Heiss JD, Lonser RR, Camphausen K, Zhuang Z: Protein 
 259 
Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic 
Catastrophe and Tumor Growth Delay in Glioblastoma. Mol Cancer Ther 2015, 
14:1540–7. 
265. Bai X, Zhi X, Zhang Q, Liang F, Chen W, Liang C, Hu Q, Sun X, Zhuang Z, 
Liang T: Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to 
chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated 
angiogenesis. Cancer Lett 2014, 355:281–7. 
266. Fu Q-H, Zhang Q, Zhang J-Y, Sun X, Lou Y, Li G-G, Chen Z-L, Bai X-L, Liang 
T-B: LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib 
during hypoxia by activation of Smad3 phosphorylation. Tumour Biol 2015. 
267. Shan S, Wang YD, Ren T: [LB100 reverses the acquired resistance to 
gefitinib in lung adenocarcinoma cells with EGFR mutation]. Zhonghua Yi Xue Za 
Zhi 2016, 96:3398–3402. 
268. Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, 
Johnson F, Kovach JS: Safety, Tolerability, and Preliminary Activity of LB-100, 
an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: 
An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Clin Cancer Res 
2017, 23:3277–3284. 
269. Browne B: The role of receptor tyrosine kinase signalling in HER-2-positive 
cells and Trastuzumab ( Herceptin ) Resistance in Breast Cancer . A Thesis 
submitted for the degree of Ph . D . by Brigid Browne , BSc The work in this 
thesis was carried out under the supe. 2008(October). 
270. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies 
MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, 
Zhang F, Overgaard J, Alsner J, Neve RM, Kuo W-L, Gray JW, Borresen-Dale A-L, 
Mills GB: A Technical Assessment of the Utility of Reverse Phase Protein Arrays 
for the Study of the Functional Proteome in Non-microdissected Human Breast 
Cancers. Clin Proteomics 2010, 6:129–151. 
271. Chen R, Im H, Snyder M: Whole-Exome Enrichment with the Agilent 
SureSelect Human All Exon Platform. Cold Spring Harb Protoc 2015, 2015:626–
33. 
272. Mukaka MM: Statistics corner: A guide to appropriate use of correlation 
coefficient in medical research. Malawi Med J 2012, 24:69–71. 
273. Chou T-C: Drug Combination Studies and Their Synergy Quantification 
 260 
Using the Chou-Talalay Method. Cancer Res 2010, 70:440–446. 
274. Burris HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, 
Smith DA, Pandite L, Spector N, Wilding G, Wilding G: A phase I and 
pharmacokinetic study of oral lapatinib administered once or twice daily in 
patients with solid malignancies. Clin Cancer Res 2009, 15:6702–8. 
275. Von Minckwitz G, Loibl S, Untch M: What is the current standard of care for 
anti-HER2 neoadjuvant therapy in breast cancer? Oncology (Williston Park) 
2012, 26:20–6. 
276. Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Ito Y: 
Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease 
Progression in HER2-Positive Breast Cancer. Clin Breast Cancer 2015, 15:432–
439. 
277. Eichhorn PJ a, Creyghton MP, Bernards R: Protein phosphatase 2A regulatory 
subunits and cancer. Biochim Biophys Acta 2009, 1795:1–15. 
278. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T: A novel 
immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia 
cells. Br J Pharmacol 2003, 138:1303–1312. 
279. Seshacharyulu P, Pandey P, Datta K, Batra SK: Phosphatase: PP2A structural 
importance, regulation and its aberrant expression in cancer. Cancer Lett 2013, 
335:9–18. 
280. Organ SL, Tsao M-S: An overview of the c-MET signaling pathway. Ther Adv 
Med Oncol 2011, 3(1 Suppl):S7–S19. 
281. Oda K, Matsuoka Y, Funahashi A, Kitano H: A comprehensive pathway map 
of epidermal growth factor receptor signaling. Mol Syst Biol 2005, 1:2005.0010. 
282. Valdiglesias V, Prego-Faraldo M, Pásaro E, Méndez J, Laffon B: Okadaic Acid: 
More than a Diarrheic Toxin. Mar Drugs 2013, 11:4328–4349. 
283. Clinchy B, Gazdar A, Rabinovsky R, Yefenof E, Gordon B, Vitetta ES: The 
growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in 
male SCID mice. Breast Cancer Res Treat 2000, 61:217–28. 
284. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, 
Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, 
 261 
Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA, Navaratnam V, Ryder S: 
Guidelines for the welfare and use of animals in cancer research. Br J Cancer 
2010, 102:1555–1577. 
285. Kocatürk B, Versteeg HH: Orthotopic injection of breast cancer cells into the 
mammary fat pad of mice to study tumor growth. J Vis Exp 2015. 
286. Azim HA, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger 
JG, Smith I, Jackisch C, Kim S-B, Aktas B, Huang C-S, Vuylsteke P, Hsieh RK, 
Dreosti L, Eidtmann H, Piccart M, de Azambuja E: Pattern of rash, diarrhea, and 
hepatic toxicities secondary to lapatinib and their association with age and 
response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin 
Oncol 2013, 31:4504–11. 
287. Moy B, Goss PE: Lapatinib-associated toxicity and practical management 
recommendations. Oncologist 2007, 12:756–65. 
288. Turner P V, Brabb T, Pekow C, Vasbinder MA: Administration of substances 
to laboratory animals: routes of administration and factors to consider. J Am 
Assoc Lab Anim Sci 2011, 50:600–13. 
289. Swingle M, Ni L, Honkanen RE: Small-molecule inhibitors of ser/thr protein 
phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 
2007, 365:23–38. 
290. Baldacchino S, Saliba C, Petroni V, Fenech AG, Borg N, Grech G: 
Deregulation of the phosphatase, PP2A is a common event in breast cancer, 
predicting sensitivity to FTY720. EPMA J 2014, 5:3. 
291. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, Evans GA: 
Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 
282:284–7. 
292. Madden SF, Clarke C, Gaule P, Aherne ST, O’Donovan N, Clynes M, Crown J, 
Gallagher WM: BreastMark: an integrated approach to mining publicly available 
transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 
2013, 15:R52. 
293. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, 
Isola J, Darbon J-M, Kallioniemi O, Thezenas S, Westermarck J: CIP2A Is 
Associated with Human Breast Cancer Aggressivity. Clin Cancer Res 2009, 
15:5092–5100. 
 262 
294. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, 
Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios 
CH, Gnant M, Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano 
AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M: 
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-
positive breast cancer (ExteNET): a multicentre, randomised, double-blind, 
placebo-controlled, phase 3 trial. Lancet Oncol 2016, 17:367–377. 
295. Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P: Clinical Pharmacokinetics 
and Pharmacodynamics of Afatinib. Clin Pharmacokinet 2017, 56:235–250. 
296. De P, Hasmann M, Leyland-Jones B: Molecular determinants of trastuzumab 
efficacy: What is their clinical relevance? Cancer Treat Rev 2013, 39:925–934. 
297. Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, Grimminger 
F, Seeger W, Banat GA, Schermuly RT, Pullamsetti SS: Expression and Activity of 
Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The 
Role of Phosphodiesterase 4. Mol Biol Cell 2009, 20:4751–4765. 
298. Masugi Y, Yamazaki K, Emoto K, Effendi K, Tsujikawa H, Kitago M, Itano O, 
Kitagawa Y, Sakamoto M: Upregulation of integrin β4 promotes epithelial–
mesenchymal transition and is a novel prognostic marker in pancreatic ductal 
adenocarcinoma. Lab Investig 2015, 95:308–319. 
299. Ni M, Shi X-L, Qu Z-G, Jiang H, Chen Z-Q, Hu J: Epithelial mesenchymal 
transition of non–small–cell lung cancer cells A549 induced by SPHK1. Asian 
Pac J Trop Med 2015, 8:142–146. 
300. Cormier K, Harquail J, Ouellette RJ, Tessier PA, Guerrette R, Robichaud GA: 
Intracellular expression of inflammatory proteins S100A8 and S100A9 leads to 
epithelial-mesenchymal transition and attenuated aggressivity of breast cancer 
cells. Anticancer Agents Med Chem 2014, 14:35–45. 
301. Zhou F, Drabsch Y, Dekker TJA, de Vinuesa AG, Li Y, Hawinkels LJAC, 
Sheppard K-A, Goumans M-J, Luwor RB, de Vries CJ, Mesker WE, Tollenaar 
RAEM, Devilee P, Lu CX, Zhu H, Zhang L, Dijke P ten: Nuclear receptor NR4A1 
promotes breast cancer invasion and metastasis by activating TGF-β signalling. 
Nat Commun 2014, 5:3388. 
302. Yu D-H, Zhang X, Wang H, Zhang L, Chen H, Hu M, Dong Z, Zhu G, Qian Z, 
Fan J, Su X, Xu Y, Zheng L, Dong H, Yin X, Ji Q, Ji J: The essential role of TNIK 
gene amplification in gastric cancer growth. Oncogenesis 2014, 2:e89. 
 263 
303. Lee T-G, Jeong E-H, Kim SY, Kim H-R, Kim CH: The combination of 
irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated 
cell death to overcome acquired resistance in EGFRT790M-mutated lung 
cancer. Int J Cancer 2015, 136:2717–2729. 
304. Hedrick E, Lee S-O, Doddapaneni R, Singh M, Safe S: Nuclear receptor 4A1 
as a drug target for breast cancer chemotherapy. Endocr Relat Cancer 2015, 
22:831–840. 
305. Peiró G, Ortiz-Martínez F, Gallardo A, Pérez-Balaguer A, Sánchez-Payá J, 
Ponce JJ, Tibau A, López-Vilaro L, Escuin D, Adrover E, Barnadas A, Lerma E: Src, 
a potential target for overcoming trastuzumab resistance in HER2-positive 
breast carcinoma. Br J Cancer 2014, 111:689–95. 
306. Eustace AJ, Crown J, Clynes M, O’Donovan N: Preclinical evaluation of 
dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 
2008, 6:53. 
307. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong K-
L, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ: Activity of the 
multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 2009, 
101:1699–1708. 
308. Le X-F, Mao W, Lu Z, Carter BZ, Bast RC: Dasatinib induces autophagic cell 
death in human ovarian cancer. Cancer 2010, 116:4980–4990. 
309. Chao T-T, Wang C-Y, Chen Y-L, Lai C-C, Chang F-Y, Tsai Y-T, Chao C-HH, 
Shiau C-W, Huang Y-CT, Yu C-J, Chen K-F: Afatinib induces apoptosis in 
NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. 
Oncotarget 2015, 6:2164–2179. 
310. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 2002, 418:191–195. 
311. Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of 
HMGB1 during apoptotic cell death. AJP Cell Physiol 2006, 291:C1318–C1325. 
312. Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy 
O, Goldstein LJ: Dasatinib as a Single Agent in Triple-Negative Breast Cancer: 
Results of an Open-Label Phase 2 Study. Clin Cancer Res 2011, 17:6905–6913. 
313. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, 
Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, 
 264 
Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra 
N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, 
Cortazar P: FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of 
Patients with HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 2014, 
20:4436–4441. 
314. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale 
G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, 
Bines J, Gelber RD, Piccart M, Baselga J, APHINITY Steering Committee and 
Investigators: Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive 
Breast Cancer. N Engl J Med 2017, 377:122–131. 
315. Kalous O, Conklin D, Desai AJ, O’Brien NA, Ginther C, Anderson L, Cohen DJ, 
Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS: Dacomitinib (PF-
00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-
amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol 
Cancer Ther 2012, 11:1978–87. 
316. Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, 
Montero AJ: Cost-effectiveness analysis of 1st through 3rd line sequential 
targeted therapy in HER2-positive metastatic breast cancer in the United States. 
Breast Cancer Res Treat 2016. 
317. Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G: The combination of 
trastuzumab and pertuzumab administered at approved doses may delay 
development of trastuzumab resistance by additively enhancing antibody-
dependent cell-mediated cytotoxicity. MAbs 2016, 8:1361–1370. 
318. Harbeck N, Huang C-S, Hurvitz S, Yeh D-C, Shao Z, Im S-A, Jung KH, Shen K, 
Ro J, Jassem J, Zhang Q, Im Y-H, Wojtukiewicz M, Sun Q, Chen S-C, Goeldner R-G, 
Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M: Afatinib plus vinorelbine versus 
trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic 
breast cancer who had progressed on one previous trastuzumab treatment 
(LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 2016. 
319. Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, Fidias P, 
Muzikansky A, Engelman JA, Sequist L V.: Acquired Resistance to First-Line 
Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol 
2016, 11:2022–2026. 
320. Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R: FDA 
Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR 
Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res 2016, 22:1307–
1312. 
 265 
321. Khozin S, Blumenthal GM, Jiang X, He K, Boyd K, Murgo A, Justice R, Keegan 
P, Pazdur R: U.S. Food and Drug Administration Approval Summary: Erlotinib 
for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With 
Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) 
Substitution Mutations. Oncologist 2014, 19:774–779. 
322. Miller VA, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, Zhou C, Su W-
C, Wang M, Sun Y, Heo DS, Crino L, Tan E-H, Chao T-Y, Shahidi M, Cong XJ, 
Lorence RM, Yang JC-H: Afatinib versus placebo for patients with advanced, 
metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, 
and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised 
trial. Lancet Oncol 2012, 13:528–38. 
323. Everett AD, Stoops TD, Nairn AC, Brautigan D: Angiotensin II regulates 
phosphorylation of translation elongation factor-2 in cardiac myocytes. Am J 
Physiol Hear Circ Physiol 2001, 281:H161-167. 
324. Gergs U, Boknik P, Buchwalow I, Fabritz L, Matus M, Justus I, Hanske G, 
Schmitz W, Neumann J: Overexpression of the catalytic subunit of protein 
phosphatase 2A impairs cardiac function. J Biol Chem 2004, 279:40827–34. 
325. Wong LL, Zhang D, Chang CF, Koay ESC: Silencing of the PP2A catalytic 
subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. Exp 
Cell Res 2010, 316:3387–96. 
326. Boudreau RTM, Conrad DM, Hoskin DW: Apoptosis induced by protein 
phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by 
PP2A-associated p38 mitogen-activated protein kinase. Cell Signal 2007, 19:139–
51. 
327. Li W, Chen Z, Gong F-R, Zong Y, Chen K, Li D-M, Yin H, Duan W-M, Miao 
Y, Tao M, Han X, Xu Z-K: Growth of the pancreatic cancer cell line PANC-1 is 
inhibited by protein phosphatase 2A inhibitors through overactivation of the c-
Jun N-terminal kinase pathway. Eur J Cancer 2011, 47:2654–64. 
328. Kiely M, Kiely PA: PP2A: The Wolf in Sheep’s Clothing? Cancers (Basel) 
2015, 7:648–669. 
329. Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S: Fingolimod (FTY720): 
First approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother 
2011, 2:49–51. 
330. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, 
 266 
Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De 
Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin R V., Perrotti D, Ogretmen B: 
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung 
tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. 
EMBO Mol Med 2013, 5:105–121. 
331. Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, 
Madoz-Gúrpide J, Rojo F, García-Foncillas J: Activation of the Tumor Suppressor 
PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate 
Cancer. Mar Drugs 2015, 13:3276–3286. 
332. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld A-K, 
Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, 
Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, 
Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, 
Perrotti D: Antagonistic activities of the immunomodulator and PP2A-activating 
drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. 
Blood 2013, 122:1923–34. 
333. Zonta F, Pagano MA, Trentin L, Tibaldi E, Frezzato F, Trimarco V, Facco M, 
Zagotto G, Pavan V, Ribaudo G, Bordin L, Semenzato G, Brunati AM: Lyn sustains 
oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-
mediated inhibition of PP2A. Blood 2015, 125:3747–3755. 
334. Pai P, Velmurugan BK, Kuo C-H, Yen C-Y, Ho T-J, Lin Y-M, Chen Y-F, Lai C-
H, Day CH, Huang C-Y: 17β-Estradiol and/or estrogen receptor alpha blocks 
isoproterenol-induced calcium accumulation and hypertrophy via 
GSK3β/PP2A/NFAT3/ANP pathway. Mol Cell Biochem 2017, 434:181–195. 
335. Oaks J, Ogretmen B: Regulation of PP2A by Sphingolipid Metabolism and 
Signaling. Front Oncol 2014, 4:388. 
336. Yokoyama N, Miller WT: Inhibition of Src by direct interaction with protein 
phosphatase 2A. FEBS Lett 2001, 505:460–4. 
337. Lee T, Kim SJ, Sumpio BE: Role of PP2A in the regulation of p38 MAPK 
activation in bovine aortic endothelial cells exposed to cyclic strain. J Cell Physiol 
2003, 194:349–355. 
338. Oji Y, Tatsumi N, Fukuda M, Nakatsuka S-I, Aoyagi S, Hirata E, Nanchi I, 
Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S, 
Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, 
Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, 
Yoshimine T, Okumura M, et al.: The translation elongation factor eEF2 is a novel 
 267 
tumor‑associated antigen overexpressed in various types of cancers. Int J Oncol 
2014, 44:1461–1469. 
339. Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S-I, Hirata E, Shibata S, Fukuda M, 
Yamamoto Y, Fukuda I, Tatsumi N, Ueda T, Fujiki F, Nomura M, Nishida S, 
Shirakata T, Hosen N, Tsuboi A, Oka Y, Nezu R, Mori M, Doki Y, Aozasa K, 
Sugiyama H, Oji Y: Overexpression of eukaryotic elongation factor eEF2 in 
gastrointestinal cancers and its involvement in G2/M progression in the cell 
cycle. Int J Oncol 2009, 34:1181–1189. 
340. Xia W, Mullin RJ, Keith BR, Liu L-H, Ma H, Rusnak DW, Owens G, Alligood 
KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase 
inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and 
AKT pathways. Oncogene 2002, 21:6255–6263. 
341. Chen Y-J, Yeh M-H, Yu M-C, Wei Y-L, Chen W-S, Chen J-Y, Shih C-Y, Tu C-
Y, Chen C-H, Hsia T-C, Chien P-H, Liu S-H, Yu Y-L, Huang W-C: Lapatinib–
induced NF-kappaB activation sensitizes triple-negative breast cancer cells to 
proteasome inhibitors. Breast Cancer Res 2013, 15:R108. 
342. Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, 
Foley KM, Bowman T, Miron A, Brown M, Iglehart JD, Biswas DK: NF-κB 
activation-induced anti-apoptosis renders HER2-positive cells drug resistant and 
accelerates tumor growth. Mol Cancer Res 2014, 12:408–20. 
343. Chen C-T, Kim H, Liska D, Gao S, Christensen JG, Weiser MR: MET 
activation mediates resistance to lapatinib inhibition of HER2-amplified gastric 
cancer cells. Mol Cancer Ther 2012, 11:660–9. 
344. Letourneux C, Rocher G, Porteu F: B56-containing PP2A dephosphorylate 
ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J 
2006, 25:727–738. 
345. Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein 
kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291–3310. 
346. McDermott M: Mechanisms of resistance to lapatinib in HER2-positive 
breast cancer A thesis submitted for the degree of PhD The work in this thesis 
was carried out under the supervision of. Dublin City University; 2012. 
347. Zhang L, Shao L, Creighton CJ, Zhang Y, Xin L, Ittmann M, Wang J: Function 
of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. 
Oncotarget 2015, 6:6281–6294. 
 268 
348. Li W, Chen Z, Zong Y, Gong F, Zhu Y, Zhu Y, Lv J, Zhang J, Xie L, Sun Y, 
Miao Y, Tao M, Han X, Xu Z: PP2A inhibitors induce apoptosis in pancreatic 
cancer cell line PANC-1 through persistent phosphorylation of IKKα and 
sustained activation of the NF-κB pathway. Cancer Lett 2011, 304:117–127. 
349. Wee P, Wang Z: Epidermal Growth Factor Receptor Cell Proliferation 
Signaling Pathways. Cancers (Basel) 2017, 9. 
350. Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, Croce 
CM, Barbanti-Brodano G, Russo G, Negrini M: Low frequency of alterations of the 
alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-
threonine phosphatase 2A in human neoplasms. Oncogene 2000, 19:1191–5. 
351. Chen J, Martin BL, Brautigan DL: Regulation of protein serine-threonine 
phosphatase type-2A by tyrosine phosphorylation. Science 1992, 257:1261–4. 
352. Longin S, Zwaenepoel K, Louis J V, Dilworth S, Goris J, Janssens V: Selection 
of protein phosphatase 2A regulatory subunits is mediated by the C terminus of 
the catalytic Subunit. J Biol Chem 2007, 282:26971–80. 
353. Takai A, Murata M, Torigoe K, Isobe M, Mieskes G, Yasumoto T: Inhibitory 
effect of okadaic acid derivatives on protein phosphatases. A study on structure-
affinity relationship. Biochem J 1992, 1:539–44. 
354. Walsh AH, Cheng A, Honkanen RE: Fostriecin, an antitumor antibiotic with 
inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) 
and 2A (PP2A), is highly selective for PP2A. FEBS Lett 1997, 416:230–4. 
355. Kadioglu O, Kermani NS, Kelter G, Schumacher U, Fiebig H-H, Greten HJ, 
Efferth T: Pharmacogenomics of cantharidin in tumor cells. Biochem Pharmacol 
2014, 87:399–409. 
356. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, Zhuang Z: Inhibition 
of serine/threonine phosphatase PP2A enhances cancer chemotherapy by 
blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 
2009, 106:11697–702. 
357. Lanthaler K, Bilsland E, Dobson PD, Moss HJ, Pir P, Kell DB, Oliver SG: 
Genome-wide assessment of the carriers involved in the cellular uptake of drugs: 
a model system in yeast. BMC Biol 2011, 9:70. 
358. Citrin DE: Short-Term Screening Assays for the Identification of 
Therapeutics for Cancer. Cancer Res 2016, 76:3443–5. 
 269 
359. Keller PJ, Lin A, Arendt LM, Klebba I, Jones AD, Rudnick JA, DiMeo TA, 
Gilmore H, Jefferson DM, Graham RA, Naber SP, Schnitt S, Kuperwasser C: 
Mapping the cellular and molecular heterogeneity of normal and malignant 
breast tissues and cultured cell lines. Breast Cancer Res 2010, 12:R87. 
360. Zhang C, Peng Y, Wang F, Tan X, Liu N, Fan S, Wang D, Zhang L, Liu D, 
Wang T, Wang S, Zhou Y, Su Y, Cheng T, Zhuang Z, Shi C: A synthetic 
cantharidin analog for the enhancement of doxorubicin suppression of stem cell-
derived aggressive sarcoma. Biomaterials 2010, 31:9535–9543. 
361. Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, 
Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, 
Adams VR: Phase I pharmacokinetic studies evaluating single and multiple doses 
of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New 
Drugs 2005, 23:39–49. 
362. Moy B, Goss PE: Lapatinib-associated toxicity and practical management 
recommendations. Oncologist 2007, 12:756–65. 
363. Wallace J: Humane Endpoints and Cancer Research. ILAR J 2000, 41:87–93. 
364. Fantozzi A, Christofori G: Mouse models of breast cancer metastasis. Breast 
Cancer Res 2006, 8:212. 
365. Werbeck JL, Thudi NK, Martin CK, Premanandan C, Yu L, Ostrowksi MC, 
Rosol TJ: Tumor microenvironment regulates metastasis and metastasis genes of 
mouse MMTV-PymT mammary cancer cells in vivo. Vet Pathol 2014, 51:868–81. 
366. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, Yumul R, Feng Q, 
Song H, Bartek J, Fender P, Lieber A: Epithelial junction opener JO-1 improves 
monoclonal antibody therapy of cancer. Cancer Res 2011, 71:7080–90. 
367. De Goeij BECG, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, 
Zhu T, Chen G, Miao D, van Berkel PHC, Parren PWHI: High turnover of tissue 
factor enables efficient intracellular delivery of antibody-drug conjugates. Mol 
Cancer Ther 2015, 14:1130–40. 
368. Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E: Differential induction 
of apoptosis in human breast tumor cells by okadaic acid and related inhibitors 
of protein phosphatases 1 and 2A. Cell Growth Differ 1994, 5:995–1004. 
369. Morimoto H, Morimoto Y, Ohba T, Kido H, Kobayashi S, Haneji T: Inhibitors 
of protein synthesis and RNA synthesis protect against okadaic acid-induced 
 270 
apoptosis in human osteosarcoma cell line MG63 cells but not in Saos-2 cells. J 
Bone Miner Metab 1999, 17:266–73. 
370. Kiguchi K, Giometti C, Chubb CH, Fujiki H, Huberman E: Differentiation 
induction in human breast tumor cells by okadaic acid and related inhibitors of 
protein phosphatases 1 and 2A. Biochem Biophys Res Commun 1992, 189:1261–7. 
371. Fujita M, Goto K, Yoshida K, Okamura H, Morimoto H, Kito S, Fukuda J, 
Haneji T: Okadaic acid stimulates expression of Fas receptor and Fas ligand by 
activation of nuclear factor kappa-B in human oral squamous carcinoma cells. 
Oral Oncol 2004, 40:199–206. 
372. Hirai A, Bold RJ, Ishizuka J, Hirai M, Townsend CM, Thompson JC: 
Hyperphosphorylation of retinoblastoma protein and stimulation of growth by 
okadaic acid in human pancreatic cancer. Dig Dis Sci 1996, 41:1975–80. 
373. Ehlers A, These A, Hessel S, Preiss-Weigert A, Lampen A: Active elimination 
of the marine biotoxin okadaic acid by P-glycoprotein through an in vitro 
gastrointestinal barrier. Toxicol Lett 2014, 225:311–317. 
374. Ikema S, Takumi S, Maeda Y, Kurimoto T, Bohda S, Chigwechokha PK, 
Sugiyama Y, Shiozaki K, Furukawa T, Komatsu M: Okadaic acid is taken-up into 
the cells mediated by human hepatocytes transporter OATP1B3. Food Chem 
Toxicol 2015, 83:229–236. 
375. Ruediger R, Pham HT, Walter G: Alterations in protein phosphatase 2A 
subunit interaction in human carcinomas of the lung and colon with mutations in 
the Aβ subunit gene. Oncogene 2001, 20:1892–1899. 
376. Hashida S, Yamamoto H, Shien K, Miyoshi Y, Ohtsuka T, Suzawa K, Watanabe 
M, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S: Acquisition of 
cancer stem cell-like properties in non-small cell lung cancer with acquired 
resistance to afatinib. Cancer Sci 2015, 106:1377–1384. 
377. Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, 
Rijavec E, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, Grossi F: 
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and 
MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. 
Target Oncol 2015, 10:393–404. 
378. Lee Y, Wang Y, James M, Jeong JH, You M: Inhibition of IGF1R signaling 
abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung 
cancer cells. Mol Carcinog 2015. 
 271 
379. Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji 
M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T: 
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented 
Sensitivity to Afatinib or Neratinib as Compared with First- or Third-
Generation TKIs. Clin Cancer Res 2015, 21:5305–5313. 
380. Hashida S, Yamamoto H, Shien K, Miyoshi Y, Ohtsuka T, Suzawa K, Watanabe 
M, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S: Acquisition of 
cancer stem cell-like properties in non-small cell lung cancer with acquired 
resistance to afatinib. Cancer Sci 2015. 
381. Dong J, Ramachandiran S, Tikoo K, Jia Z, Lau SS, Monks TJ: EGFR-
independent activation of p38 MAPK and EGFR-dependent activation of 
ERK1/2 are required for ROS-induced renal cell death. Am J Physiol Renal 
Physiol 2004, 287:F1049-58. 
382. Mueller K, Powell K, Madden J, Eblen S, Boerner J: EGFR Tyrosine 845 
Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer 
Cells Require Activation of p38 MAPK. Transl Oncol 2012, 5:327–IN1. 
383. Khabele D, Kabir SM, Dong Y, Lee E, Rice VM, Son D-S: Preferential Effect 
of Akt2-Dependent Signaling on the Cellular Viability of Ovarian Cancer Cells 
in Response to EGF. J Cancer 2014, 5:670–678. 
384. Formisano L, Nappi L, Rosa R, Marciano R, D’Amato C, D’Amato V, Damiano 
V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De 
Placido S, Bianco R: Epidermal growth factor-receptor activation modulates Src-
dependent resistance to lapatinib in breast cancer models. Breast Cancer Res 
2014, 16:R45. 
385. Wang H-Y, Hsu M-K, Wang K-H, Tseng C-P, Chen F-C, Hsu JT-A: Non-small-
cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase 
inhibition through immediate adhesion-related responses. Onco Targets Ther 
2016, 9:2961–73. 
386. Sato K-I: Cellular functions regulated by phosphorylation of EGFR on 
Tyr845. Int J Mol Sci 2013, 14:10761–90. 
387. Hedrick E, Lee S-O, Kim G, Abdelrahim M, Jin U-H, Safe S, Abudayyeh A: 
Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell 
Adenocarcinoma. PLoS One 2015, 10:e0128308. 
388. Lee S-O, Li X, Hedrick E, Jin U-H, Tjalkens RB, Backos DS, Li L, Zhang Y, 
 272 
Wu Q, Safe S: Diindolylmethane Analogs Bind NR4A1 and Are NR4A1 
Antagonists in Colon Cancer Cells. Mol Endocrinol 2014, 28:1729–1739. 
389. Lee S-O, Jin U-H, Kang JH, Kim SB, Guthrie AS, Sreevalsan S, Lee J-S, Safe S: 
The Orphan Nuclear Receptor NR4A1 (Nur77) Regulates Oxidative and 
Endoplasmic Reticulum Stress in Pancreatic Cancer Cells. Mol Cancer Res 2014, 
12:527–538. 
390. Kim H-P, Han S-W, Song S-H, Jeong E-G, Lee M-Y, Hwang D, Im S-A, Bang 
Y-J, Kim T-Y: Testican-1-mediated epithelial-mesenchymal transition signaling 
confers acquired resistance to lapatinib in HER2-positive gastric cancer. 
Oncogene 2014, 33:3334–41. 
391. Shaw FL, Harrison H, Spence K, Ablett MP, Simões BM, Farnie G, Clarke RB: 
A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem 
Cell Activity. J Mammary Gland Biol Neoplasia 2012, 17:111–117. 
392. Lombardo Y, de Giorgio A, Coombes CR, Stebbing J, Castellano L: 
Mammosphere formation assay from human breast cancer tissues and cell lines. 
J Vis Exp 2015. 
393. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications 
and therapeutic opportunities. Nat Rev Cancer 2010, 10:9–22. 
394. Pastuszak-Lewandoska D, Kordiak J, Antczak A, Migdalska-Sęk M, Czarnecka 
KH, Górski P, Nawrot E, Kiszałkiewicz JM, Domańska-Senderowska D, 
Brzeziańska-Lasota E: Expression level and methylation status of three tumor 
suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer. 
Med Oncol 2016, 33:75. 
395. Mostovich LA, Prudnikova TY, Kondratov AG, Loginova D, Vavilov P V., 
Rykova VI, Sidorov S V., Pavlova T V., Kashuba VI, Zabarovsky ER, Grigorieva E 
V.: Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast 
tumors. Cell Adh Migr 2011, 5:395–401. 
396. Nawaz I, Hu L-F, Du Z-M, Moumad K, Ignatyev I, Pavlova T V., Kashuba V, 
Almgren M, Zabarovsky ER, Ernberg I: Integrin &amp;alpha;9 gene promoter is 
hypermethylated and downregulated in nasopharyngeal carcinoma. Oncotarget 
2015, 6:31493–31507. 
397. Leng C, Zhang Z, Chen W, Luo H, Song J, Dong W, Zhu X, Chen X, Liang H, 
Zhang B: An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung 
metastases by enhancing anchorage independence through activation of FAK–
 273 
AKT pathway. Cancer Lett 2016, 376:188–196. 
398. Kawakami K, Fujita Y, Kato T, Mizutani K, Kameyama K, Tsumoto H, Miura 
Y, Deguchi T, Ito M: Integrin β4 and vinculin contained in exosomes are potential 
markers for progression of prostate cancer associated with taxane-resistance. Int 
J Oncol 2015, 47:384–90. 
399. Liu S, Ge D, Chen L, Zhao J, Su L, Zhang S, Miao J, Zhao B: A small molecule 
induces integrin &amp;beta;4 nuclear translocation and apoptosis selectively in 
cancer cells with high expression of integrin &amp;beta;4. Oncotarget 2016, 
7:16282–16296. 
400. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, 
Park MA, Yacoub A, Fisher PB, Grant S, Dent P: Lapatinib resistance in HCT116 
cells is mediated by elevated MCL-1 expression and decreased BAK activation 
and not by ERBB receptor kinase mutation. Mol Pharmacol 2008, 74:807–22. 
401. Eustace A, Browne B, Madden S, O’Driscoll L, McDermott M, O’Brien N, 
Watson W, Crown J, Walsh N, O’Donovan N: Effect of acquired resistance to 
lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members 
MCL-1 and BAX. In ASCO; 2012. 
402. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, Lin B, Chen G, Lu J, 
Lin F, Xie Z, Fontana JA, Reed JC, Zhang X: Cytochrome c release and apoptosis 
induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 
2000, 289:1159–64. 
403. Pawlak A, Strzadala L, Kalas W: Non-genomic effects of the 
NR4A1/Nur77/TR3/NGFIB orphan nuclear receptor. Steroids 2015, 95:1–6. 
404. Inamoto T, Papineni S, Chintharlapalli S, Cho S-D, Safe S, Kamat AM: 1,1-
Bis(3’-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor 
Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther 2008, 7:3825–3833. 
405. Cho SD, Lei P, Abdelrahim M, Yoon K, Liu S, Guo J, Papineni S, 
Chintharlapalli S, Safe S: 1,1-bis(3′-indolyl)-1-(p-methoxyphenyl)methane 
activates Nur77-independent proapoptotic responses in colon cancer cells. Mol 
Carcinog 2008, 47:252–263. 
406. Canonici A, Ibrahim M, Fanning K, Cremona M, Morgan C, Hennesy B, Solca 
F, Crown J, O’Donovan N: Biomarkers for afatinib and dasatinib treatment in 
triple negative breast cancer | OncologyPRO. In ESMO; 2016. 
 274 
407. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, 
Corey SJ: Dasatinib synergizes with doxorubicin to block growth, migration, and 
invasion of breast cancer cells. Br J Cancer 2009, 101:38–47. 
408. Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, 
Muñoz M, Carrasco E, Urruticoechea A: A phase I study of the SRC kinase 
inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for 
patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 
study. Oncotarget 2017. 
409. Stanley A, Ashrafi GH, Seddon AM, Modjtahedi H: Synergistic effects of 
various Her inhibitors in combination with IGF-1R, C-MET and Src targeting 
agents in breast cancer cell lines. Sci Rep 2017, 7:3964. 
410. Du G-J, Lin H-H, Xu Q-T, Wang M-W: Bcl-2 switches the type of demise 
from apoptosis to necrosis via cyclooxygenase-2 upregulation in HeLa cell 
induced by hydrogen peroxide. Cancer Lett 2006, 232:179–188. 
411. Zhan W, Zhu J, Wang L: Inhibition of proliferation and induction of 
apoptosis in RB116 retinoblastoma cells by afatinib treatment. Tumor Biol 2016, 
37:9249–9254. 
412. Wang S, Liu S, Zhao B, Yang F, Wang Y, Liang Q-Y, Sun Y, Liu Y, Song Z, 
Cai Y, Li G: Afatinib reverses multidrug resistance in ovarian cancer via dually 
inhibiting ATP binding cassette subfamily B member 1. Oncotarget 2015, 
6:26142–60. 
413. Bianchi ME, Manfredi A: Chromatin and cell death. Biochim Biophys Acta - 
Gene Struct Expr 2004, 1677:181–186. 
414. Holliday DL, Speirs V: Choosing the right cell line for breast cancer 
research. Breast Cancer Res 2011, 13:215. 
415. Zhou S-F: Drugs behave as substrates, inhibitors and inducers of human 
cytochrome P450 3A4. Curr Drug Metab 2008, 9:310–22. 
416. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D: Pharmacokinetics of oral 
neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin 
Pharmacol 2011, 71:522–7. 
417. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-
Chirchir A, Feng ;, Luo R, Sy O, Kaul S, Chiappori AA: Phase 1 Pharmacokinetic 
and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid 
 275 
Tumors. Cancer 2010. 
 
 
  
 276 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 277 
Table 9-1: All significant copy number variations in SKBR3-A compared to SKBR3-
Par cells. Copy number ratio is given as a relative number of gene copies in SKBR3-
A cells to SKBR3-Par cells. A cut of > 1.4 and < 0.35 copy ratio was used. 
Gene Gene description Copy ratio 
LSM5 LSM5 Homolog, U6 Small Nuclear RNA 
And MRNA Degradation Associated 
0.350 
STS Steroid Sulfatase 0.394 
STAC SH3 And Cysteine Rich Domain 0.527 
ITGA9 Integrin Subunit Alpha 9 0.581 
MUC16 Mucin 16 1.401 
TRAF4 TNF Receptor Associated Factor 4 1.401 
ENPP2 Ectonucleotide 
Pyrophosphatase/Phosphodiesterase 2 
1.403 
BPTF Bromodomain PHD Finger Transcription 
Factor 
1.404 
C17orf58 Chromosome 17 Open Reading Frame 58 1.404 
LINC00674 Long Intergenic Non-Protein Coding RNA 
674 
1.404 
AMZ2 Archaelysin Family Metallopeptidase 2 1.404 
CCNL1 Cyclin L1 1.406 
KRT8 Keratin 8 1.406 
JPH1 Junctophilin 1 1.406 
MUC16 Mucin 16 1.408 
MRPL13 Mitochondrial Ribosomal Protein L13 1.411 
ENPP2 Ectonucleotide 
Pyrophosphatase/Phosphodiesterase 2 
1.411 
DCLK3 Doublecortin Like Kinase 3 1.412 
NFE2L3 Nuclear Factor, Erythroid 2 Like 3 1.412 
HNRNPA2B1 Heterogeneous Nuclear Ribonucleoprotein 
A2/B1 
1.412 
CBX3 Chromobox 3 1.412 
RGAG1 Retrotransposon GAG Domain-Containing 
Protein 1 
1.412 
MUC16 Mucin 16 1.412 
ZNFX1 Zinc Finger NFX1-Type Containing 1 1.413 
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ZNF217 Zinc Finger Protein 217 1.414 
FRMPD3 FERM And PDZ Domain Containing 3 1.414 
CX3CR1 C-X3-C Motif Chemokine Receptor 1 1.415 
MRPS28 Mitochondrial Ribosomal Protein S28 1.415 
ANKMY1 Ankyrin Repeat And MYND Domain 
Containing 1 
1.417 
SCN5A Sodium Voltage-Gated Channel Alpha 
Subunit 5 
1.417 
SCN10A Sodium Voltage-Gated Channel Alpha 
Subunit 10 
1.418 
TRAM1 Translocation Associated Membrane 
Protein 1 
1.420 
NUDT8 Nudix Hydrolase 8 1.423 
RBM39 RNA Binding Motif Protein 39 1.425 
ZNF799 Zinc Finger Protein 799 1.426 
GPRASP1 G Protein-Coupled Receptor Associated 
Sorting Protein 1 
1.426 
SPATA7 Spermatogenesis Associated 7 1.427 
CTDNEP1 CTD Nuclear Envelope Phosphatase 1 1.428 
KPNA2 Karyopherin Subunit Alpha 2 1.430 
ID3 Inhibitor Of DNA Binding 3, HLH Protein 1.433 
ANKRD11 Ankyrin Repeat Domain 11 1.433 
TRPS1 Transcriptional Repressor GATA Binding 1 1.434 
SCN11A Sodium Voltage-Gated Channel Alpha 
Subunit 11 
1.435 
TRPS1 Transcriptional Repressor GATA Binding 1 1.435 
TPD52 Tumor Protein D52 1.437 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.438 
LOC286190 LACTB2 antisense RNA 1 1.438 
SLITRK4 SLIT And NTRK Like Family Member 4 1.438 
ZCCHC14 Zinc Finger CCHC-Type Containing 14 1.443 
SNAI3-AS1 SNAI3 Antisense RNA 1 1.443 
APRT Adenine Phosphoribosyltransferase 1.443 
DEF8 Differentially Expressed In FDCP 8 
Homolog 
1.443 
MAGEC1 MAGE Family Member C1 1.444 
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THOP1 Thimet Oligopeptidase 1 1.446 
PTPRS Protein Tyrosine Phosphatase, Receptor 
Type S 
1.446 
MUC16 Mucin 16 1.446 
EIF3G Eukaryotic Translation Initiation Factor 3 
Subunit G 
1.446 
PDE4A Phosphodiesterase 4A 1.446 
ZNF799 Zinc Finger Protein 799 1.446 
RTBDN Retbindin 1.446 
HIST1H3J Histone Cluster 1 H3 Family Member J 1.446 
TRPM8 Transient Receptor Potential Cation 
Channel Subfamily M Member 8 
1.447 
BCORL1 BCL6 Corepressor Like 1 1.447 
BPTF Bromodomain PHD Finger Transcription 
Factor 
1.448 
ACTB Actin Beta 1.450 
IRS4 Insulin Receptor Substrate 4 1.452 
ITPR1 Inositol 1,4,5-Trisphosphate Receptor Type 
1 
1.456 
PTPN21 Protein Tyrosine Phosphatase, Non-
Receptor Type 21 
1.458 
LRRC27 Leucine Rich Repeat Containing 27 1.464 
NRDE2 NRDE-2, Necessary For RNA Interference, 
Domain Containing 
1.465 
STMN2 Stathmin 2 1.466 
RNF213 Ring Finger Protein 213 1.466 
NUDT4P2 Nudix Hydrolase 4 Pseudogene 2 1.468 
BRWD3 Bromodomain And WD Repeat Domain 
Containing 3 
1.469 
CENPI Centromere Protein I 1.469 
TCP11X2 T-Complex 11 Family, X-Linked 2 1.469 
LINC00630 Long Intergenic Non-Protein Coding RNA 
630 
1.469 
CLDN2 Claudin 2 1.469 
COL4A6 Collagen Type IV Alpha 6 Chain 1.469 
ACSL4 Acyl-CoA Synthetase Long-Chain Family 1.469 
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Member 4 
LRCH2 Leucine Rich Repeats And Calponin 
Homology Domain Containing 2 
1.469 
PLS3 Lipoprotein Lipase 1.469 
SEPT6 Septin 6 1.469 
CT47A4 Cancer/Testis Antigen Family 47, Member 
A4 
1.469 
IGSF1 Immunoglobulin Superfamily Member 1 1.469 
CT45A5 Cancer/Testis Antigen Family 45 Member 
A5 
1.469 
MCF2 MCF.2 Cell Line Derived Transforming 
Sequence 
1.469 
MAGEC3 MAGE Family Member C3 1.469 
SPANXN4 SPANX Family Member N4 1.469 
SPANXN2 SPANX Family Member N2 1.469 
NSDHL NAD(P) Dependent Steroid 
Dehydrogenase-Like 
1.469 
DNASE1L1 Deoxyribonuclease 1 Like 1 1.469 
DKC1 Dyskerin Pseudouridine Synthase 1 1.469 
MIR1184-1 MicroRNA 1184-1 1.469 
PLCL2 Phospholipase C Like 2 1.470 
TRANK1 Tetratricopeptide Repeat And Ankyrin 
Repeat Containing 1 
1.470 
TPD52 Tumor Protein D52 1.471 
XIRP1 Xin Actin Binding Repeat Containing 1 1.473 
PKM Pyruvate Kinase, Muscle 1.474 
MTBP MDM2 Binding Protein 1.475 
FLRT2 Fibronectin Leucine Rich Transmembrane 
Protein 2 
1.478 
GALC Galactosylceramidase 1.478 
SPATA7 Spermatogenesis Associated 7 1.478 
PTPN21 Protein Tyrosine Phosphatase, Non-
Receptor Type 21 
1.478 
ZC3H14 Zinc Finger CCCH-Type Containing 14 1.478 
TTC7B Tetratricopeptide Repeat Domain 7B 1.478 
GPR68  Protein-Coupled Receptor 68 1.478 
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TC2N Tandem C2 Domains, Nuclear 1.478 
TRIP11 Thyroid Hormone Receptor Interactor 11 1.478 
CSNK1A1 Casein Kinase 1 Alpha 1 1.480 
CTU2 Cytosolic Thiouridylase Subunit 2 1.481 
LOC100132891 MSC antisense RNA 1 1.481 
PLXNA3 Plexin A3 1.483 
MYO15B Myosin XVB 1.485 
TRIP11 Thyroid Hormone Receptor Interactor 11 1.487 
CCR8 C-C Motif Chemokine Receptor 8 1.488 
MYO15B Myosin XVB 1.489 
NID2 Nidogen 2 1.494 
TXNDC16 Thioredoxin Domain Containing 16 1.494 
DDX27 DEAD-Box Helicase 27 1.495 
ZNFX1 Zinc Finger NFX1-Type Containing 1 1.495 
SNORD12B Small Nucleolar RNA, C/D Box 12B 1.495 
PLCL2 Phospholipase C Like 2 1.499 
TRPS1 Transcriptional Repressor GATA Binding 1 1.501 
TFAP2C Transcription Factor AP-2 Gamma 1.501 
ZBTB33 Zinc Finger And BTB Domain Containing 
33 
1.502 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.506 
QRICH2 Glutamine Rich 2 1.511 
ZNFX1 Zinc Finger NFX1-Type Containing 1 1.514 
EIF4G2 Eukaryotic Translation Initiation Factor 4 
Gamma 2 
1.520 
TPD52L2 Tumor Protein D52 Like 2 1.524 
F8 Coagulation Factor VIII 1.524 
USP26 Ubiquitin Specific Peptidase 26 1.528 
EPM2AIP1 EPM2A Interacting Protein 1 1.530 
CASKIN2 CASK Interacting Protein 2 1.531 
DCLK3 Doublecortin Like Kinase 3 1.531 
TRANK1 Tetratricopeptide Repeat And Ankyrin 
Repeat Containing 1 
1.531 
MLH1 MutL Homolog 1 1.531 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.538 
ATP6V0D2 ATPase H+ Transporting V0 Subunit D2 1.539 
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CNGB3 yclic Nucleotide Gated Channel Beta 3 1.539 
ITPR1 Inositol 1,4,5-Trisphosphate Receptor Type 
1 
1.541 
GRM7 Glutamate Metabotropic Receptor 7 1.541 
DSCC1 DNA Replication And Sister Chromatid 
Cohesion 1 
1.542 
MSC Musculin 1.542 
TRPA1 Transient Receptor Potential Cation 
Channel Subfamily A Member 1 
1.542 
TERF1 Telomeric Repeat Binding Factor 1 1.542 
STAU2 Staufen Double-Stranded RNA Binding 
Protein 2 
1.542 
TCEB1 Transcription elongation factor B 
polypeptide 1 
1.542 
JPH1 Junctophilin 1 1.542 
PEX2 Peroxisomal Biogenesis Factor 2 1.542 
STMN2 Stathmin 2 1.542 
MRPS28 Mitochondrial Ribosomal Protein S28 1.542 
TPD52 Tumor Protein D52 1.542 
KCNB2 Potassium Voltage-Gated Channel 
Subfamily B Member 2 
1.543 
KCNB2 Potassium Voltage-Gated Channel 
Subfamily B Member 2 
1.551 
S100A9 S100 Calcium Binding Protein A9 1.551 
BHLHE40 Basic Helix-Loop-Helix Family Member 
E40 
1.553 
RHBDF2 Rhomboid 5 Homolog 2 1.554 
RDH10 Retinol Dehydrogenase 10 1.556 
KIAA1210 KIAA1210 1.559 
FLNA Filamin A 1.560 
STAU2 Staufen Double-Stranded RNA Binding 
Protein 2 
1.565 
HERPUD1 Homocysteine Inducible ER Protein With 
Ubiquitin Like Domain 1 
1.565 
COL14A1 Collagen Type XIV Alpha 1 Chain 1.567 
MRPL13 Mitochondrial Ribosomal Protein L13 1.567 
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MTBP MDM2 Binding Protein 1.567 
ZACN Zinc Activated Ion Channel 1.569 
C17orf80 Chromosome 17 Open Reading Frame 80 1.570 
MYO15B Myosin XVB 1.574 
MTBP MDM2 Binding Protein 1.577 
SEC16B SEC16 Homolog B, Endoplasmic 
Reticulum Export Factor 
1.579 
PDE4D Phosphodiesterase 4D 1.584 
GPR112 G protein-coupled receptor 112 1.590 
FOXK2 Forkhead Box K2 1.598 
JPH1 Junctophilin 1 1.617 
DLEC1 Deleted In Lung And Esophageal Cancer 1 1.628 
SCN5A Sodium Voltage-Gated Channel Alpha 
Subunit 5 
1.628 
SCN10A Sodium Voltage-Gated Channel Alpha 
Subunit 10 
1.628 
CSRNP1 Cysteine And Serine Rich Nuclear Protein 
1 
1.628 
CX3CR1 C-X3-C Motif Chemokine Receptor 1 1.628 
RPSA Ribosomal Protein SA 1.628 
FAM104A Family With Sequence Similarity 104 
Member A 
1.631 
GPRC5C G Protein-Coupled Receptor Class C Group 
5 Member C 
1.631 
MYO15B Myosin XVB 1.631 
ITGB4 Integrin Subunit Beta 4 1.631 
EXOC7 Exocyst Complex Component 7 1.631 
SPHK1 Sphingosine Kinase 1 1.631 
CYTH1 Cytohesin 1 1.631 
RPTOR Regulatory Associated Protein Of MTOR 
Complex 1 
1.631 
NPB Neuropeptide B 1.631 
TUFT1 Tuftelin 1 1.649 
SCYL1 SCY1 Like Pseudokinase 1 1.670 
TAF2 TATA-Box Binding Protein Associated 
Factor 2 
1.682 
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DEPTOR DEP Domain Containing MTOR 
Interacting Protein 
1.682 
PRKDC Protein Kinase, DNA-Activated, Catalytic 
Polypeptide 
1.712 
NR4A1 Nuclear Receptor Subfamily 4 Group A 
Member 1 
1.751 
REEP2 Receptor Accessory Protein 2 1.834 
HIST1H2BD Histone Cluster 1 H2B Family Member D 1.866 
TNIK TRAF2 And NCK Interacting Kinase 1.892 
KRT7 Keratin 7 1.921 
HIST2H3A Histone Cluster 2 H3 Family Member A 1.950 
FLJ42969 Uncharacterized LOC441374 1.966 
TXNRD1 Thioredoxin Reductase 1 2.055 
CCDC57 Coiled-Coil Domain Containing 57 2.160 
AADACL2 Arylacetamide Deacetylase Like 2 2.217 
 
 
 
 
 
